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Chapter 1  •  General introduction and aims of the studies
COPD: importance of a highly prevalent disease
Patients with Chronic Obstructive Pulmonary Disease (COPD) have a lung 
disorder that limits daily activities and contributes considerably to emotional 
distress [1]. Most patients with COPD experience airway symptoms such as 
cough, sputum production and dyspnea at exertion. Subgroups of patients 
have periods with aggravation of symptoms, so-called exacerbations or “lung 
attacks”. The presence of symptoms and exacerbations diminishes health 
status. According to the Global Initiative for COPD (GOLD) guidelines COPD is 
defined as “a common preventable and treatable disease that is characterised 
by persistent airflow limitation that is usually progressive and associated with 
an enhanced chronic inflammatory response in the airways and the lung to 
noxious particles or gases”. Exacerbations and comorbidities contribute to the 
overall severity in individual patients [2].
COPD is a highly common disease with a prevalence of 7 to 8% worldwide, 
whereas most European countries have a lower prevalence around 3 to 4% 
[3]. In The Netherlands, a standard general practice of 2300 patient takes care 
of around 60 patients with COPD [4]. In 2010 COPD moved from the fourth 
leading cause of death to the third in the United States [5]. The complexity of 
the disease, including many comorbidities, and aging of the population in the 
upcoming years will provide an enormous burden on the health care system. 
With advanced disease the health services will be used more intensively, 
because of exacerbations and hospitalizations. Currently, in The Netherlands 
many patients with COPD in general practice are not diagnosed and chronic 
care for these patients is still lacking in many places [6]. However, in recent 
years some important health policy changes have occurred and chronic care 
is slowly improving. This, for example, resulted in ‘de Zorgstandaard COPD’ 
which is a practical guideline for daily primary care practice in the Netherlands 
[7]. Also, the GOLD guidelines attempt to build a bridge between science and 
daily practice. The difficulties  that have to be faced can be demonstrated when 
interpreting the scheme from chapter 2 of the GOLD guidelines for assessment 
of association between symptoms, spirometric classification, and future risk of 
exacerbations [2]. A three-dimensional graph is reduced to a two-dimensional 
scheme and it is not easy to classify patients correctly. Structured disease 
management may provide significant improvements for COPD patients, such 
as increased physical activity [8], improved quality of life [9], and reduced 
exacerbations [10], hospitalisation and emergency department visits [11]. This 
may provide a setting for a shift from a doctor’s perspective towards tailored 
interventions based on a more patient centred perspective. 
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Patient centred perspective
From the patients’ perspective the most important features of COPD are 
distressing symptoms, such as dyspnea, cough and sputum production and 
perceived limitation in daily activities (Figure 1). The distress can temporarily 
enhance during exacerbations. This can have a major impact on a patients’ 
individual quality of life. Consequently, care providers seek to improve 
symptoms and improve functional status. In clinical trials health status 
measurement is a way of objectively measuring the impact of disease on a 
patients’ daily life, health and well-being [12]. Disease-specific health status 
questionnaires such as the St. George Respiratory Questionnaire (SGRQ) [13], 
the Clinical COPD Questionnaire (CCQ) [14] and the  COPD Assessment Test 
(CAT) [15] address airway symptoms, emotional and psychological distress 
and limitation of activities and daily disturbances. 
The actual burden of COPD differs between patients. Some patients experience 
few symptoms, whereas others are completely handicapped or even 
bedridden by the disease. In addition, health status is only weakly associated 
with the underlying severity of airflow limitation [16-18]. Health status seems 
to be more closely associated with factors such as dyspnea, depression, 
anxiety and exercise tolerance than with forced expiratory volume (FEV1)  [19]. 
This may be due to the fact that COPD symptoms can be linked to different 
components of the disease. Breathlessness is an important characteristic of 
COPD and is mostly subjectively associated with exercise. The improvement 
in dyspnea by bronchodilators at rest is associated with improvements in 
forced inspiratory volume (FIV1) rather than FEV1 [20]. Static lung volumes are 
increased in COPD and the functional residual capacity rises even further at 
exercise, which is called dynamic hyperinflation. The improvement in dyspnea 
by a bronchodilator during exercise is also associated with inspiratory capacity 
rather than FEV1 [21]. This dynamic hyperinflation may be associated with the 
underlying chronic inflammatory process and small airway disease. To date, 
no previous studies have investigated whether there is an association between 
health status and the severity of airway inflammation in COPD. Knowledge of 
the relationship between health status and the severity of airway inflammation 
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Figure 1. Patient perspective on COPD
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Clinical phenotypes
In patients with a disease as complex as COPD, effective care is only possible 
if we determine the individual profile. Insight in the underlying components 
of COPD is important to understand the disease in its full spectrum and to 
be able to influence prognosis and treatment. Ultimately, this will lead to 
tailoring treatment in individual patients [22]. Many patho-physiological 
abnormalities may determine different phenotypes, such as airway disease 
versus emphysema; rapid vs non-rapid decliners, frequent vs non-frequent 
exacerbators, chronic bronchitis vs non-chronic bronchitis. Early concepts 
of COPD were illustrated using a so-called ‘Venn diagram’ [23]. This diagram 
included overlapping components with chronic bronchitis, emphysema and 
subtypes of asthma with airways obstruction. More recent studies have 
shown that this diagram does not include all subgroups of patients with 
COPD [24]. Interestingly there are also patients with COPD without chronic 
bronchitis, emphysema or asthma [25]. Currently, the GOLD guidelines focus 
on symptoms, airflow limitation and future risk of exacerbations (Figure 2) [2].
However, it remains unclear whether these are the only important phenotypes. 
The group with few symptoms, severe airflow limitation and frequent 
exacerbations is probably small, whereas the group of patients with few 
exacerbations is probably larger with more heterogeneity. The latter could 
be due to the fact that patients frequently do not report to their physician 
[26]. However, the Evaluation of COPD Longitudinally to Identify Surrogate 
Endpoints (ECLIPSE) study showed that there may also be a specific phenotype 
that is more susceptible to exacerbations. From a clinical perspective it is 
important to identify specific phenotypes that have prognostic value for the 
effect of interventions on outcomes. A clinical phenotype can be defined as “a 
single or combination of disease attributes that describe differences between 
individuals with COPD as they relate to clinically meaningful outcomes” [27]. 
Taking into account the large heterogeneity of the disease, it can be expected 
that subgroups of patients may benefit from a given treatment. Hence, which 
clinical phenotypes are important in COPD? 
Chronic bronchitis
One third of patients with COPD have symptoms of chronic cough and 
sputum production [28;29]. The presence of chronic bronchitis can be defined 
clinically as daily cough and sputum production for more than 3 months 
per year for > 1 year [30]. Patients with chronic bronchitis have lower health 
status, more severe breathlessness, more upper airway symptoms and fewer 
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exacerbations than patients without chronic bronchitis [31]. In addition, the 
presence of chronic bronchitis is associated with a steeper decline in FEV1 
[30;32] and mortality [33], even apart from GOLD stages [34]. This can have a 
major impact on the clinical well-being of these patients and clinicians often 
treat patients in order to relieve these symptoms. Still, there has been much 
debate as to whether chronic bronchitis is a specific phenotype that could be 
treated in order to slow down the progression of the disease. As early as 1950, 
‘The British Hypothesis’ proposed that smoking caused mucus hypersecretion 
and worsened lung defences, leading to chronic infection, obstruction and 
emphysema [35]. However, Fletcher et al were unable to show an association 
between chronic mucus hypersecretion and the progression of COPD [36]. 
As a consequence, chronic bronchitis has long been considered as a benign 
condition with harmless symptoms. 
Recent large epidemiological studies have found new evidence on the role of 
chronic bronchitis within COPD and thereby opinions are changing [37]. Inhaled 
noxious gases may damage the lung’s innate defence system in early disease. 
Figure 2. Symptoms, spirometric classification and future risk on exacerbations (modified 
 from GOLD [2])
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This includes reducing mucociliary clearance, producing an ineffective cough, 
disrupting the epithelial barrier, and initiating an acute inflammatory process 
in the lungs. In later stages there may be a shift from the innate to adaptive 
immune response [38]. The Copenhagen City Heart study showed that chronic 
mucus hypersecretion can be associated with accelerated decline in lung 
function in patients with more advanced disease [30]. At this stage the airways 
may become more colonised and infected which may provide a rationale 
for the link between chronic bronchitis and progression of the disease. The 
excess of sputum has been associated with the chronic inflammatory process 
that involves the epithelial lining of the airway lumen, bronchial glands and 
gland ducts of the central airways in patients with COPD. COPD patients with 
chronic bronchitis have increased numbers of neutrophils in the epithelium 
and more neutrophils, macrophages and CD8+ cells in their bronchial glands 
as compared to asymptomatic non-COPD subjects [39]. This suggests that 
inflammatory cells and their mediators provide a major drive for mucus 
hypersecretion and subsequent symptoms of chronic bronchitis [40].  Hence, 
chronic bronchitis may reflect a specific phenotype in COPD and deserves 
specific attention not only to improve symptoms, but also to influence the 
progression of the disease.
Frequent exacerbations
Acute exacerbations can have enormous impact on patients with COPD. As 
an example the following patient (own experience in daily practice): 
“A male patient of 65 years with moderate COPD who has increased coughing 
and sputum production for two weeks. His wife had ordered him to go see 
the general practitioner, but he wanted to wait and see whether his symptoms 
would wear off with time. During the weekend, he felt much worse. He now 
experiences dyspnea with just a little exertion. An unknown physician visits him 
at home. The general practitioner has limited information about the severity of 
the COPD and comorbidity of the patient and sends him to hospital where the 
patient subsequently stays for some days.” 
One can imagine the distress and major impact this experience brings to the 
patient and his family. In addition, patients with frequent exacerbations have 
an increased risk of death and a more rapid decline in lung function [28;41]. 
Particularly, patients with more advanced disease have more frequent and 
severe exacerbations. However, the ECLIPSE study showed that also patients 
with less severe airways obstruction can have frequent exacerbations, 
suggesting an independent susceptible phenotype [42]. Several studies have 
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reported prevention of exacerbation by treatment. A study with 233 patients 
with moderate COPD provided these patients with individualised action plans 
and ongoing support from a case manager. During 6 months of follow-up 
they showed that early detection and treatment of exacerbations may lead 
to accelerated recovery decreased impact of exacerbations on health status 
[43]. Treatment with inhaled corticosteroids with or without long-acting 
bronchodilators can reduce the frequency of exacerbations in patients with 
moderate to very severe COPD [44;45]. Interestingly, a recent study showed 
that daily azithromycin for one year, when added to usual treatment, can 
reduce the frequency of exacerbations in middle-aged patients with moderate 
to severe COPD [46]. However, significantly more patients using azithromycin 
reported hearing loss compared to placebo (25% vs 20%, P=0.04), and there 
was an increased prevalence of macrolide resistant colonisation of the airways, 
a drawback that has to be weighed against the beneficial effects. In conclusion, 
many studies have shown that patients with frequent exacerbations represent 
a specific phenotype in COPD, which has led for the GOLD guidelines to 
include the risk of future events such as exacerbations in the assessment of 
disease severity in order to guide therapy [2].
Accelerating decline in FEV1 
The progressive decline in lung function is an important characteristic of 
the disease. It is widely used as a composite objective measurement of the 
structural changes of the lung and describes severity of the lung. Current 
guidelines use FEV1 level as an indicator of diagnosis, assessment of severity 
and treatment. In healthy individuals the lung function declines with 25-
30 ml per year. In patients with COPD, this rate of decline is around 60 ml/
year. While symptoms vary enormously between patients, a progressive 
loss of lung function is observed in all patients with COPD. It has to be 
noted that FEV1 decline may be larger in early disease, and that the rate of 
decline differs amongst patients. It is noted that rapid decliners may reflect 
a specific phenotype where close monitoring is needed, since there is more 
to gain by adequate intervention. Still, not all patients experience a rapid 
progression of their disease [47;48]. Also, it is widely accepted that COPD is 
much more complex than being a disease based on the level or decline of 
FEV1 and many other components influence the course of the disease [49;50]. 
Airway hyperresponsiveness has been associated with a more rapid decline 
in FEV1, which may indicate a distinct phenotype [51]. However, it is not yet 
clear how these clinical and structural changes in COPD are associated 
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with the underlying inflammatory process in the airways. Novel approaches 
for addressing the complexity of COPD phenotypes are emerging, such as 
those based on a ‘systems medicine’ approach, in which composite biological 
phenotypes are integrated with clinical phenotypes by using a multi-scale 
‘systems medicine’ approach [52;53]. 
Pathogenesis
The smaller airways (2mm diameter) are the major site of obstruction in COPD 
[54]. A recent study examined the relationship between small airway obstruction 
and emphysema in COPD [55]. Multidetector Computed Tomography (CT) and 
microCT was used in 78 patients with varying degrees of airflow limitation. 
This was applied in sections of isolated lungs from 12 patients who underwent 
lung transplantation and controls (donor lungs). The number of small airways 
was reduced in mild disease and was even further reduced in more advanced 
disease. Interestingly, it was suggested that the narrowing and loss of terminal 
bronchioles preceded the onset of emphysematous destruction. This may 
explain the increased resistance in patients with COPD. However, results 
should be interpreted with caution because of the cross-sectional design of the 
study. The pathogenesis of COPD is characterised by a complex inflammatory 
reaction to inhaled noxious gases [56]. Cigarette smoke is an important risk 
factor in developing COPD. Smoking causes an inflammatory response in the 
lungs. Still, only 20% of smokers develop COPD and it is suggested that the 
inflammatory response is enhanced or abnormally regulated in susceptible 
patients. In patients with established COPD, airway inflammation in sputum, 
biopsies and bronchoalveolar lavage (BAL) persists even after cessation of 
smoking [57]. 
In addition, the number of macrophages and neutrophils is similar in bronchial 
biopsies from current and ex-smokers with COPD [58]. However, percentages 
of macrophages with anti-inflammatory characteristics are higher in BAL from 
ex-smokers than current smokers, suggesting that smoking cessation may 
lead to a more anti-inflammatory phenotype. The mechanisms explaining this 
are still poorly understood. Important pathological phenotypes include chronic 
bronchitis, emphysema and small airways disease. Chronic bronchitis is linked 
to the presence of mucus hypersecretion which may be due to the inflammatory 
response in the submucosal glands and surface epithelium. Emphysema is 
due to the destruction of alveolar walls. The destruction of the tissue can be 
the result of ‘insufficient tissue repair’ [59]. Ultimately this leads to enlargement 
of the airspaces. Small airways (also referred to as peripheral airways) can 
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also be affected in COPD and are characterised as having an internal diameter 
<2mm. Inflammation in the small airways includes accumulation of neutrophils, 
macrophages, mast cells, CD4+, CD8+ cells and B cells. Tissue injury can 
exceed the ability to repair due to ongoing inflammation, a direct effect of 
cigarette smoke or ‘exaggerated tissue repair’ [54;60]. Tissue remodelling in 
the small airways can than be responsible for thickening of the small airways 
and fibrosis. Consequent narrowing of the airway lumen may lead to airflow 
limitation. Excessive mucus production and plugging of the small airways 
contributes to airway obstruction.
However, many different inflammatory responses are linked to multiple 
pathways and it is far from easy to classify the pathological process into 
specific phenotypes [61]. The underlying mechanisms comprise a balance 
or imbalance of exaggerated airway inflammation, protease/antiprotease 
imbalance, oxidative stress, necrosis and activation of programmed cell 
death (apoptosis). The enhanced inflammatory cell numbers may be cleared 
by endogenous protective mechanisms, such as apoptosis and subsequent 
phagocytosis of the apoptotic cells. Alternatively, airway inflammation may be 
resolved by transepithelial migration [62]. Leucocytes then migrate through 
tissue components and across the epithelial cells into the airway lumen. Mucus 
hypersecretion and mucociliary clearance can eliminate the inflammatory 
cells subsequently. It can be speculated that impaired endogenous protective 
mechanisms play a role in the susceptibility for COPD.
Airway inflammation plays a key role in COPD. The inflammatory process 
affects the whole respiratory tract and there are different ways to assess the 
severity and nature of the inflammatory process. One may use airway wall 
tissue from bronchoscopies, resected lung tissue or autopsy studies. Other 
approaches include indirect evaluation of airway inflammation with induced 
sputum samples and BAL. Even peripheral blood seems to be suitable for 
inflammatory characterisation in COPD when using modern techniques such 
as proteomics [63]. C-reactive protein (CRP) is raised in COPD and even further 
during exacerbations [64]. Fibrinogen is also raised in COPD and may be a 
more promising biomarker, because it shows less variability among patients 
with COPD. Techniques such as bronchoscopy, can provide reliable results 
in airway wall biopsies, but are invasive and provide large inconvenience 
for patients. Non-invasive techniques are therefore imperative and include 
exhaled breath volatile organic compounds, exhaled breath condensate and 
exhaled nitric oxide. Exhaled molecular components are associated with a 
specific inflammatory profile in COPD, suggesting that breath analysis can be 
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used as a phenotypic marker [65]. 
Inflammation and immunity 
In COPD there is a chronic amplification of the normal inflammatory response 
of the lungs to noxious particles and gases (especially cigarette smoke) in 
susceptible patients [66] (Figure 3).
Figure 3. Innate and adaptive immunity
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It is mainly characterised by neutrophils, macrophages and CD8+ T lymphocytes 
[67]. In addition, CD4+ T lymphocytes, mast cells and eosinophils may play a 
role. In response to injury of the lungs by infection or cigarette smoke, the instant 
non-specific innate immune system is triggered. Neutrophils are recruited to 
the airways by chemotactic factors such as interleukin (IL)-8 and leukotriene B4 
(LTB4). The number of neutrophils is increased in induced sputum and BAL of 
COPD [68]. They may contribute to wound healing, but can also cause tissue 
injury. Activated neutrophils may cause mucous hypersecretion by the release 
of serine proteases such as elastase and matrix metalloproteinases (MMPs). 
In addition, production of neutrophil elastase contributes to the destruction 
of lung tissue leading to emphysema. Macrophage numbers are increased in 
the airway wall, lung parenchyma, BAL and sputum of patients with COPD 
[60]. They release inflammatory mediators such as tumor necrosis factor 
(TNF)-α, IL-8 and LTB4, and may contribute to emphysema by e.g. release of 
MMP12. Eosinophils and mast cells are known to be important in asthma, but 
may also play a role in COPD. Some studies show an increase in eosinophils 
in COPD which may point to a specific phenotype [69;70]. In patients with 
moderate to severe COPD clinical exacerbation clusters can be determined. 
Especially bacteria- and sputum eosinophil-associated exacerbations can 
be identified using biomarker profiles which may be important for directing 
therapy [71]. Interestingly, a recent study showed that COPD patients with 
higher circulating eosinophils maintained their level of FEV1 during a follow-
up of 5 years. In a study from our centre comparing 16 patients with COPD 
with 15 patients without COPD inflammatory infiltrate was examined from 
tissue that was removed for lung cancer. The results showed that patients with 
COPD exhibited more mast cells in the epithelium, but not in the remainder of 
the airway wall [72]. In a recent study with endobronchial airway biopsies mast 
cells were more prominent in the lamina propria and the reticular basement 
membrane in COPD than in patients without COPD [73]. Epithelial cells may 
contribute to the inflammatory process by secreting a variety of inflammatory 
mediators such as TNF-α, transforming growth factor (TGF-β) and IL-8.
Dendritic cells link the innate immune system to the adaptive immune system 
which can recognize and remember specific pathogens in order to generate 
adaptive immunity. Adaptive immunity includes T lymphocytes (CD4+, CD8+) 
and B Lymphocytes. CD8+ T lymphocytes are increased in the large [69;74] 
and small [75] airways of subjects with COPD. An important function of CD8+ 
cells is to attack viruses by causing cell death of infected cells. However, T 
lymphocytes can also cause tissue destruction by direct cytolytic activity 
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by cytotoxic mediators such as granzyme or perforins. The specific role of 
CD4+ cells in COPD is less clear. CD4+ lymphocytes release pro-inflammatory 
cytokines such as TNF-α, granulocyte-macrophage colony-stimulating factor 
(GM-CSF), IFN-γ, IL-2 (Th1), and IL-4, IL-13 and IL-5. CD4+ cells are T helper 
cells and may provide help for B cell activation and support CD8+ cells by 
maintaining their memory and ensuring their survival. In the GLUCOLD study, 
we found that the number of B cells in bronchial biopsies of central airways is 
higher in COPD than in patients without COPD [76]. In more advanced COPD 
the number of B cells follicles increased in the small airways in resected lung 
tissue [38]. However, the role of B cells is not yet clear. The accumulation of 
B cells may be due to stimulation by viruses or bacteria, and may serve a 
protective function to prevent infection. However, B cells may react to specific 
auto-antigens with autoantibodies against e.g. epithelial cells and elastin. This 
suggests that the increase in B cells may also point into the direction of an 
autoimmune process that may be involved in the pathogenesis of COPD [77], 
or it may be an epiphenomenon resulting from the extensive tissue injury. 
Tissue repair and remodelling
Remodelling of the airways is associated with narrowing of the airway lumen, 
increased thickness of the airway wall and remodelling of the parenchyma 
[60]. An imbalance between matrix synthesis and degradation during the 
repair process may cause emphysema or fibrosis of the small airways. This 
may contribute to increased airway responsiveness, fixed airway obstruction 
and accelerated decline of lung function [78]. However, remodelling may also 
be protective. The increased thickness may be beneficial in decreasing the 
effect of the inflammatory response to specific antigens. In the lungs matrix 
proteins and antiproteinases maintain a balance in order to preserve the 
elasticity of the lung [79]. The increased airflow resistance in COPD is partly 
caused by early airway closure due to reduced elastic recoil. Reduction of 
decorin in the peribronchial area of severe COPD may contribute to loosening 
of collagen structures and alveolar attachments [80]. Elastic fibers containing 
elastin, provide physical recoil in de alveolar region of the lung and contribute 
to normal physiological function. Neutrophil elastase is a strong protease that 
can degrade mature elastin which leads to development of emphysema. In 
recent years many other proteases, such as serine and metalloproteinases, 
were shown to contribute to tissue injury during inflammatory processes. 
Various proteinase inhibitors restrict the activity of these proteinases, including 
the serine proteinase inhibitors alpha-1-antitrypsin and secretory leucocyte 
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protease inhibitor (SLPI), and the metalloproteinase inhibitor family of TIMPs.
Biomarkers 
One of the most important challenges in current research is the use of 
biomarkers. A biomarker is any molecule or material (e.g. cells or tissue) 
that reflect the disease progress. Biomarkers are increasingly important in 
identifying specific phenotypes and act as surrogate outcomes in clinical trials. 
One example of a biomarker that clearly defines a subset of patients with 
COPD is the level of serum α1-antitrypsin, i.e. a specific subset of COPD with 
α1-antitrypsin deficiency. Many biomarkers are currently under investigation 
[81]. Studies such as the ECLIPSE study use proteomics and metabolomics 
techniques to examine for example blood samples, induced sputum, 
exhaled breath condensate, blood and urine [82]. A recent study showed the 
relationship between exhaled breath components and inflammatory cell counts 
in sputum in 12 patients with mild COPD and 16 patients with moderate COPD 
[65]. Exhaled markers were significantly associated with sputum neutrophils 
and eosinophils, which may offer a clinically relevant, non-invasive marker 
for patients with early COPD. It is likely that specific or composite molecular 
and cellular patterns will eventually be used as biomarkers for the phenotype, 
severity and progression of COPD [53]. 
Treatment
Smoking cessation is the most effective way to slow down the progression of 
the disease [83]. Therapy with tiotropium has been shown to improve health 
status exacerbations and mortality in patients with COPD in the Understanding 
Potential Long-Term Impacts on Function with Tiotropium (UPLIFT) study [84; 
85]. Interestingly it reduced decline in FEV1 in a subgroup of patients  with 
earlier disease as based on GOLD stages [86].
Inhaled corticosteroids (ICS) are the mainstay of anti-inflammatory treatment 
in COPD and are prescribed to many patients. Treatment with ICS in patients 
with COPD results in short-term improvement in postbronchodilator FEV1 
[44;87;88]. Earlier large studies have not demonstrated that long-term ICS can 
exert a more permanent, disease modifying effect, as based on a decline in 
lung function [44;87;89;90]. However, it cannot  be excluded that any effect 
on FEV1 decline has been underestimated due to drop-out of patients with the 
most rapid FEV1 decline [91] and/or the selection of COPD patients with prior 
usage of ICS [44]. Disease modification by ICS is plausible since long-term 
therapy improves airway hyperresponsiveness [90], which in itself constitutes a 
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risk factor for accelerated FEV1 decline in COPD [51;92]. In a post-hoc analysis 
of the Towards a Revolution in COPD Health (TORCH) study the effects were 
studied of fluticasone 500 mcg plus salmeterol, either component alone or 
placebo. The rate of decline was reduced for all active treatments versus 
placebo, but similar among ICS-containing treatment arms and salmeterol 
alone [93]. 
At present, meta-analyses are still inconclusive regarding the benefits of long-
term ICS on FEV1 decline in patients with COPD [94-96], as well regarding any 
sustained beneficial effects on patient oriented outcomes, such as dyspnea 
[90] and health status [44]. Recent studies provide indirect support for the 
beneficial effects of ICS on FEV1 decline in COPD showing that discontinuation 
resulted in a decrease in FEV1 during one year follow-up, associated with 
worsening of dyspnea and an increase in exacerbation frequency [97-99]. 
However, it is as yet unclear whether longer duration of cessation of inhaled 
corticosteroid therapy leads to renewed accelerated decline in FEV1 either or 
not associated with a relapse in airway hyperresponsiveness.
At present, long-acting ß2-agonists (LABA) are prescribed to reduce dyspnea in 
COPD [2]. Their efficacy is presumed to run via reduction in airways obstruction 
and dynamic lung hyperinflation, although additional benefits on inflammatory 
and epithelial cells cannot be excluded [100]. Notably, combination therapy of 
LABA with ICS has been shown to provide additional improvements in health 
status in patients with moderate to severe COPD [45;101]. Consequently, the 
latest international guidelines recommend combination therapy for patients 
with FEV1<50% and frequent exacerbations [2]. However, the vast majority of 
patients throughout the world has less severe COPD, and there is no evidence 
yet to support long-term combination therapy in patients with less advanced 
COPD. 
Clinical and anti-inflammatory benefits of ICS in asthma are well established. 
In asthma CD4+ T cells, eosinophils and mast cells are effectively reduced by 
ICS, which is accompanied with subjective and objective clinical improvement. 
The anti-inflammatory effects of ICS in COPD are less clear. The pattern of 
inflammation in COPD is different, but may be mediated, at least partially, 
by the anti-inflammatory efficacy of ICS. Short-term (2-3 months) treatment 
with ICS with or without LABA has been shown to differentially influence the 
numbers of macrophages, neutrophils and CD8+ T cells in bronchial biopsies 
of patients with moderate to severe COPD [102-105]. A meta-analysis using 
data from several short-term studies showed overall reductions in sputum 
neutrophils, lymphocytes and epithelial cell counts [106]. Interestingly, studies 
24
Chapter 1  •  General introduction and aims of the studies
with a duration < 6 weeks had predominantly negative results, were studies 
with a duration > 6 weeks were mostly positive. So far, long-term anti-
inflammatory effects by these interventions have not been reported.
Aims of the present study
This thesis describes studies directed at detailed phenotyping of COPD and 
effects of inhaled corticosteroid therapy and long-acting ß2-agonist. The 
present studies include investigations on health status, the presence of chronic 
bronchitis, long-term effects of inhaled corticosteroid therapy and long-acting 
ß2-agonist and prediction of effects of ICS in patients with moderate to severe 
COPD. This thesis is based on analyses from the Groningen Leiden Universities 
Corticosteroids in Obstructive Lung Disease (GLUCOLD) study.
The aims of the current thesis were to answer the following research questions:
1. To what extent are clinical symptoms and airway inflammation distinctive 
components of COPD? 
2. Does airway inflammation contribute to impaired health status in COPD?
3. Does chronic bronchitis reflect an inflammatory sub-phenotype among 
COPD?
4. Does maintenance therapy with ICS have anti-inflammatory and clinical 
effects in COPD?
5. Can patients with specific phenotypes of COPD benefit more from ICS?
6. Does maintenance therapy with ICS have effect on day-to-day health 
status and peak-flow?
All studies were performed as part of the GLUCOLD project. The study was 
an investigator-initiated trial (registered as NCT00158847). The protocol was 
written by the GLUCOLD study group, and all procedures and analyses were 
carried out by the investigators only. The GLUCOLD study group applied for, 
and received grants from: the Netherlands Organization for Scientific Research 
(NWO) in a collaborative program with the Netherlands Asthma Foundation 
(grant 3.4.93.96.3), GlaxoSmithKline (The Netherlands), Stichting Astma 
Bestrijding (SAB), and the University Medical Center Groningen (UMCG) and 
the Leiden University Medical Center (LUMC). 
The overall aims of the GLUCOLD study were to examine whether i) Long-
term maintenance therapy with ICS with or without a LABA provides anti-
inflammatory effects (primary outcome) in the airways of COPD patients; 
ii). Such effects are associated with clinical improvements; and iii) ICS 
discontinuation induces a flare-up of inflammation and clinical deterioration. 
The GLUCOLD study was a double blind, randomised, controlled trial in 
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patients with COPD comparing the clinical, functional and pathological 
benefits of:
- Long-term maintenance therapy (2,5 year) with ICS 
- Addition of long-term LABA to ICS 
- Discontinuation of inhaled fluticasone after 6 months 
- Placebo
Outline of the GLUCOLD study
The GLUCOLD study was investigator-initiated with a double-blind, parallel, 
four-arm, placebo-controlled, randomised design. Patients in this study 
were aged 45-75 years, they were all current or ex-smokers, with at least 10 
pack-years of smoking (Table 1). The lung function levels were compatible 
with the GOLD guidelines stages II and III [2]. They were not allowed to have 
used ICS within 6 months prior to randomisation. Patients with asthma were 
carefully excluded by doctor’s diagnosis and selfreported history, symptoms, 
treatment, or diagnosis of asthma. Almost all patients were recruited from 
family practices. Recruitment and follow-up was between 2000 and 2007. 
Patients were randomly assigned to (Figure 4):
1) short-term fluticasone propionate 500 μg twice daily, followed by placebo 
2) long-term fluticasone 500 μg twice daily
3) combination of long-term fluticasone and salmeterol 500/50 μg twice daily
4) long-term placebo 
Figure 4. Study design 
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Table 1. In- and exclusion criteria
Inclusion criteria
1. Age: 45-75 years
2. > 10 packyears of smoking
3. At least one of the following symptoms: chronic cough, chronic sputum production, 
frequent exacerbations, or dyspnea on exertion
4. No course of oral corticosteroids during last 3 months, no maintenance treatment 
with inhaled or oral steroids during last 6 months
5. Postbronchodilator value (after 400 μg of inhaled salbutamol) of FEV1 below the 
90% confidence interval (90% CI) of the predicted FEV1, and postbronchodilator 
FEV1/IVC ratio below the 90% CI of the predicted FEV1/IVC ratio [107]
6. Postbronchodilator FEV1 > 1.3 liter and > 20% of predicted value.
7. Written informed consent
Exclusion criteria
1. Prior or concomitant history of asthma
2. Alpha-1 antitrypsin deficiency (SZ, ZZ, zero phenotype)
3. Other active lung disease except for mild bronchiectasis; bronchiectasis should not 
be the main reason for chronic cough and/or sputum production with additional 
mild obstruction.
4. Contra-indications for elective bronchoscopy, such as O2 saturation <90%, 
abnormal coagulability, anti-coagulant therapy which cannot be temporarily 
withheld for performance of bronchoscopy, history of pneumothorax, uncontrolled 
angina pectoris.
5. Other diseases likely to interfere with the purpose of the study.
6. Inability to keep diary and to understand written and oral instructions in Dutch.
The predefined primary outcome was inflammatory cell counts in bronchial 
biopsies (Figure 5). Measurements of symptoms, health status, self-reported 
smoking status, medication compliance, and spirometry were made every 3 
months. Bronchoscopy, sputum induction, and methacholine challenge were 
performed at 0, 6 and 30 months.
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Every 3 months: Questionnaires, SGRQ, CCQ, Postbronchodilator spirometry, 
Compliance with medication, 2 weeks diary (CCQ and PEF)
 Baseline, 6 and 30 months:
• Day 1: Venapunction: Hb, leucocytes, IgE, α1AT phenotype; Reversibility of 
FEV1; N2 sb test;  ECG
• Day 2: Chest X-ray; Questionnaires: Rand36, QOL-RIQ, EuroQOL, TTO, 
VAS; Body box: Raw, sGaw, TLC, RV; CO-diffusion capacity; PC20 Mch
• Day 3: eNO; 6 MWD; Sputum induction
• Day 4: Bronchoscopy
Figure 5. Measurements 
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Outline of this thesis 
Airway symptoms and inflammation 
Chapter 2. Exploration of clinical symptoms and airway inflammation by factor 
analysis. 
Chapter 3. Is health status in COPD associated with inflammation? In this 
chapter the association between health status and inflammatory cell counts in 
induced sputum and bronchial biopsies are investigated.
Chapter 4. Is there a phenotype of chronic bronchitis? Are COPD patients 
with chronic bronchitis characterised by a specific inflammatory cell profile in 
bronchial biopsies and sputum? 
Effects of long-term inhaled corticosteroids and long-acting ß2-agonists
Chapter 5. Do patients benefit from short- versus long-term therapy with 
inhaled corticosteroids and long-acting ß2-agonists? The effects of 6- and 
30-month treatment were assessed on health status, lung function and airways 
inflammation in induced sputum and bronchial biopsies.
Chapter 6. Which patients benefit the most from long-term therapy with ICS 
and long-acting ß2-agonists? Long-term treatment with ICS was compared 
with placebo.
Chapter 7. Is there an effect of long-term therapy with inhaled corticosteroids 
and long-acting ß2-agonists on day-to-day health status and peak expiratory 
flow?
Conclusions, general discussion and future implications
Chapter 8. A summary of the main results and conclusions of the different 
studies is presented. In addition, implications of these findings for clinical 
practice and future directions for research are discussed.  
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Abstract
Chronic obstructive pulmonary disease (COPD) is defined by progressive, 
irreversible airflow limitation and an inflammatory response of the lungs, usually 
to cigarette smoke. However, COPD is a heterogeneous disease in terms of 
clinical, physiological, and pathological presentation. We aimed to evaluate 
whether airflow limitation, airway responsiveness, and airway inflammation 
are separate entities underlying the pathophysiology of COPD by using factor 
analysis. A total of 114 patients (99 males/15 females, age 62 ± 8 years, 42 
pack-years smoking, no inhaled or oral steroids >6 months) with irreversible 
airflow limitation (postbronchodilator FEV₁ 63 ± 9% predicted, FEV₁/
inspiratory vital capacity [IVC] 48 ± 9%) and symptoms of chronic bronchitis 
or dyspnea were studied in a cross-sectional design. Postbronchodilator 
FEV₁ and FEV₁/IVC, reversibility to inhaled β2-agonists, diffusing capacity, 
provocative concentration of methacholine required to produce a 20% 
drop in FEV₁, total serum IgE, exhaled nitric oxide, and induced sputum cell 
counts (% eosinophils, % neutrophils) were collected. Factor analysis yielded 
4 separate factors that accounted for 63.6% of the total variance. Factor 1 
was comprised of FEV₁, FEV₁/IVC, and residual volume/total lung capacity. 
Factor 2 included reversibility, IgE, provocative concentration of methacholine 
required to produce a 20% drop in FEV₁, and diffusing capacity. Factor 3 
contained exhaled nitric oxide and factor 4 included sputum % neutrophils 
and % eosinophils. We conclude that airflow limitation, airway inflammation, 
and features commonly associated with asthma are separate and largely 
independent factors in the pathophysiology of COPD.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a disease characterized by 
progressive airflow limitation, which is not fully reversible [1]. However, COPD 
has been recognized as a heterogeneous disorder [2], with components of 
chronic bronchitis, small airways disease, emphysema, and in some patients 
perhaps, features of asthma [3]. This is accompanied by pathophysiological 
characteristics, such as partial reversibility to bronchodilators, air trapping, 
impaired diffusing capacity, and airway hyperresponsiveness [4]. The 
presence and contribution of these features to the severity of COPD varies 
between patients and may reflect distinct pathophysiological mechanisms in 
development, clinical presentation, and course of the disease. It is increasingly 
recognized that such disease heterogeneity provides opportunities for targeted 
interventions [3;5].
Airway inflammation is thought to play an important role in the pathogenesis 
of COPD [6]. The cellular inflammatory response is characterized by an 
increase in neutrophils, macrophages, and CD8-positive T lymphocytes 
in small and large airways as well as in lung parenchyma [7]. The major cell 
type in induced sputum is the neutrophil, the quantity of which is associated 
with the severity of airflow limitation [8;9]. Although induced sputum does 
not cover all the inflammatory and structural changes of the lungs in patients 
with COPD, it does represent a noninvasive marker of inflammation that is 
potentially useful for disease monitoring. Sputum eosinophilia has also been 
observed in patients with stable COPD, but its relationship to airflow limitation 
is controversial [8;10;11]. It has been argued that sputum eosinophilia is 
related to concomitant features of asthma [12]. This link would indicate that 
the pathophysiological entities underlying the clinical phenotypes in COPD 
may be diverse and are still largely unknown.
The aim of this study was to objectively specify the heterogeneity of COPD 
by categorizing various functional and inflammatory features of COPD into 
separate, complementary domains without a priori assumptions. Factor 
analysis allows reducing multiple disease characteristics to a few independent 
factors, in which each factor groups associated parameters. Because this is 
essentially accomplished free of predetermined hypothesis on any interrelated 
parameters, this technique can be considered as a hypothesis-generating 
analysis.
Factor analysis has been applied previously in studies of patients with asthma 
[13-16] and COPD [17]. In patients with asthma, it has demonstrated that lung 
function, baseline airway hyperresponsiveness, and eosinophilic inflammation 
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in sputum are nonoverlapping dimensions [13], suggesting that evaluation of 
patients with asthma should include measurement of all these parameters. 
In COPD, factor analysis has been applied to study the relationship between 
dyspnea ratings, exercise capacity, lung function and hyperinflation [17-23]. 
However, these studies did not include inflammatory markers and were unable 
to study the interrelationships between airway inflammation and the functional 
features of COPD. Therefore, in this study, we performed factor analysis, 
including lung function indices and markers of inflammation in induced 
sputum and exhaled air, in 114 patients with clinically stable COPD. Some 




Hundred fourteen patients (15 women) aged between 45 and 75 years with 
COPD, participating in a multi-center trial (Groningen Leiden Universities and 
Corticosteroids in Obstructive Lung Disease; GLUCOLD study), were included 
in this study. Patients were recruited from our outpatient clinics, as well as 
by advertisements in local newspapers, and by screening lung functions 
from patients in general practice in and around Leiden and Groningen, The 
Netherlands. All patients were current or ex-smokers and had a history of 
at least 10 pack years of smoking. They had irreversible airflow limitation 
(postbronchodilator FEV₁ and FEV₁/IVC < 90% confidence interval (CI) of 
the predicted value [25], FEV₁ ≥ 1.3 liter and > 20% of the predicted value) 
and at least one of the following symptoms: chronic cough, chronic sputum 
production, or dyspnea on exertion. In choosing the 90% CI of predicted 
values as selection criterion, as opposed to percentage of predicted values 
per se, we followed the recommendation by the European Respiratory Society 
[25]. Patients with a prior or concomitant history of asthma, alpha-1 antitrypsin 
deficiency (SZ, ZZ, zero phenotype), or other active lung disease except for 
mild bronchiectasis were not permitted to the study. The patients did not use 
a course of oral or inhaled steroids during the last three months, and did not 
have maintenance treatment with inhaled or oral steroids during the last six 
months. Maintenance drug therapy of non-selective beta-antagonists, long-
acting bronchodilators, methylxanthines, N-acetylcysteine or NSAID’s was 
not permitted. Patients were allowed to use short acting β2-agonists and 
ipratropium bromide as rescue medication. The patients were in clinically 
41
stable condition and had no symptoms of respiratory tract infection for at least 
two weeks prior to the study. The Medical Ethics Committees of each center 
approved the study and all patients gave their written informed consent.
Study Design
The present study had a cross-sectional design, consisting of baseline 
measurements of the GLUCOLD Study. At visit 1 spirometry was performed 
before and after inhalation of salbutamol and blood was collected for 
measurement of total IgE. Body plethysmography, CO-diffusing capacity, and 
bronchial responsiveness to methacholine were obtained at a second visit. 
Finally, at the third visit exhaled NO was measured and hypertonic saline-
induced sputum was collected. Inhaled bronchodilators were withheld for at 
least 8 hrs prior to visit day 1 and 2. All visits were performed within six weeks.
Lung Function
Spirometry was performed according to international guidelines [26]. A daily-
calibrated pneumotachograph (Masterscreen Pneumo or Masterscreen IOS; 
Jaeger, Würzburg, Germany) was used throughout the study. First, 3 slow 
inspiratory vital capacity maneuvers (IVC, largest value used) were carried out. 
Second, maximally 8 forced expiratory vital capacity (FVC) maneuvers were 
performed to obtain at least 3 technically satisfactory expiratory flow-volume 
curves from which the forced expiratory volume in 1 second (FEV₁) and FVC 
did not deviate > 5% or 100 ml from the largest FEV₁ and FVC. From these 
curves, we used values of the curve with the largest sum of FEV₁ and FVC [26].
Reversibility of airflow limitation (ΔFEV₁) was measured 15 min after 
administration of 400 μg salbutamol per metered dose-inhaler connected to a 
spacer [27]. The response was expressed as change in FEV₁ as percentage of 
predicted value [27].
Total lung capacity (TLC) and residual volume (RV) were measured using a 
constant volume body plethysmograph (Masterscreen body or Masterlab 
body; Jaeger, Würzburg, Germany), using panting at 0.5 Hz [25].
The diffusing capacity (transfer factor) for carbon monoxide (TLCO) and 
TLCO per liter alveolar volume (KCO) were measured using the single breath 
holding method with a rolling seal closed system (Masterscreen MS-CS-FRC, 
Masterlab transfer or Compactlab transfer; Jaeger, Würzburg, Germany) [28]. 
Reference values for all lung function measurements were obtained from 
Quanjer et al [25].
Methacholine challenge tests were performed according to the tidal breathing 
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method [29], using serial doubling concentrations methacholine-bromide 
(0.038 to 39.2 mg/ml) in saline. Methacholine was aerosolized (DeVilbiss 646, 
Somerset, PA) and inhaled by the 2-min tidal breathing method at 5-minute 
intervals until FEV₁ dropped by ≥ 20% (lowest of two FEV₁ values; at 30 and 
90 seconds) from baseline. The response was expressed as the provocative 
concentration causing 20% fall in FEV₁ (PC20).
Sputum induction and processing
Sputum was induced and processed according to a validated technique [30], 
with some modifications. Prior to sputum induction, 200 μg salbutamol was 
administered and baseline FEV₁ was recorded. Hypertonic sodium chloride 
aerosols (4.5 w/v %) were generated by a DeVilbiss Ultraneb 2000 ultrasonic 
nebulizer with a calibrated particle size (MMAD 4.5 μm) at maximal output (2.5 
ml/min). The aerosols were inhaled via the mouth through a two-way valve 
(No. 2700; Hans-Rudolph, Kansas City, MO, USA), with the nose clipped. 
Subsequently, the patients inhaled hypertonic saline aerosols during 3 periods 
of 5 min and sputum was expectorated after each inhalation. Salbutamol was 
administered when FEV₁ dropped by > 10% from post-salbutamol baseline 
value and the procedure was interrupted when FEV₁ dropped by > 20%.
Whole sputum samples were processed. The sample was then mixed with an 
equal volume of dithiothreitol 0.1% w/v (Sputolysin, Calbiochem, USA) and 
placed in a shaking water bath at 37ºC for 15 min. Then sputum was filtered 
through a nylon gauze (pore-size approximately 48 μm) and centrifuged 
(450 x g) for 10 minutes at 20oC. The cell pellet was then resuspended in 
phosphate-buffered saline (PBS) containing 1 % (w/v) human serum albumin 
(HSA), pH 7.4. Cell viability and total cell counts were performed by Trypan 
blue exclusion using a hemacytometer. Subsequently, cytocentrifuge slides 
were prepared (450 rpm, 6 minutes, 100 μl/slide, Cytospin 3, Shandon, Life 
Sciences International, Veldhoven, NL) and differential cell counts were 
performed on May-Grünwald-Giemsa-stained cytospins by a qualified 
technician. Differential leucocyte and cylindric epithelial cell counts were 
expressed as a percentage of nucleated cells excluding squamous cells. A 
sputum sample was considered adequate when the percentage squamous 
cells was less than 80% [30].
Exhaled nitric oxide
Exhaled NO (eNO) levels were determined according to a standardized 
procedure [31] with some modifications, using a chemiluminescence analyzer 
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(Sievers NOA 270B or ECO physics CLD 700 AL). Patients were asked not 
to smoke for at least 1 hour prior to the test. A slow vital expiratory capacity 
maneuver with a constant expiratory flow of 100 mL/sec against an expiratory 
resistance of 5 cm H2O was performed. Expiratory NO concentration was 
sampled continuously from the center of the mouthpiece and the average 
concentration was determined during a period of 10 seconds. Three 
reproducible successive recordings were made at 30-s intervals, from which 
the mean values of exhaled NO were used in the analysis.
Peripheral blood measurements
Total serum IgE concentrations were measured by fluoroimmunoassay (FEIA) 
using the Pharmacia CAP system (Pharmacia Diagnostics, Uppsula, Sweden).
Statistical analysis
Mean values and SD were computed. When appropriate variables were 
logarithmically transformed before statistical analysis and presented as 
median with interquartile range.
Exploratory factor analysis included the following variables: postbronchodilator 
FEV₁ (%pred), postbronchodilator FEV₁/IVC (%), ΔFEV₁ (%pred), KCO 
(%pred), PC20 (mg/ml), RV/TLC (%), eNO (ppb), sputum % neutrophils and 
% eosinophils and total serum IgE (IU/ml). The possibility to perform factor 
analysis was tested by Bartlett’s test of sphericity. The Kaiser-Meyer-Olkin 
(KMO), a measure of sampling adequacy based on correlation and partial 
correlation, was also evaluated. A high KMO (maximum 1.0) indicates that 
data are likely to factor well since correlations between pairs of variables 
can be explained by the other variables (low partial correlation coefficients). 
Correlation coefficients were analyzed by principal component factor analysis 
and subsequent rotation according to the standard Varimax criterion [32]. 
In this type of analysis, the correlation between parameters is attributed to 
their common dependence on independent entities called “factors”. The 
parameters are separated into independent subgroups, and the correlation of 
parameters within subgroups is due to their common factor. The coefficients 
that link parameters to factors are called “factor loadings”, and are the 
correlation coefficient between parameters and factors. The number of factors 
is chosen to be as small as possible but large enough to account for most of 
the variation within the data. The number of factors was determined by the 
number of eigenvalues, an index of the proportion of variance explained by 
successive factors, whose magnitude was ≥ 1 on the Scree plot. 
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However, also the percentage of total variance explained by the factors was 
taken into account. The Varimax rotation procedure aims to increase the 
interpretability of the factors by rotation to a simple structure with optimal 
loadings, such that they are high or low. Ideally, each variable would have a 
high loading on one factor, whereas its loadings on other factors would be 
low. In the Varimax rotation this is technically achieved by maximalizing the 
variation within a factor. Finally, we conducted three additional factor analyses 
to determine the stability of the factor structures, and thus the robustness 
of our findings. First, we excluded outliers from the data set, defined as 
data outside the range of mean ± 3 x SD, and repeated the factor analysis. 
Next, the analysis was repeated with number of neutrophils and eosinophils 
per ml sputum, instead of % neutrophils and eosinophils. Since smoking is 
the main risk factor for development of COPD, an additional factor analysis 
was performed in which the number of pack years was added. Univariate 
correlations were evaluated using Pearson correlation coefficient. All analyses 




Patient characteristics of the 114 participants are presented in Table 1. The 
mean (SD) postbronchodilator FEV1 was 63.0 (8.8) %pred, with a range from 
40.8 to 77.7 %pred. This result indicates that all patients were classified as 
having moderate to severe COPD according to Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria (GOLD stage II and III) [1]. The 
patients were heavy smokers with a median of 41.8 pack-years and most of 
them were current smokers (63.2%).
Definition and abbreviations: ΔFEV1 = change in FEV1 as percentage of predicted (reversibility to salbutamol); eNO 
= exhaled nitric oxide; IQR = interquartile range (25th and 75th percentile”); IVC = inspiratory vital capacity; KCO = dif-
fusing capacity for carbon monoxide per liter alveolar volume; %pred = percentage of predicted; PC20 = provocative 
concentration of methacholine causing a 20% fall in FEV1; RV = residual volume, TLC = total lung capacity. *Median 
(IQR). †Geometric mean ± doubling dose.
Table 1. Patient characteristics
n Mean (SD or IQR)
Clinical characteristics
   Sex, male/female 114 99 / 15
   Age, yr 114 62 (8)
   Smoking history, pack-years * 114 41.8 (31.2-54.8)
   Current smoker, yes/no, n 114 72 / 42
   IgE, IU/ml* 113 40 (11.5-125)
Lung Function
   Post FEV1, %pred 114 63.0 (8.8)
   Post FEV1/IVC, % 114 48.2 (8.5)
   ΔFEV1, %pred 113 6.9 (4.9)
   KCO, %pred 112 75.9 (25.5)
   PC20, mg/ml 
† 110 0.60 (2.76)
   RV/TLC, % 113 48.5 (8.8)
Airway inflammation
   eNO, ppm 92 13.1 (12.7)
   Sputum eosinophils, % * 106 1.1 (0.3-2.2)
   Sputum neutrophils, % 106 69.4 (16.0)
   Sputum eosinophils, n (x 104/ml) * 106 1.4 (0.4-4.5)
   Sputum neutrophils, n (x 104/ml) * 106 102 (47-229)
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Factor analysis
Bartlett’s test of sphericity indicated a correlation between the presently used 
variables because the correlation matrix was statistically different from an 
identity matrix (approximate χ2 = 165.864, degrees of freedom = 45, p<0.001). 
The Kaiser-Meyer-Olkin value was 0.594. Factor analysis yielded 3 separate 
factors, explaining only 53.7% of the total variance in the data set when the 
eigenvalue 1 criterion was applied. Therefore, an additional factor analysis was 
performed with the same data in which 4 factors were selected. This resulted 
in an increase of total explained variance to 63.6%.
The correlations with the original variables obtained for each Varimax-rotated 
factor (called factor loadings) and the eigenvalues are displayed in Table 2. 
FEV₁, FEV₁/IVC, and RV/TLC loaded significantly on factor 1. Factor 2 included 
ΔFEV₁, total IgE, PC20, and KCO. eNO loaded on factor 3, whereas sputum % 
neutrophils and eosinophils loaded on factor 4. Interestingly, KCO contributed 
also to factor 1, and % neutrophils contributed also to factor 3.
Additional Factor Analyses
Factor analysis without outliers in the data set resulted in a similar four-factor 
structure as the original one, accounting for 63.4% of the total variance, with 
Definition and abbreviations: ΔFEV1 = change in FEV1 as percentage of predicted (reversibility to salbutamol); eNO = 
exhaled nitric oxide; IVC = inspiratory vital capacity; KCO = diffusing capacity for carbon monoxide per liter alveolar 
volume; %pred = percentage of predicted; PC20 = provocative concentration of methacholine causing a 20% fall 
in FEV1; RV = residual volume, TLC = total lung capacity. Bold values represent the highest loadings of a variable.
Table 2. Varimax Rotated Factor-loading Matrix from Factor Analysis
Factor 1 Factor 2 Factor 3 Factor 4
Postbr. FEV1, %pred 0.89 -0.16 -0.09 -0.07
Postbr. FEV1/IVC, % 0.82 0.04 -0.23 0.22
RV/TLC, % -0.59 -0.36 -0.03 0.15
ΔFEV1, %pred -0.06 -0.72 0.08 0.11
IgE, IU/ml -0.09 0.61 0.10 -0.07
PC20, mg/ml 0.36 0.51 -0.35 0.14
KCO, %pred 0.44 0.49 0.25 0.31
eNO, ppb -0.09 0.10 0.89 -0.11
Sputum eosinophils, % -0.09 0.02 0.19 -0.84
Sputum neutrophils, % -0.18 -0.25 0.47 0.54
Eigenvalue 2.67 1.50 1.20 0.99
Total variance explained, % 26.7 15.0 12.0 9.9
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the exception that % neutrophils loaded on factor 3 with eNO and not on 
factor 4.
Factor analysis with number of neutrophils and eosinophils per ml sputum, 
instead of % neutrophils and eosinophils, did not change the contents of 
the factors essentially. Again four factors, accounting for 66.0% of the total 
variance, were found using the eigenvalue 1 criterion. Factor 1 was the 
same as in the original analysis. Factor 2 included numbers of neutrophils 
and eosinophils, both with a positive factor loading. Factor 3 contained the 
variables that originally loaded on factor 2: ΔFEV₁, total IgE, and PC20. Finally, 
factor 4 included eNO and KCO.
Factor analysis with inclusion of number of pack-years as an additional 
variable revealed four factors explaining 59.1% of total variance, according 
to the eigenvalue 1 criterion. All factors were similar to the original analysis 
described previously, with the exception that KCO and PC20 switched from 
factor 2 to factor 1. Number of pack-years smoked loaded on factor 2 together 
with ΔFEV₁ and total IgE (Table 3).
 
Definition and abbreviations: ΔFEV1 = change in FEV1 as percentage of predicted (reversibility to salbutamol); eNO = 
exhaled nitric oxide; IVC = inspiratory vital capacity; KCO = diffusing capacity for carbon monoxide per liter alveolar 
volume; %pred = percentage of predicted; PC20 = provocative concentration of methacholine causing a 20% fall 
in FEV1; RV = residual volume, TLC = total lung capacity. Bold values represent the highest loadings of a variable.
Table 3. Varimax Rotated Factor-loading Matrix from Factor Analysis with pack years
Factor 1 Factor 2 Factor 3 Factor 4
Postbr. FEV1/IVC, % 0.77 -0.0002 -0.33 0.20
Postbr. FEV1, %pred 0.72 -0.19 -0.24 -0.03
RV/TLC, % -0.68 -0.05 -0.20 0.25
KCO, %pred 0.59 0.25 0.37 0.24
PC20, mg/ml 0.59 0.28 -0.13 -0.03
Pack-years -0.22 0.70 -0.32 0.06
ΔFEV1, %pred -0.29 -0.62 -0.11 0.20
IgE, IU/ml 0.07 0.61 0.18 -0.05
eNO, ppb -0.18 0.05 0.84 0.02
Sputum eosinophils, % -0.23 0.09 0.16 -0.74
Sputum neutrophils, % -0.28 -0.08 0.25 0.68
Eigenvalue 2.67 1.56 1.22 1.06
Total variance explained, % 24.2 14.2 11.1 9.6
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Univariate correlations
The univariate relationships among physiological and inflammatory parameters 
(sputum neutrophils, eosinophils, and eNO) were as follows. ΔFEV₁ was not 
associated with inflammatory parameters; however, RV/TLC was associated 
with sputum % neutrophils (r=0.203, p=0.04), and postbronchodilator FEV₁, 
RV/TLC, and PC20 were associated with number of neutrophils/ml sputum 
(r=-0.246, p=0.01; r=0.213, p=0.03 and r=-0.338, p<0.001, respectively). 
Postbronchodilator FEV₁, PC20, and FEV₁/IVC were associated with eNO levels 
(r=-0.203, p=0.05; r=-0.207, p=0.05 and r=-0.304, p=0.003, respectively). 
FEV₁/IVC was also related to sputum % eosinophils (r=-0.219, p=0.02), while 
postbronchodilator FEV₁, KCO, PC20, and FEV₁/IVC were also associated with 
number of eosinophils/ml sputum (r=-0.207, p=0.03; r=-0.204, p=0.04; r=-
0.243, p=0.01 and r=-0.242, p=0.01, respectively).
Discussion
The aim of this study was to objectively specify the heterogeneity of COPD, 
by categorizing the various functional and inflammatory features of COPD into 
separate, complementary domains without a priori assumptions. Therefore, 
we performed a factor analysis using physiological and inflammatory data of 
114 patients with moderate to severe COPD, not treated with inhaled steroids. 
This resulted in a four-factor structure, explaining 63.6% of the total variance. 
Factor 1 included: FEV₁, FEV₁/IVC and hyperinflation; factor 2: β2-response, 
total serum IgE, airway hyperresponsiveness and KCO; factor 3 included: 
eNO, and factor 4 included: sputum % neutrophils and eosinophils. These 
four factors indicate that airflow limitation, features commonly associated 
with asthma, and airway inflammation are separate, largely independent 
dimensions that characterize patients with COPD.
To our knowledge, this is the first study in patients with COPD combining 
functional parameters and markers of airway inflammation in a factor analysis. 
Previous studies have applied factor analysis on quality-of-life, symptoms 
scores, exercise capacity, and lung function parameters in patients with stable 
COPD, without evaluating inflammatory indices [17-23]. However, the latter 
have been part of factor analysis in recent asthma research [13;15;16]. In 
patients with mild to moderate asthma, Rosi and colleagues demonstrated by 
factor analysis that airway function, bronchial responsiveness with reversibility, 
and eosinophilic inflammation, as assessed in sputum, are independent 
dimensions [13]. Our current results demonstrate that airway function, 
49
bronchial responsiveness with reversibility, and inflammation as assessed in 
sputum or exhaled are predominantly nonoverlapping dimensions in patients 
with COPD as well.
Interestingly, this study showed that measurements of airflow limitation, 
traditionally used to determine disease severity in COPD [33], and 
hyperinflation, a measure of air trapping, were combined in the first factor. 
According to the statistical method of factor analysis, these measurements 
represent an important, separate dimension in the assessment of patients 
with stable COPD. This result is consistent with some [17;23], but not all 
[21;22] previous factor analyses of lung function parameters in COPD. The 
second factor extracted from the data included reversibility of FEV₁, airway 
hyperresponsiveness, total serum IgE, and diffusing capacity. Similarly, Ries 
and colleagues reported that bronchodilator response and diffusing capacity 
of COPD patients were grouped into separate factors from expiratory flow 
rates and hyperinflation [17]. To our knowledge, there are no other studies 
in patients with COPD that have included these variables in a factor analysis. 
Finally, the third and fourth factor included eNO and sputum % neutrophils 
and eosinophils, respectively. This is a novel finding, illustrating the partial 
independency of these markers of inflammation from the traditionally used 
functional disease markers in COPD.
We included a large (n=114) group of patients with stable COPD, not using 
inhaled steroids for at least 6 months and without a clinical diagnosis of 
asthma. In terms of disease severity, patient characteristics included COPD 
patients of GOLD Stage II and III. Inclusion of very mild or very severe patients 
could have produced different results, and therefore our results potentially lack 
generalizability. In contrast to some other studies, we did not exclude patients 
with COPD who were partially reversible to a bronchodilator, because the 
selection of non-reversible patients only would have excluded a large group 
of patients with COPD [34-36]. Furthermore, it needs to be emphasized that 
this is a cross-sectional analysis of patients with stable COPD, and that the 
results do not account for exacerbations and other temporal events. Sputum 
cell counts and eNO were measured as noninvasive markers of inflammation. 
Obviously, this does not cover all the inflammatory and structural changes of 
the airways in COPD, but it does represent the markers that are potentially 
useful for disease monitoring.
Factor analysis is not an approach that is widely applied, presumably because 
of its complexity. A simple example that clarifies its value and interpretation 
has recently been described by Juniper and colleagues [14]. The purpose of 
50
Chapter 2  •  Heterogeneity in COPD
this procedure is to reduce a large set of variables and to clarify (absence 
of) relationships between various parameters without reference to a specific 
criterion. Factor analysis does not regroup variables that are highly correlated, 
but factors are created based on calculated estimates of shared variance 
among variables, with the restriction that the factors reflect independent 
sources of variation. This procedure allows the user to determine whether 
associations between parameters are attributable to noise of measurements. In 
clinical research, factor analysis allows the many parameters that characterize 
the disease to be reduced to a few, relatively independent factors. We 
applied standard procedures of exploratory factor analysis with respect to the 
number of variables used in the analysis, the selection of number of factors, 
and the factor rotation [32]. Additional factor analyses with replacement of 
% neutrophils and % eosinophils by cell counts per ml sputum, exclusion of 
outliers from the data set, and addition of the cumulative amount of smoking 
resulted in similar factor structures as the original analysis. This demonstrates 
the robustness of the current findings.
The disease heterogeneity in COPD in terms of lung function and inflammation 
suggests that distinct pathophysiological pathways contribute to COPD. 
In agreement with this concept, we observed that multiple functional 
and inflammatory characteristics were categorized into four independent 
dimensions. Interestingly, none of the parameters of factors 1 or 2 showed 
significant additional loadings on factors 3 or 4, and vice versa, which 
strengthens the independence of functional and inflammatory dimensions. One 
exception to this was KCO, which loaded together with eNO in the additional 
factor analysis using number of sputum cells instead of cell percentages. The 
value of using factor analysis in mapping disease heterogeneity is illustrated by 
our finding that some of the parameters were found to provide complementary 
information (loading on different factors) despite the existence of mutual 
correlation in univariate analyses.
The first factor can be interpreted as irreversible airflow limitation. The fact 
that diffusing capacity also had modest loading on this factor confirms earlier 
findings that the destruction of lung tissue is associated with increased airflow 
limitation and hyperinflation [37]. Alternatively, diffusing capacity could also be 
a descriptor of the status of altered pulmonary circulation in COPD: another 
structural component of COPD. Hence, restructuring of airways as well as 
lung tissue seems to be an important mechanism resulting in airflow limitation. 
Interestingly, our data suggest that this process is greatly independent of 
neutrophilic and eosinophilic inflammation in the larger airways (grouped into 
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factor 4). Neutrophils are able to induce tissue damage through the release 
of serine proteases and oxidants. However, this is not a prominent feature 
of other pulmonary diseases where chronic airway neutrophilia is even more 
prominent, such as cystic fibrosis and bronchiectasis [38]. This suggests 
that other factors are involved in the generation of emphysema. In addition, 
increased neutrophil numbers are found in the airway lumen, but they are not a 
prominent feature of the airway wall or parenchyma in patients with COPD [7]. 
Furthermore, the presence and role of eosinophils in COPD are uncertain [38]. 
The observed increased levels of eosinophil cationic protein and eosinophil 
peroxidase in induced sputum from COPD patients suggest the eosinophils 
are degranulated [39], which may be the result of the high neutrophil elastase 
levels in COPD [40]. Our data supports this close relationship between 
neutrophils and eosinophils in COPD, but apparently, airflow limitation requires 
more than the presence of these granulocytes per se.
Parameters that are known to be associated with asthma predominantly 
grouped into the second factor. This may not be unexpected, since airway 
hyperresponsiveness, partial reversibility of airflow limitation, and increased 
serum IgE levels are not uncommon in COPD [41]. An alternative interpretation 
would be that this second factor represents risk factors for progression of 
COPD, because bronchodilator response, airway hyperresponsiveness, and 
serum IgE levels have been associated with lung function decline [42]. The 
finding that number of pack-years also loaded on factor 2 strengthens this 
concept, because smoking is known to be the main risk factor for progression 
of COPD [43]. Although factor 2 also included KCO, its parallel loading on 
factor 1 suggests that gas exchange impairment is associated with diverse 
pathophysiology.
The current separation of airway hyperresponsiveness and FEV₁ into different 
factors supports epidemiological evidence that these disease characteristics 
provide complementary information on COPD [44], the PC20 in COPD not 
simply being a result of airflow limitation per se. However, the fact that PC20 
also had moderate loading on the first factor and even highest loading the 
first factor in some of the additional factor analyses on, is in agreement with 
previous studies that suggest that PC20 is to some extent dependent on airway 
caliber in COPD [45]. Although it has been reported previously that partial 
reversibility of airflow limitation is associated with sputum eosinophilia and 
elevated eNO in COPD [34], our factor analysis suggests that these features 
are largely independent. This confirms a previous factor analysis in asthma [13] 
and again may challenge the concept that eosinophilic airways inflammation 
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is closely related to the “twitchiness” of the airways. Interestingly, we found 
that number of pack-years also loaded on the second factor with IgE and β2-
response, and not with airflow limitation or sputum neutrophils. A significant 
relationship between total IgE and the degree of tobacco smoking has been 
reported previously [46], suggesting that the increase in IgE may be partly 
due to tobacco smoking. Although, in this study, univariate analysis revealed 
significant correlations between eNO and FEV₁, FEV₁/IVC, and PC20, eNO was 
extracted into a factor independent from functional parameters as well as 
sputum cell counts. This indicates that this exhaled marker might be a rather 
autonomic phenomenon and bodes ill for the use of eNO in monitoring of 
disease activity.
In conclusion, this analysis has categorized multiple disease features of COPD 
without a priori assumptions on their interrelationships. Our data suggest that 
airflow limitation, asthma-like components, eNO and sputum inflammatory cell 
counts offer separate and additive information about the pathophysiological 
condition of COPD patients. This confirms the complex heterogeneity of 
the disease and may change some of the current concepts on the distinct 
pathophysiological pathways involved. Accordingly, it needs to be examined 
whether the clinical evaluation of patients with COPD should include each of 
these complementary entities.
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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized 
by irreversible airflow limitation and airway inflammation, accompanied by 
decreased health status. It is still unknown which factors are responsible for 
the impaired health status in COPD. We postulated that airway inflammation 
negatively contributes to health status in COPD. 
Methods: In 114 COPD patients (99 male, age: 62±8 yr, 41 [31-55] pack-years, 
no inhaled or oral corticosteroids, postbronchodilator FEV1: 63±9 %pred, 
FEV1/IVC: 48±9%) we obtained induced sputum and measured health status 
(St. George’s respiratory questionnaire (SGRQ)), postbronchodilator FEV₁, 
hyperinflation (RV/TLC), and airway hyperresponsiveness to methacholine 
(PC20). Sputum was induced by hypertonic saline and differential cell counts 
were obtained in 102 patients.
Results: Univariate analysis showed that SGRQ total and symptom score 
were positively associated with % sputum macrophages (r=0.20, p=0.05; 
and r=0.20, p=0.04, respectively). Multiple regression analysis confirmed 
these relationships, providing significant contributions of % sputum 
macrophages (B=0.25, p=0.021) and RV/TLC (B=0.60, p=0.002) to SGRQ total 
score. Furthermore, SGRQ symptom score was associated with % sputum 
macrophages (B=0.30, p=0.03) and RV/TLC (B=0.48, p=0.044), whilst SGRQ 
activity score was associated with % sputum macrophages (B=0.46, p=0.002), 
RV/TLC (B=0.61, p=0.015), and PC20 (B=-9.3, p=0.024). Current smoking 
and FEV₁ were not significantly associated with health status in the multiple 
regression analysis. 
Conclusion: We conclude that worse health status in COPD patients is 
associated with higher inflammatory cell counts in induced sputum. Our 
findings suggest that airway inflammation and hyperinflation independently 
contribute to impaired health status in COPD. This may provide a rationale for 
anti-inflammatory therapy in this disease. 
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Background
Chronic obstructive pulmonary disease (COPD) is a major and growing cause 
of morbidity and mortality [1;2]. It is characterized by progressive and not fully 
reversible airflow limitation, as measured with the forced expiratory volume 
in one second (FEV1). The airflow limitation is associated with a chronic 
inflammatory process in the airways and lung parenchyma in response to 
noxious particles or gases, in particular tobacco smoking [1;2].
In daily life COPD patients are bothered by airway symptoms such as dyspnea, 
cough and sputum production [2;3]. This is accompanied by a serious 
decrease of health status [4]. Several studies have attempted to link health 
status to the severity of airflow limitation in patients with COPD [4] and show 
that the relationship is at best a loose one. Even the largest study assessing 
health status by the St. George’s respiratory questionnaire (SGRQ) provides 
only weak associations with the degree of airflow limitation, as measured by 
FEV₁ [5;6]. This suggests that other factors additionally contribute to the health 
status in COPD. One of those may be dynamic hyperinflation, i.e. increased 
residual volume and total lung capacity [7], possibly as a consequence of 
chronic inflammation and restructuring of the airways and/or parenchyma [8; 
9].
The chronic inflammatory process in COPD is characterized by infiltration of 
the airways by neutrophils, macrophages and CD8-positive T cells [10;11]. 
Such features of inflammation in COPD are likely driven by various cellular 
pathways, including pro-inflammatory cytokines and mediators of oxidative 
stress [12;13]. These cytokines and mediators may not only be responsible 
for local airway inflammation but can also induce features of systemic 
inflammation in COPD [14-16]. The latter is assumed to be linked with impaired 
functional status in COPD [12], just as it has been shown in other chronic 
inflammatory conditions such as bronchiectasis, rheumatoid arthritis, chronic 
end-stage renal disease and inflammatory bowel syndrome [17;18]. Hence, it 
is not unlikely that the underlying local airway inflammation in COPD can drive 
impairment of health status as well [12]. 
We hypothesized that health status in COPD is affected by the severity of airway 
inflammation. The aim of our study was to test this hypothesis in a large cross-
sectional study by assessing the relationship between airway inflammation, 
as measured by cell counts in induced sputum, and health status in COPD. In 
order to examine the independent effects of airway inflammation, the influence 
of clinical disease markers such as smoking, lung function, hyperinflation and 
airways hyperresponsiveness on health status was included.
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Detailed information about subjects and methodology has been published 
previously [20]. In brief, 114 patients with COPD were included for the 
Groningen Leiden Universities Chronic Obstructive Lung Disease (GLUCOLD) 
Study. Patients (45-75 years, current or ex-smokers ≥10 pack-years) had 
at least one of the following symptoms: chronic cough, sputum production, 
or dyspnea on exertion. Postbronchodilator forced expiratory volume in 
one second (FEV1) was > 1.3 liter and > 20% predicted and below the 90% 
confidence interval of the predicted FEV₁ [21]. Postbronchodilator FEV₁/IVC 
ratio was below the 90% confidence interval of the predicted FEV₁/IVC ratio. 
These lung function levels are compatible with GOLD stages II and III [2]. 
Patients were clinically stable for more than 2 months and free of common cold 
symptoms for 2 weeks before the measurements. They did not use a course of 
inhaled or oral corticosteroids during the past 3 months prior to randomisation 
and did not have maintenance treatment with these drugs during the past 6 
months. Patients with considerable co-morbidity were excluded. Usage of 
short-acting bronchodilators was allowed during the study. Each center’s 
local medical ethics committee approved the protocol and patients provided 
written informed consent.
This study represents a cross-sectional analysis of baseline data from the 
GLUCOLD Study. Health status was measured using the St. George’s 
respiratory questionnaire [22]. This is a well-validated, standardized, self-
administered questionnaire, specifically designed for respiratory diseases. 
It contains 50 items and is divided into three sections: symptoms (distress 
Median [IQR]
Total SGRQ score 32 [19-43]
Symptom SGRQ score 44 [34-55]
Activity SGRQ score 42 [23-54]
Impact SGRQ score 18 [8.0-30]
Table 1. St. George’s respiratory questionnaire (SGRQ): median scores (n=102)
The SGRQ scores from 102 patients with adequate questionnaires and sputa. Data are presented as median [inter-
quartile range (IQR)]. Higher SGRQ scores indicate worse health status: 0=best,100=worse.
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caused by respiratory symptoms), activity (physical activities that cause or 
are limited by breathlessness), and impact (social and psychological effects of 
the disease). The total score and the three separate component scores were 
calculated. The scores range from zero to 100, where zero indicates best and 
100 represents worst health status. 
Sputum was induced and processed according to a validated technique 
[23]. After inhaling 200 μg salbutamol the patients inhaled hypertonic sodium 
chloride aerosols (4.5 w/v %) during 3 periods of 5 min. Whole sputum 
samples were processed within two hours from sputum induction. Differential 
cell counts were expressed as a percentage of nucleated cells, excluding 
squamous cells. A sputum sample was considered adequate when the 
percentage squamous cells was less than 80% [23].
Spirometry was performed, according to international guidelines [24], using 
the Quanjer reference values [21]. Total lung capacity (TLC) and residual 
volume (RV) were measured using a constant volume bodyplethysmograph 
[21]. Airway hyperresponsiveness was determined using the 2-minute tidal 
breathing method [25] and expressed as the provocative concentration 
causing a 20% fall in FEV₁ (PC20). The diffusion capacity for carbon monoxide 
per liter alveolar volume (KCO) was measured using the single breathholding 
method [26]. The associations of the SGRQ total, symptom, activity and 
impact scores with inflammatory cell counts and various other study variables 
were examined using Pearson’s and Spearman’s rank correlation. Differences 
between smokers and ex-smokers were analyzed with the Student t test 
and Mann Whitney U. Skewed data (pack-years, PC20, % and numbers of 
inflammatory cells in sputum) were transformed when appropriate. Multiple 
linear regression analyses (ENTER method) were performed to assess the 
relation between health status (SGRQ total, symptom, activity and impact 
scores) and sputum inflammatory cell counts, independent of  age, gender, 
current smoking, postbronchodilator FEV₁, RV/TLC, and PC20. Probability 
values of ≤0.05 were considered significant. All analyses were performed 
using the Statistical Package for Social Sciences (SPSS)-12.  
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Results
Characteristics 
A total of 114 patients were enrolled in the study. Patient characteristics have 
been published in extensive detail [20]. In short, most patients (87%) were 
middle-aged males (mean±standard deviation (SD) 62%±8). They had a median 
of 41 pack-years of smoking, 37% being ex-smokers. Patients had moderate 
to severe COPD as based on their postbronchodilator FEV₁ (mean±SD 63%±9 
of predicted (pred)) and exhibited a wide range in RV/TLC (mean±SD 48±8) 
and PC20 (geometric mean, inter quartile range (IQR) 0.6 [0.17-2.40]). A total of 
110 patients adequately completed the SGRQ and 102 from these were able 
to produce an acceptable sputum sample. Data from the 102 patients were 
used for all analyses. The median SGRQ scores were indicative of moderately 
impaired health status (Table 1). Number and differential counts of sputum 
cells are shown in Table 2. 
Univariate analysis 
The total and symptom scores were positively associated with % macrophages 
(r=0.20, p=0.050; and r=0.20, p=0.041, respectively). The univariate relationship 
between the SGRQ scores and sputum inflammatory cell counts is shown in 
Table 3. The regression coefficient (B) in Table 3 represents the strenght of the 
association. Our results show that an increase in sputum macrophages of 1 % 
is associated with an increase of the mean total score of 0.22 point. In addition, 
figure 1 shows the effect-size of a higher percentage of sputum macrophages 
on the SGRQ scores. Patients with <15% sputum macrophages have a mean 
total score of 27. The total score is on average 5 points higher in patients 
with 15-45 % sputum macrophages, and 9 points higher in patients with > 
Absolute numbers (104/ml) Percentage
Total cell count 135.0 [76.8-311.3] -
Neutrophils 99.2 [46.7-228.6] 72.6 [59.5-82.2]
Macrophages 32.3 [17.9-61.1] 22.8 [14.8-33.3]
Eosinophils 1.4 [0.3-4.8] 1.1 [0.3-2.2]
Lymphocytes 2.1 [1.0-6.8] 1.7 [1.2-2.3]
Epithelial cells 1.3 [0.6-3.8] 1.0 [0.3-2.3]
Table 2. Inflammatory cells in induced sputum (n=102)
Data are presented as median [IQR]. Total cell count refers to the total number of non- squamous cells 
in sputum.
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45 % sputum macrophages. A significant threshold of four units in SGRQ 
scores may be considered as clinically relevant [27]. The activity and impact 
scores were not significantly associated with sputum % macrophages (r=0.19, 
p=0.061; rs=0.14, p=0.16, respectively). No significant associations were 
found between all SGRQ scores and percentages of neutrophils, eosinophils, 
lymphocytes, epithelial cells, nor with absolute numbers of total sputum cells, 
neutrophils, macrophages, lymphocytes, and epithelial cells. 
With regard to clinical and functional parameters, the total, symptom and 
impact scores were higher among smokers, as compared with ex-smokers 
(median total score=33.2 vs 25.8, p=0.040; median symptom score=46.8 vs 
40.9, p<0.01; median impact score=19.7 vs 11.3, p=0.023, for smokers and 
ex-smokers, respectively). Higher symptom scores were associated with 
a larger amount of pack-years (r=0.29, p<0.01). Higher activity scores were 
associated with lower postbronchodilator FEV₁ (r=-0.24, p=0.017), increased 
lung hyperinflation, as assessed by RV/TLC ratio (r=0.25, p=0.012) and less 
hyperresponsiveness, as assessed by PC20 (r=-0.22, p=0.033). No associations 
were found between any of the SGRQ scores and CO-diffusion capacity, as 
assessed by KCO (data not shown). 
Multiple regression analysis 
Multiple regression analysis confirmed the relationship between SGRQ total 
score and % sputum macrophages (B=0.25, p=0.021), with an explained 
variance of 14%. In this model there was a significant contribution of RV/TLC 
(B=0.60, p=0.002). Age, current smoking, gender, postbronchodilator FEV₁, 
or PC20 were not significantly associated with the total score in this model. 
The symptom domain also remained significantly associated with % sputum 
SGRQ total score symptom score activity sore impact score
Total cell count † B (95% CI) -1.7 (-8.0 to 4.6) -4.6 (-12 to 3.4) -0.74 (-9.2 to 7.7) -1.1 (-7.3 to 5.1)
% Neutrophils B (95% CI) -0.17 (-0.36 to 0.02) -0.20 (-0.44 to 0.04) -0.24 (-0.49 to 0.02)‡‡ -0.11 (-0.30 to 0.08)
% Macrophages B (95% CI) 0.22 (<0.01 to 0.43)* 0.28 (0.01 to 0.56)* 0.28(-0.01 to 0.56)‡ 0.15 (-0.07 to 0.36)
% Eosinophils # B (95% CI) 0.22 (-4.0-4.5) -0.73 (-6.13-4.67) 2.42 (-3.27-8.10) -0.61(-4.80-3.58)
Table 3. Association between sputum cell differential counts and health status assessed with  
 SGRQ (n=102), results from linear regression analyses
The univariate association between SGRQ scores (dependent) and sputum cell counts (independent) was expressed 
by regression coefficient B with corresponding 95% confidence intervals (95% CI). The regression coefficient B 
represents the strength of the association. Our results show that an increase in sputum macrophages of 1 % is as-
sociated with an increase of the mean total score of 0.22 point, indicating that an increase in sputum macrophages 
of 20% is associated with an increase of the mean total score of 4.4 points, which exceeds the clinically relevant 
threshold of four units in SGRQ scores. †Total cell count was logtransformated, #% eosinophils were transformed 
using the square root. *p≤0.05, ‡p=0.061, ‡‡p=0.068.
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macrophages in the multiple regression analysis (B=0.30, p=0.03), together 
with RV/TLC (B=0.48, p=0.044). Finally, multiple regression analysis showed a 
relationship between the activity score and % sputum macrophages (B=0.46, 
p=0.002), again with a significant contribution of RV/TLC (B=0.61, p=0.015) 
and also with PC20 (B=-9.3, p=0.024).
Discussion
This study demonstrates that health status in COPD is associated with 
inflammatory cell counts in induced sputum. The larger the percentage of 
sputum macrophages was, the more impaired a patient’s health status was. 
This relationship was marginally modulated by the severity of hyperinflation 
and airways hyperresponsiveness.
These findings suggest that airway inflammation independently contributes to 
impaired health status in COPD.
Figure 1. Relationship between percentages macrophages in induced sputum (x-axis) and  
 SGRQ scores (y-axis) (n=102). Results from linear regression analyses (B and 95%  
 confidence interval)
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The novelty of this study is that we observed a relationship between health 
status and inflammatory cell counts in induced sputum in steroid naive, 
clinically stable patients with moderately severe COPD. In general, health 
status was markedly impaired, as indicated by a median SGRQ total score of 32 
[5]. Interestingly, our data suggest that the inflammatory process is a stronger 
determinant of health status than physiological measures of hyperinflation 
or airflow limitation. After taking percentage sputum macrophages into 
account, only RV/TLC demonstrated a consistent association with the total 
score and subdomains of the SGRQ. This points towards an independent 
role of hyperinflation among the determinants of health status. Indeed, 
patients with a relatively high degree of hyperinflation are known to have 
increased breathlessness and reduced physical activities, which is even 
more pronounced during exercise [28;29]. This is likely to affect health status, 
especially with regard to the activities domain. In addition, we found some 
evidence of a contribution of airway hyperresponsiveness, which extends 
previous observations in the general population [30;31]. Although smoking is 
associated with health status, our results show that the relationship between 
health status and sputum percentages macrophages, within patients with 
COPD, is similar in smokers as compared with ex-smokers. 
Our patient selection and methods seem to be appropriate for the current 
study. The sample size of 102 patients with a complete data set provided 
sufficient data for multivariate analysis. In general, some relationships might 
have been arisen by chance given the potential for multiple comparisons. 
However, the univariate associations between inflammatory cell counts 
and health status found in this study remained statistically significant when 
adjusted for other relevant parameters using multiple regression analysis, 
suggesting an independent and consistent role for inflammation with regard 
to health status in patients with COPD. Patients with clinically relevant co-
morbidity were excluded. We reasoned that marked co-morbidity additionally 
affects disease-specific health status [32], which could potentially introduce 
confounders. We excluded all patients with maintenance therapy of inhaled 
corticosteroids during the last six months. Inhaled corticosteroids influence 
the inflammatory cell counts in induced sputum in patients with COPD [33;34], 
which easily might have disturbed any disease-related associations between 
the inflammatory process and health status. 
How can we explain the observed positive association between the percentage 
macrophages in sputum and health status? In previous studies, neutrophils 
have been linked to the severity of COPD, as measured with FEV₁ [35]. In 
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a previous report from our study group Lapperre et el. categorized various 
functional and inflammatory features of COPD into separate complementary 
domains using a different statistical analysis, a so-called factor analysis. 
This revealed that FEV₁ and neutrophilic inflammation are complementary 
dimensions that characterize patients with COPD [20]. However, several 
studies suggest a central role for macrophages in inflammatory processes and 
structural changes in the lung of patients with COPD [36;37]. 
Chemokines, such as monocyte chemoattractant protein 1 (MCP-1) and its 
receptor C-C chemokine receptor 2 (CCR2), have been implicated in the 
recruitment of macrophages into the bronchiolar epithelium in COPD [38]. 
These macrophages can release a large variety of inflammatory cytokines such 
as tumor necrosis factor (TNF-α), IL-8, CXC-chemokines, LTB4, and reactive 
oxygen species that are likely to drive airway inflammation in COPD. Moreover 
they produce elastolytic enzymes, e.g. metalloproteinases [39;40] such as 
macrophage elastase (MME), that may degrade the extracellular matrix and 
thus contribute to the development of parenchymal damage and thereby to 
pulmonary emphysema in COPD [13;36;41]. 
The novelty of this study is that associations were observed between health 
status and local airways inflammation, whilst previous studies suggested 
associations between impaired health status and systemic inflammation 
in COPD [14;42]. Previously, it has been suggested that the systemic 
inflammatory response may be due to a overflow of pulmonary mediators 
from the airways [14]. However, Vernooy et al showed that soluble tumour 
necrosis factor receptor (sTNF-R) and IL8 in sputum and plasma were not 
correlated, suggesting that the inflammatory process in the local and systemic 
compartment are regulated differentially [43;44]. In the airways neutrophilic 
inflammation is associated with lower FEV₁ levels in COPD [45]. The role of 
airway macrophages may be linked to different pathophysiological processes 
as mentioned above. Environmental exposures such as tobacco smoke may 
promote macrophage-induced alveolar damage [46], leading to impaired 
alveolar-capillary gastransport and accompanying changes in health status. 
Interestingly, our results are suggestive of a distinct role for the differential 
cell counts rather than the total amount of macrophages. Taken together, we 
may speculate that the local and systemic inflammatory responses are partly 
differentially regulated, mutually determining the COPD phenotype. If so, this 
will be of major importance when developing effective interventions in this 
disease.
The percentage macrophages in sputum was associated with the SGRQ total 
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score (a summary measure of health status), as well as the SGRQ symptom 
score (severity of symptoms) and SGRQ activity score (physical activities that 
cause or are limited by breathlessness). As shown in figure 1, the differences in 
health status between patients with relatively higher and lower percentages of 
macrophages can be considered as clinically relevant, because they reached 
the clinically significant threshold of four units in SGRQ scores [27]. This 
suggests that airway inflammation in COPD is relevant for disease outcome 
in daily life. Inflammatory cell counts in sputum were not associated with the 
impact score. This score measures social and psychological effects of the 
disease, such as anxiety and coping, and it is plausible that this score is less 
influenced by the inflammatory component of the disease. It is important to 
notice that only a limited part of health status could be explained by the severity 
of airway inflammation. The likely reason for this is that a wide spectrum of 
disease processes potentially affects health status [4]. Furthermore, other 
factors such as coping or the presence and frequency of exacerbations might 
also play an additional role in its impairment in patients with COPD [47].
We observed a consistent and independent contribution of hyperinflation on 
health status in patients with mild to moderate COPD. This is in line with a 
previous study, where hyperinflation was associated with poor health status in 
very severe patients with COPD who were using long-term oxygen treatment 
[48]. Hyperinflation causes an increase in lung volume with a concomitant 
increase of work of breathing, functional impairment of inspiratory muscle 
function, and adverse effects on haemodynamics which all may contribute 
to dyspnea [49]. In a recent study in COPD tiotropium bromide significantly 
decreased the residual volume [7], which was correlated with a decrease 
in dyspnea. This is indicative of the clinical relevance of hyperinflation in 
COPD, and the more so because dyspnea appears to be an important 
factor influencing health status [50]. In addition, the activity score measures 
physical activities that on the one hand induce breathlessness, and on the 
other may become limited by this particular symptom. Therefore, the current 
associations between hyperinflation and various domains of health status are 
not unexpected. 
  
In conclusion, we have observed that a worse health status in COPD is 
significantly associated with higher inflammatory cell counts in induced sputum, 
whereas only marginally additional contributions were found for lung function 
measures reflecting hyperinflation. Our observation that airway inflammation 
negatively affects health status of COPD patients may have clinical relevance. 
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At present, anti-inflammatory therapy with inhaled corticosteroids is a 
recommended treatment option in patients with advanced COPD [2]. This has 
been shown to reduce deterioration in health status [5;51]. If health status is 
partly driven by the local inflammatory process in COPD this may provide a 
rationale for the usage of anti-inflammatory therapy in COPD. It now needs to 
be examined whether the severity of airway inflammation predicts the benefits 
of long-term anti-inflammatory intervention on health status in COPD. 
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Chronic bronchitis sub-phenotype within COPD: 
inflammation in sputum and biopsies
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Abstract
Rationale: The presence of chronic bronchitis predicts more rapid decline 
of FEV1 in patients with chronic obstructive pulmonary disease (COPD). The 
hallmark of COPD is airway inflammation. It was hypothesised that COPD 
patients with chronic bronchitis are characterised by a distinct inflammatory 
cell profile as measured in bronchial biopsies and sputum.
Methods: From 114 COPD patients (male/female ratio 99/15, mean±SD age 
62±8 yrs, current smoking 63%, post-bronchodilator FEV1 63±9% predicted, 
no steroids), with and without chronic bronchitis, inflammatory cell counts in 
bronchial biopsies and induced sputum were measured. Analysis was carried 
out by logistic regression. 
Results: COPD patients with chronic bronchitis had lower eosinophil counts 
in biopsies and higher percentages of sputum eosinophils than patients 
without those symptoms, which remained after adjustment for smoking and 
sex. Patients with chronic bronchitis also showed higher percentages of 
macrophages and lower percentages of neutrophils in sputum, which could 
be explained by differences in smoking and sex. 
Conclusion: It was concluded that chronic bronchitis reflects an inflammatory 
sub-phenotype among patients with COPD. The present results indicate a 
preferential distribution of eosinophils towards the airway lumen in those with 
chronic bronchitis. This may have implications for anti-inflammatory treatment 
of COPD patients with chronic bronchitis.
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a leading cause of death and 
disability worldwide [1]. COPD is characterised by progressive and not fully 
reversible airflow limitation, as measured by the forced expiratory volume in one 
second (FEV₁). The airflow limitation is associated with a chronic inflammatory 
response of the airways and lung parenchyma to noxious particles or gases, 
in particular tobacco smoking. Nonetheless there is increasing evidence that 
COPD is a heterogeneous disease and that different phenotypes contribute, to 
a variable extent, to the severity of the disease. On average 34 % of patients 
with COPD suffer from chronic cough and sputum expectoration [2]. However, 
it is still unclear whether these coexisting symptoms of chronic bronchitis 
among patients with COPD are relevant for the progression and treatment of 
COPD. 
Early epidemiological studies in the 1980s did not observe an association 
between clinical symptoms of chronic bronchitis and the progression of 
disease in patients with mild COPD, as measured by the annual decline of 
FEV₁ [3]. However, subsequent findings suggested that chronic sputum 
expectoration is associated with a low FEV₁ in patients with alpha-1 antitrypsin 
deficiency [4], and a steeper decline in FEV₁ in population based studies 
(including patients with COPD)  [5;6]. In addition, chronic cough and sputum 
expectoration is associated with an increased risk in COPD-related mortality 
[7;8]. These follow-up studies suggest that the presence of chronic bronchitis 
is not just an innocent bystander, but might contribute to, or is a reflection of, 
the more rapid progression of COPD [9]. 
In COPD the inflammatory process is characterised predominantly by 
neutrophils, macrophages and CD8+ cells in the airways [10]. The role 
of excessive mucus production in the pathophysiology in COPD is still 
controversial. Chronic mucus hypersecretion per se is associated with distinct 
pathological features, such as persistent epithelial goblet cell hyperplasia and 
submucosal gland hypertrophy in the airways [11]. However, no differences 
have been observed in total mucin content of the surface epithelium between 
COPD patients with and without symptoms of chronic bronchitis [12]. Goblet 
cells in the surface epithelium are the main producers of the mucin MUC5AC, 
whereas MUC5B is a characteristic product of the submucosal glands [13]. 
COPD patients with chronic bronchitis have increased numbers of neutrophils 
in the epithelium and more neutrophils, macrophages and CD8+ cells in their 
bronchial glands, as compared with asymptomatic non-COPD subjects 
[14]. This suggests that inflammatory cells and their mediators provide a 
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major drive for mucus hypersecretion and subsequent symptoms of chronic 
bronchitis [11]. However, among patients with established COPD it is still 
unclear whether chronic bronchitis is featured by a distinct inflammatory cell 
profile in the airways. If so, the presence of chronic bronchitis in COPD may 
have therapeutic implications for current or future therapies [15].
Therefore, the hypothesis that COPD patients with concurrent clinical 
symptoms of chronic bronchitis are characterised by a distinct inflammatory 
cell profile in the airways was tested. This was addressed by measuring 
inflammatory cell counts in bronchial biopsies and induced sputum in well-
characterised patients with COPD.
 
Methods
Detailed information about subjects and methodology has been published 
previously [16]. In brief, 114 patients with COPD were included for the 
Groningen Leiden Universities Chronic Obstructive Lung Disease (GLUCOLD) 
Study. Patients were 45-75 years, current or ex-smokers with a history 
of ≥10 pack-years and respiratory symptoms. Postbronchodilator forced 
expiratory volume in one second (FEV1) was >1.3 l and >20% predicted and 
less than the upper limit of the 90% confidence interval of the predicted 
FEV1 [17]. Postbronchodilator FEV1/IVC ratio was below the 90% confidence 
interval of the predicted FEV1/IVC ratio. Patients were clinically stable for 
>2 months before the measurements. They did not use a course of inhaled 
or oral corticosteroids during the previous 3 months prior to randomisation 
or maintenance treatment with these drugs during the past 6 months. The 
medical ethics committee of the Leiden University Medical Center (Leiden, The 
Netherlands) and the University Medical Center Groningen (Groningen, The 
Netherlands) approved the protocol, and patients provided written informed 
consent.
Design and definition of chronic bronchitis   
This study represents cross-sectional data from the GLUCOLD study and 
contained four visits. Chronic bronchitis was considered to be present when 
subjects reported daily cough and sputum production for ≥3 months per year, 
for >1 year [5]. 
Pulmonary function tests
Spirometry was performed according to international guidelines [18], using the 
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reference values of Quanjer et al [17]. Total lung capacity and residual volume 
were measured using a constant volume bodyplethysmograph [17]. Airway 
hyperresponsiveness was determined using the 2-min tidal breathing method 
[19] and expressed as the provocative concentration causing a 20% fall in 
FEV₁. 
Sputum induction and processing
Sputum was induced and processed according to a validated technique using 
the so called ‘full sample’ method [20]. After inhaling 200 μg salbutamol, 
patients inhaled hypertonic sodium chloride aerosols (4.5 weight/ volume %) 
during three periods of 5 min. Differential cell counts were expressed as a 
percentage of nucleated cells, excluding squamous cells. A sputum sample 
was considered adequate when the percentage squamous cells was ≤80%. 
Bronchial biopsies 
Fibreoptic bronchoscopy was performed using a standardised protocol and 
has been described in detail previously [21]. In brief, four paraffin embedded 
biopsies were cut in 4-μm thick sections. Haematoxylin eosin staining was used 
for evaluation and selection of the two morphological best biopsies per patient. 
Specific antibodies against T lymphocytes (CD3 and CD8: DAKO, Glostrup, 
Denmark; CD4, Novocastra, Newcastle upon Tyne, UK), macrophages 
Data are presented as mean±standard deviation (SD) or median (interquartile range), unless stated otherwise. BMI: 
body mass index; FEV1 = forced expiratory volume in one second; % pred: % predicted; IVC: inspiratory vital capa-
city; PC20 methacholine = the provocative concentration of methacholine that causes a decrease in FEV1 of 20%; 
RV: residual volume; TLC: total lung capacity; TLCO: transfer factor of the lung for carbon monoxide; VA: alveolar 
volume. #:adjusted for length; ¶geometric mean (IQR). *:p=<0.05.
Table 1. Clinical characteristics of COPD patients with and without chronic bronchitis (CB)
With CB Without CB p-value
Subjects n 53 60
Age, yrs 61±8 62±7 0.28
Male / female 42 / 11 56 / 4 0.028*
BMI 25.1±4 25.3±4 0.87
Current smoking yes/no 40 / 13 31 / 29 0.009*
Pack-yrs 42 (34-56) 40 (28-53) 0.12
Post-bronchodilator FEV1 
 L # 2.01±0.4 2.04±0.5 0.49
Post-bronchodilator FEV1 % pred 63±8 63±10 0.54
Post-bronchodilator FEV1/IVC % 49±8 47±9 0.34
Reversibility FEV1 % pred 6.8±5 6.9±5 0.92
PC20 methacholine 
¶ mg/ml 0.59 (0.15-2.72) 0.61 (0.17-2.07) 0.89
RV/TLC % 48.6±10 47.8±7 0.61
TLCO/VA % pred 73.8±25 77.2±26 0.49
TLCO/VA % pred 73.8±25 77.2±26 0.49
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(CD68, DAKO), neutrophil elastase (NE, DAKO), mast cell tryptase (AA1, 
DAKO), plasma cells (CD138, IQ Products, Groningen, The Netherlands) and 
eosinophils (EG2, Pharmacia Diagnostics, Uppsala, Sweden) were used. Fully 
automated inflammatory cell-counting procedures were performed according 
to previously described validated methods [22]. The number of sub-epithelial 
positively staining inflammatory cells was counted within the largest possible 
area of maximal 125 μm deep beneath the basement membrane, per biopsy 




Data were presented as mean±SD or medians (interquartile range). The 
differences between patients with and without chronic bronchitis were 
analysed using the unpaired t-tests for normally distributed continuous 
variables. Chi-squared tests were used for categorical data. Non-normally 
distributed data were log transformed. Multiple logistic regression analysis was 
used to investigate the independent association between chronic bronchitis 
and inflammatory cells. In this model the dependent variable was the presence 
of chronic cough and sputum expectoration, whereas independent variables 
were bronchial and sputum inflammatory cells, with additional adjustment for 
smoking habits and sex. Differences at p-values <0.05 were considered to be 
statistically significant (tested two-sided). 
Data are presented as median (interquartile range) of bronchial inflammatory cells (per 0.1 mm2 of sub-epithelial 
area), unless stated otherwise. EG2: eosinophils. #: Data from one patient was excluded as biopsy specimens were 
not adequate for analysis. Data *: p=<0.05.
Table 2. Comparison of bronchial inflammatory cells in COPD patients with and without   
 chronic  bronchitis #
With CB Without CB p-value
Subjects n 53 59
CD3+ lymphocytes 124 (71-182) 121 (60-193) 0.95
CD4+ lymphocytes 45 (24-72) 48 (28-75) 0.61
CD8+ lymphocytes 18 (11-33) 23 (9.0-42) 0.48
CD4/CD8 % 2.04 (1.2-4.5) 2.08 (1.2-3.8) 0.96
CD8/CD3 % 0.16 (0.11-0.34) 0.20 (0.11-0.31) 1.00
CD4/CD3 % 0.37 (0.26-0.63) 0.43 (0.25-0.74) 0.51
EG2+ cells 1.0 (0.25-2.5) 2.0 (1.0-5.5) 0.019*
Neutrophils 3.0 (2.0-5.5) 5.5 (2.0-8.5) 0.080
Plasma cells 8.0 (3.5-15) 9.0 (4.0-14.5) 0.34
CD68+ cells 8.5 (4.3-11.8) 10 (5.0-14) 0.20
AA1+ cells 27 (21-34) 26 (18-35) 0.80
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Results
The patient characteristics of COPD patients with and without chronic 
bronchitis are shown in Table 1. Data on the presence of chronic bronchitis 
were available for 113 out of 114 patients with COPD. All patients had 
moderate to severe COPD as based on an average postbronchodilator FEV₁ 
of 63±9% of predicted and most of them were current smoking, middle-
aged males. A minority of patients was mildly reversible to salbutamol, as 
based on FEV₁ (% pred) post minus 
pre-salbutamol.  A total of 18 (16%) 
patients showed a change in FEV₁ 
that was >12 % pred and > 200 
ml, whereas nine out of these 18 
patients had chronic bronchitis. COPD 
patients with and without chronic 
bronchitis exhibited a wide range of 
hyperresponsiveness to methacholine, 
were slightly hyperinflated and were 
mildly impaired in carbon monoxide 
diffusion capacity per alveolar volume. 
Patients with chronic bronchitis were 
more likely to be current smokers than 
patients without these symptoms. 
Relatively more female patients 
reported chronic bronchitis. Other 
patient characteristics were similar 
between the two groups (Table 1).
Bronchial inflammatory cell counts in COPD patients with and without 
chronic bronchitis
Data on the number of bronchial inflammatory cells were available for 53 
patients and 59 patients with without chronic bronchitis (Table 2). Patients 
with chronic bronchitis had significantly fewer eosinophils in biopsies than 
patients without chronic bronchitis (p=0.019, Figure 1). Logistic regression 
analysis confirmed this association. After adjustment for smoking and sex, 
there was a statistically significant lower chance of 16% of having chronic 
bronchitis for each doubling in bronchial eosinophils (odds ratio (OR) 0.84 
(95% CI 0.72-0.98): p=0.028). Patients with chronic bronchitis tended to have 
Figure 1.
The number of eosinophils (EG2) in bronchial biopsies 
(per 0.1 mm-2 sub-epithelial area) in chronic obstructive 
pulmonary disease patients with and without chronic 
bronchitis (CB). The horizontal lines represent 
the median.
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fewer neutrophils in biopsies than patients without chronic bronchitis, but this 
difference was not statically significant (p=0.080). The remaining inflammatory 
parameters in bronchial biopsies were similar between the two groups. 
Sputum inflammatory cells in COPD patients with and without chronic 
bronchitis
Table 3 shows the numbers and percentages of inflammatory cells in induced 
sputum for COPD patients with and without chronic bronchitis. COPD patients 
with chronic bronchitis had significantly higher percentages of sputum 
eosinophils (p=0.033) than COPD patients without these symptoms (Figure 2a). 
After adjustment for smoking and sex, each doubling in sputum % eosinophils 
was borderline significantly associated with a 24% higher chance of having 
chronic bronchitis (OR=1.24 (95% CI 0.99-1.54); p=0.057). When using a 
sputum eosinophil percentage of > 3% as threshold, sputum eosinophils 
had a specificity of 87% in identifying patients with chronic bronchitis. 
COPD patients with chronic bronchitis had significantly higher percentages 
of macrophages (p=0.039; Figure 2b), and lower percentages of sputum 
neutrophils (p=0.049) than COPD patients without those symptoms. After 
adjustment for smoking and sex, these differences lost statistical significance 
(OR 1.45 (95% CI 0.94-2.24); p=0.097 and 0.96, (0.91-1.01), p=0.11, for 
macrophages and neutrophils respectively). No differences between patients 
Data are presented as median (interquartile range), unless stated otherwise. #:Sputa from 106 patients were available 
for analysis. *: p=<0.05.
Table 3. Comparison of nonsquamous sputum inflammatory cells in COPD patients with and  
 without chronic bronchitis (CB) #
With CB Without CB p-value
Subjects n 50 55
Absolute numbers x104/ml
Total cell count 135.0 (78.6-283.9) 149.1 (73.8-313.0) 0.54
Neutrophils 90.0 (46.1-204.6) 110.0 (56.3-231.0) 0.31
Macrophages 32.6 (18.8-64.8) 29.6 (13.0-59.3) 0.45
Lymphocytes 2.2 (1.0-5.6) 2.1 (1.0-7.2) 0.94
Eosinophils 1.7 (0.48-4.9) 1.1 (0.2-3.3) 0.13
Epithelial cells 1.26 (0.69-3.39) 1.37 (0.43-3.82) 0.40
Basophils 0 (0-0) 0 (0-0) -
Percentages
Neutrophils 69.9 (55.0-97.5) 73.8 (65.8-83.7) 0.046*
Macrophages 23.0 (17.7-35.1) 21.3 (12.7-28.3) 0.039*
Lymphocytes 1.8 (1.2-2.4) 1.7 (0.8-2.2) 0.47
Eosinophils 1.4 (0 .5-2.3) 0.7 (0.2-1.7) 0.033*
Epithelial cells 1.0 (0.5-2.3) 1.3 (0.2-2.3) 0.32
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with or without chronic bronchitis were found for percentages of lymphocytes 
and epithelial cells, or numbers of total cell counts, neutrophils, macrophages, 
lymphocytes, and epithelial cells in induced sputum. 
Relation between sputum and bronchial inflammatory cell counts
Percentages of eosinophils in sputum 
were positively associated with 
eosinophil counts in biopsies within 
the chronic bronchitis groups as well 
as within the group of patients without 
chronic bronchitis. Interestingly, the 
percentages of sputum eosinophils 
were doubled in patients with chronic 
bronchitis compared to patients 
without chronic bronchitis for a 
given number of eosinophils in the 




Relationship between the percentages of eosinophils 
in induced sputum (y-axis) and eosinophils (per 0.1 
mm-2 sub-epithelial area) in bronchial biopsies (x-axis) 
in chronic obstructive pulmonary disease patients with 
and without chronic bronchitis.
Figure 2.
Percentages of a) eosinophils and b) macrophages in induced sputum in chronic obstructive pulmonary disease 
patients with and without chronic bronchitis (CB). The horizontal lines represent the median.
a) b)
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Discussion
This study shows that chronic bronchitis reflects an inflammatory sub-
phenotype among patients with moderate to severe COPD, which is 
characterised by a distinct inflammatory cell profile as measured in a large 
sample of induced sputum specimens and bronchial biopsies. More specific, 
clinical symptoms of chronic bronchitis in COPD are associated with a 
distinct distribution of bronchial and sputum eosinophils. In addition, patients 
with chronic bronchitis had higher percentages of macrophages and lower 
percentages of neutrophils in their sputum. The latter could be explained by 
differences in current smoking habits and sex distribution between the two 
groups. No significant differences were found between the two groups with 
regard to other inflammatory cells in biopsies or sputum. Taken together, clinical 
symptoms of chronic bronchitis in COPD appear to represent an inflammatory 
sub-phenotype, which may have implications in anti-inflammatory treatment in 
clinical practice. 
The present study demonstrates for the first time that chronic bronchitis 
among patients with manifest COPD is characterised by a partially distinct 
inflammatory cell profile of eosinophils, macrophages and neutrophils. 
Comparison between the present findings on eosinophils and studies in 
literature is difficult as outlined hereafter, since either chronic bronchitis 
within COPD was not addressed as a separate entity [14;23] or different 
tissues were used [24]. Furthermore, in most of these studies lower numbers 
of patients were investigated [14;24]. Therefore, the present observation of 
a preferential distribution of eosinophils towards the airway lumen in COPD 
patients with chronic bronchitis extends a previous report [14], where no 
differences were observed in the number of eosinophils in the submucosa of 
the airway wall (resected lung tissue) from smokers with chronic bronchitis 
(COPD) as compared to non-smoking controls (non-COPD). Furthermore, it 
has recently been found that smokers with chronic bronchitis (COPD) have 
similar percentages of sputum eosinophils as compared to non-smoking 
controls (non-COPD) [23]. Together, these studies and the present authors’ 
observations show that comparison of COPD patients with and without 
chronic bronchitis reveals different inflammatory sub-phenotypes within 
COPD, whereas comparison of COPD patients with chronic bronchitis and 
nonsmoking controls may reflect the inflammatory process associated with 
the development of COPD.
The present authors observed that COPD patients with chronic bronchitis 
had relatively higher percentages of macrophages and lower percentages 
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of neutrophils in sputum, which was mainly due to differences in current 
smoking habits between the two groups. These associations with smoking 
are in line with results from Willemse et al [23]. Remarkably, no differences 
were found with regard to T lymphocytes, neutrophils, macrophages or mast 
cells in bronchial biopsies between COPD patients with and without chronic 
bronchitis. This extends the findings by Saetta et al., where inflammatory 
cells in the submucosa were similar between subjects with chronic bronchitis 
(COPD) and non-smoking controls (non-COPD) [14]. However, again this may 
reflect the different populations and tissues examined.   
To the present authors’ knowledge, the present study is one of the largest using 
induced sputum as well as bronchial biopsies in well-characterised steroid-
naïve patients with COPD. Nonetheless, some limitations must be mentioned. 
There is overlap of data in biopsies and sputum between both groups. Yet, 
this is in line with results from other studies examining similar parameters in 
different and smaller groups of patients [14;25]. More importantly, for a given 
number of eosinophils in the bronchial biopsies the percentages of sputum 
eosinophils were doubled in patients with chronic bronchitis compared to 
patients without these symptoms. The presence of chronic bronchitis, as 
based on clinical symptoms only, may be biased due to different awareness 
by sex, through retrospective selection of the patients, or the influence of 
recurrent exacerbations. The present results, however, were corrected for sex, 
and it needs to be emphasized that symptoms of chronic bronchitis have been 
associated with hypersecretion of mucus from enlarged bronchial glands and 
inflammatory cells in resected lung tissue since the early 1950s [14;26;27]. Only 
9 patients experienced exacerbations (symptoms plus prednisone) in the year 
prior to our study and we believe that the influence of exacerbations on the 
presence of chronic bronchitis was limited. Furthermore, chronic symptoms of 
cough and sputum production have been associated with a more rapid decline 
in FEV1 and increased COPD-related mortality [5;8]. Therefore, despite the fact 
that chronic bronchitis is indeed likely to be a continuum, the currently used 
definition is supported by clinical and pathological data. 
It is possible that we did not investigate the right anatomic region when studying 
bronchial biopsies and that peripheral lung tissue is needed to investigate the 
total airway wall, therefore allowing the use of other parameters such as the 
Reid’s index (i.e. the ratio of the thickness of the mucous gland layer to the 
thickness of the wall between the epithelium and cartilage). However, previous 
studies showed that patients with both chronic bronchitis and fixed airway 
obstruction had the same Reid’s index compared to controls, whereas scores 
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of inflammation were better associated with mucus hypersecretion [14;27]. It 
may also be argued that the distribution of inflammatory cells obtained with 
different techniques (i.e. induced sputum and bronchial biopsies) is difficult 
to interpret. A previous study [28], however, showed fairly good agreement 
between the number of eosinophils in different compartments in the airways in 
patients with chronic bronchitis. It is noteworthy that, although not significant, 
the differences in absolute numbers of total cells, eosinophils, macrophage 
and neutrophils in sputum between patients with and without chronic 
bronchitis demonstrated the same trend and magnitude as the differences 
in percentages between both groups. In addition, inflammatory cell numbers 
may not represent cell activity, an aspect that requires more in-depth analysis. 
However this was beyond the scope of the present study. 
How can these results be interpreted? Mucus hypersecretion, which is the 
hallmark of clinical chronic bronchitis, is the result of mucin production, 
secretion and clearance [29]. Inflammatory mediators such as neutrophil 
elastase, are important secretagogues for mucin-producing cells. In COPD, 
both cigarette smoke and neutrophil elastase are main determinants of not 
only mucin production and secretion but also of clearance, by impaired 
ciliary activity and dehydration of the airway surface layer [29]. Nevertheless, 
the present study shows that chronic bronchitis is related to eosinophils in 
biopsies and sputum. Increased numbers of eosinophils in sputum that have 
migrated through the epithelial layer may contribute to mucus hypersecretion 
through the action of transforming growth factor (TGF-α) [30] or by stimulating 
degranulation of mucus-producing cells through the release of inflammatory 
mediators, including cysteinyl leukotrienes  [31]. Therefore, the present findings 
of a preferential distribution are in line with a role of eosinophils in mucus 
hypersecretion. This is further supported by other studies showing increased 
sputum eosinophils during COPD exacerbations [32] and a positive correlation 
between airway eosinophilia and increased sputum production in asthma 
[33]. A decrease in the number of eosinophils in the airway wall, especially 
around the glands, may also contribute to mucus hypersecretion. Eosinophils 
are a major cellular source of TGF-α [34] and Baraldo et al. showed that 
impaired TGF-α signalling is associated with bronchial gland enlargement [35]. 
Therefore a lower number of eosinophils around the bronchial glands may lead 
to bronchial gland enlargement and a subsequent rise in mucus in the airway 
lumen, due to a decreased local TGF-α availability. Another explanation for 
our findings is that the same mechanism is involved in eosinophil recruitment 
into the airway lumen as well as in mucus hypersecretion. T-helper cell type 
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2 cytokines may be involved in such mechanisms since the expression of 
interleukin (IL)-4 and -13 is higher in patients with chronic bronchitis [36] 
and these cytokines are involved in the regulation of both eosinophil influx 
[37] and mucin production [38]. Based on the current information, we can not 
discriminate between these two explanations for the altered distribution of 
eosinophils in COPD patients with chronic bronchitis that we observed. 
The present results also showed that patients with chronic bronchitis had 
higher percentages of macrophages in sputum, which was mainly explained 
by current smoking. This may indicate that sputum macrophages may act as 
an intermediary variable in the causal pathway of chronic bronchitis. Activated 
by cigarette smoke, macrophages might contribute to mucus hypersecretion 
directly via release of pro-inflammatory cytokines such as IL-1ß and indirectly 
by neutrophil-chemotactic factors such as leukotriene B4 and IL-8 [39]. 
Neutrophils in bronchial biopsies would be expected to be related to the 
presence of chronic bronchitis. Neutrophil elastase is thought to stimulate both 
the release and production of mucin. The present study showed no differences 
in neutrophils between patients with and without chronic bronchitis. One 
explanation might be that the submucosal glands, thought to be responsible 
for the largest amount of mucus in the large airways [11], are more important 
in defining the sub-phenotype of chronic bronchitis. 
What are the implications of this study? Previous studies showed that 
treatment with steroids may reduce numbers of sputum eosinophils in patients 
with COPD [40;41], whereas sputum eosinophilia in COPD may be predictive 
of a clinical response to steroid treatment [42;43]. Distinct inflammatory cell 
profiles may require different (anti-inflammatory) interventions. Therefore, this 
and other novel anti-inflammatory strategies [44] may need to be examined in 
COPD patients with and without chronic bronchitis.
We concluded that clinical symptoms of chronic bronchitis reflect a 
distinct sub-phenotype among patients with manifest COPD, as based on 
inflammatory cells in induced sputum and bronchial biopsies. The present 
results indicate a preferential distribution of eosinophils towards the lumen. 
This may have implications for current and future treatment strategies [41-44] 
in chronic obstructive pulmonary disease patients with clinical symptoms of 
chronic bronchitis. 
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Abstract
Background: Inhaled corticosteroids (ICS) and long-acting ß2-agonists 
(LABAs) are used to treat moderate to severe chronic obstructive pulmonary 
disease (COPD).
Objective: To determine whether long-term ICS therapy, with or without 
LABAs, reduces inflammation and improves pulmonary function in COPD.
Design: Randomised, placebo-controlled trial. (ClinicalTrials.gov registration 
number: NCT00158847)
Setting: 2 university medical centers in The Netherlands.
Patients: 114 steroid-naïve current or former smokers with moderate to severe 
COPD.
Measurements: Cell counts in bronchial biopsies and sputum (primary 
outcome); methacholine responsiveness at baseline, 6 and 30 months; and 
clinical outcomes every 3 months.
Intervention: Random assignment by minimization method to receive 
fluticasone propionate, 500 μg twice daily, for 6 months (n=31) or 30 months 
(n=26); fluticasone , 500 μg twice daily, and salmeterol, 50 μg twice daily, for 
30 months (single inhaler; n=28); or placebo twice daily (n=29).
Results: 101 Patients were greater than 70% adherent to therapy. Fluticasone 
therapy decreased counts of mucosal CD3+ cells (-55% [95% CI, -74% to 
-22%]; P = 0.004), CD4+ cells (-78% [CI, -88 to -60%]; P < 0.001), CD8+ cells 
(-57% [CI, -77% to -18%]; P = 0.010), and mast cells (-38% [CI, -60% to -2%]; 
P = 0.039] and reduced hyperresponsiveness (P = 0.036) versus placebo at 
6 months, with effects maintained after 30 months. Fluticasone therapy for 
30 months reduced mast cell count and increased eosinophil count and 
percentage of intact epithelium, with accompanying reductions in sputum 
neutrophil, macrophage, and lymphocyte counts and improvements in 
FEV1 decline, dyspnea, and quality of life. Reductions in inflammatory cells 
correlated with clinical improvements. Discontinuing fluticasone therapy at 6 
months increased counts of CD3+ cells (120% [CI, 24% to 289%]; P = 0.007), 
mast cells (218% [CI, 99% to 407%]; P < 0.001), and 
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plasma cells (118% [CI, 9% to 336%)]; P = 0.028) and worsened clinical 
outcome. Adding salmeterol improved FEV1 level.
Limitations: The study was not designed to evaluate clinical outcomes. 
Measurement of primary outcome was not available for 24% of patients at 30 
months.
Conclusions: ICS therapy decreases inflammation and can attenuate decline 
in lung function in steroid-naïve patients with moderate to severe COPD. 
Adding LABAs does not enhance these effects.
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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by a 
progressive decrease in lung function, accompanied by worsening respiratory 
symptoms and health status [1]. These clinical features are associated with 
airway inflammation (such as that resulting from neutrophils, macrophages, 
lymphocytes, and mast cells) [2-5] and alterations of the bronchial epithelium 
(such as that resulting from squamous cell metaplasia or goblet and basal cell 
hyperplasia) [6].
Current guidelines [1] recommend treating patients who have severe COPD and 
frequent exacerbations with inhaled corticosteroids (ICSs) and adding long-
acting ß2-agonists (LABAs) for Patients with moderate to severe COPD. Regular 
ICS treatment leads to clinical benefits in terms of symptoms, exacerbation 
rates, and initial improvements in FEV1 [7-10]. However, withdrawal of ICS 
treatment results in deterioration of clinical outcome [11;12]. Combining a 
LABA with an ICS provides additional clinical improvements [13;14]. A recent 
analysis of the TORCH (Towards a Revolution in COPD Health) study suggests 
that prolonged therapy with ICS and LABA attenuates FEV1 decline in COPD 
[15], in contrast to previous studies [13;14;16-19].
The clinical benefits of ICS therapy for COPD, with or without a LABA, may be 
at least partially mediated its anti-inflammatory efficacy. Short-term treatment 
of COPD (2-3 months) with ICS reduced the number of bronchial mast cells 
but not CD8+ cells, neutrophils, or macrophages [20;21]. Combination therapy 
with ICS and LABAs for 3 months provided more anti-inflammatory effects 
than ICS monotherapy by reducing bronchial CD8+ cells and macrophages 
[22]. No long-term anti-inflammatory effects have been reported for these 
interventions. Our goal was to link pathological and clinical efficacy during 
30-month treatment.
We hypothesized that: 
1) long-term maintenance therapy with ICS provides anti-inflammatory effects 
(primary outcome) in the airways of patients with COPD; 
2) such effects are associated with clinical improvements; 
3) discontinuing ICS therapy induces a flare-up of inflammation and clinical 
deterioration; and 




Our study is investigator-initiated, with a double-blind, parallel, 4-group, 
placebo-controlled, randomised design.
Setting and participants
The GLUCOLD (Groningen Leiden Universities Chronic Obstructive Lung 
Disease) project [23] enrolled patients with COPD who were aged 45 to 75 
years, were current or former smokers, had smoked for 10 or more pack-
years, and had lung function levels compatible with Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) stages II and III [1]. Exclusion criteria were 
asthma and receipt of ICS within 6 months before random assignment. We 
determined the presence of asthma on the basis of a physician ‘s diagnosis 
or selfreported history, symptoms, treatment, or diagnosis of asthma. Patients 
were clinically stable and were allowed to continue taking short-acting 
bronchodilators. We determinec smoking status on the basis of self-reports 
and gave standard clinical advice to quit smoking in accordance with Dutch 
national guidelines. We recruited almost all patients from family practices 
by electronically selecting patients aged 45 to 75 years who did not have 
an International Classification of Primary Care code for asthma (R96). Their 
general practitioner sent them a letter asking for participation in research. A 
telephone interview revealed 4617 potentially eligible patients, who received 
spirometry. In addition, were recruited patients by advertising in local 
newspapers. We performed chest radiography and electrocardiography to rule 
out important comorbid conditions. Recruitment and follow-up was between 
2000 and 2007. Both centers’ ethics committees approved the study, and all 
patients provided written informed consent.
Random assignment and interventions
We randomly assigned patients to receive 1 of 4 regimens: fluticasone 
propionate, 500 μg twice daily, for the first 6 months followed by placebo, 
twice daily, for 24 months; fluticasone, 500 μg twice daily, for 30 months; 
fluticasone, 500 μg twice daily, and salmeterol, 50 μg twice daily, in a 
single inhaler for 30 months; or placebo, twice daily, for 30 months. Study 
medications were individually numbered, and we used Diskus dry-powder 
inhalers (GlaxoSmithKline, Zeist, The Netherlands) with 60 doses per inhaler; 
all active treatment medication and placebo were identical in appearance. The 
placebo consisted of lactose monohydrate (also included in other treatment 
groups). At entry, an independent randomisation center provided patient 
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and medication numbers by using a minimization procedure that balanced 
treatment groups for center, sex, smoking status, FEV1/IVC (<60% or ≥ 60%), 
and methacholine PC20 (the provocative concentration of methacholine that 
causes a 20% decrease in FEV1) (<2 mg/mL or ≥ 2 mg/mL).
Outcomes and Measurements
Our predefined primary outcome was inflammatory cell counts in bronchial 
biopsies and induced sputum. We performed fiberoptic bronchoscopy, 
biopsy processing, and quantification as described elsewhere [24]. We 
stained paraffin-embedded biopsy sections with Periodic acid-Schiff/Alcian 
blue to identify goblet cells, epithelial intactness, and squamous metaplasia 
as described elsewhere [25]. We performed immunohistochemistry by using 
specific antibodies against T lymphocytes (CD3, CD4, and CD8), macrophages 
(CD68), neutrophil elastase, mast cell tryptase (AA1), eosinophils (EG2), plasma 
cells (CD138), and proliferating cells (Ki-67). We expressed subepithelial cells 
as number of cells per 10-7 m2 by fully automated image analysis [26]. We used 
the full sample method [23] to perform sputum induction.
Secondary outcomes included postbronchodilator spirometry and 
hyperresponsiveness to methacholine PC20, assessed by using standardized 
procedures [23], dyspnea score by the modified Medical Research Council 
(MRC) dyspnea scale (range, 1 to 5); and health status by the St. George’s 
Respiratory Questionnaire (SGRQ) (range, 0 to 100; 100 = maximum disability) 
[27] and Clinical COPD Questionnaire (CCQ) (range, 0 to 6; 6 = worst) [28].
Follow-up Procedures
We measured symptoms, health status, self-reported smoking status, 
medication adherence, and spirometry every 3 months. We checked adherence 
by counting the doses on the inhalers. We performed bronchoscopy, sputum 
induction, and methacholine challenge at baseline and at 6 and 30 months.
Statistical analysis
We based our sample size on the latest data released in 2002 [29] regarding 
the standard deviation (0.77) of the fluticasone-induced short-term change 
in submucosal CD8 cell count in patients with COPD. A 2-fold difference in 
change from baseline to 6 months and from 6 to 30 months in the fluticasone 
group versus placebo should be detectable with 80% power with 20 patients 
per treatment group. Because this was an efficacy trial, per-protocol analysis 
included all available data from randomly assigned patients who adhered to 
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their therapy regimen (using ≥70% of the prescribed dose), including data 
from patients who did not complete follow-up.
We used linear mixed-effects models with a random intercept at the patient 
level to analyze the data and assumed that data were missing at random. We 
used STATA, version 9.0 (StataCorp, College Station, Texas) for analysis. The 
linear mixed models included the main effect of treatment (3 indicators), the 
main effect of time (2 indicators), and the interaction of treatment and time. 
For outcomes with 3-month measurements, we replaced the time effect with 
terms that allowed a shift or linear change in the average outcome during 
the first 6 months and a subsequent linear change in the average outcome 
after 6 months. Because of the considerable number of model parameters 
and the sample size, we did not include center, age, or sex as covariates in 
the baseline model. We performed a post hoc analysis to adjust for smoking 
status at baseline and during the study. We present the effects as adjusted 
means in the figures and as percentage of change in estimates, CIs, and
P values in the text.
We analyzed correlations between statistically significant treatment effects on 
inflammatory outcomes and lung function by using the Spearman correlation 
coefficient (Rs). Data are presented as means (SDs) or medians (interquartile 
ranges). We considered 2-sided P values less than 0.05 to be statistically 
significant.
Role of the funding source
This was an investigator-initiated trial. The study was funded by the 
Netherlands Organization for Scientific Research, Netherlands Asthma 
Foundation, GlaxoSmithKline of The Netherlands, University Medical Center 
Groningen, and Leiden University Medical Center. The funding sources had 
no role in the design, conduct, and analysis of the study or in the decision to 
submit the manuscript for publication.
Results
Of the 114 randomly assigned patients, we analyzed 101 adherent patients 
(Figure 1). Mean postbronchodilator FEV1 was 63% predicted (SD, 9%) (91 
patients were GOLD stage II and 10 were GOLD stage III) and geometric mean 
methacholine PC20 was 0.6 mg/mL (SD, 2.6 doubling dose). Seven patients 
had ever received a short course of corticosteroids and only 5 had ever 
received ICS maintenance therapy.
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Baseline patient characteristics were similar among the 4 treatment groups 
(Table 1). Sputum and biopsy inflammatory cells counts did not differ. 
The amount of missing data, including missing data due to dropouts, for each 
study measure were 12% for FEV1, 13.9% for methacholine PC20, 12.5% for 
MRC score, 13.9% for SGRQ score, 14.7% for CCQ score, 12.5% for bronchial 
inflammatory cells, 14.2% for epithelial features, and 14.2% sputum cells.
Short-term therapy with ICS
Fluticasone therapy decreased counts of bronchial CD3+ cells (-55% [CI, -74% 
to -22%]; P = 0.004), CD4+ cells (-78% [CI, -88% to -60%]; P < 0.001), CD8+ 
cells (-57% [CI, -77% to -18%]; P = 0.010), and mast cells (-38% [CI, -60% 
to -2%]; P = 0.039) at 6 months compared with placebo (Figure 2 and Table 
2]. This was accompanied by an increase in methacholine PC20 (1.5 doubling 
dose [CI, 0.1 to 3.0]; P = 0.036) (Figure 3, B) and CCQ mental score (0.2 point 
[CI, 0.01 to 0.4 points]; P = 0.037) compared with placebo. We found no other 
Total number of patients randomised and compliant (>70% medication use) per treatment group. At each stage of 
the study (0, 6 and 30 months) the numbers are listed of those who underwent bronchoscopy amongst the number 
of patients remaining in the study. Definition of abbreviations: n = number.
















Patients, n 24 26 26 25
Clinical
Men/women, n/n 20/4 22/4 23/3 22/3 0.94
Age, y 59 (8) 64 (7) 62 (8) 62 (8) 0.31
Current smoker/ not current smoker, n/n 17/7 14/12 16/10 17/8 0.61
Median smoking history (range), pack-years 42 (34-54) 41 (29-57) 44 (31-55) 47 (31-56) 0.62
Lung Function
Prebronchodilator FEV1, % predicted 54.1 (8.3) 56.8 (11) 56.6 (9.9) 55.0 (11) 0.742
Postbronchodilator FEV1, % predicted 61 (8.3) 65 (8.6) 64 (9.1) 61 (9.4) 0.41
Change in FEV1, % predicted 
‡ 7.1 (4.5) 7.3 (5.3) 7.1 (4.0) 6.2 (6.3) 0.87
Postbronchodilator FEV1/IVC, % 47 (9.0) 51 (8.3) 49 (9.0) 46 (8.4) 0.157
Geometric mean methacholine PC20, mg/mL 
§ 0.7 (2.0) 0.7 (3.2) 0.4 (2.4) 0.7 (2.7) 0.64
KCO, % predicted 65 (19) 79 (29) 77 (22) 74 (27) 0.188
Symptoms and health status
MRC dyspnea score || 2.7 (0.8) 2.5 (0.6) 2.6 (0.6) 2.9 (1.0) 0.53
SGRQ total score ¶ 33.5 (18.5) 25.7 (15.2) 32.9 (10.9) 28.1 (13.2) 0.27
CCQ total score ** 1.77 (1.3) 1.16 (0.6) 1.26 (0.6) 1.43 (0.7) 0.35
CCQ = Clinical COPD [chronic obstructive pulmonary disease] Questionnaire; IVC = inspiratory vital capacity; KCO = 
transfer factor for carbon-monoxide; methacholine PC20 = provocative concentration of methacholine that causes a 
20% decrease in FEV1; MRC = Medical Research Council; SGRQ = St. George’s Respiratory Questionnaire.
* Values are means (SDs) unless otherwise indicated.
† By analysis of variance or Kruskall-Wallis tests between groups.
‡ Reversibility in FEV1 by 400-μg inhaled salbutamol.
§ Methacholine PC20 values are expressed as mean doubling doses.
|| Range of 1 to 5 (a higher score indicates more dyspnea).
¶ Range of 0 (best) to 100 (worst).
** Range of 0 (best) to 6 (worst).
Table 1. Patient characteristics at baseline *
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statistically significant effects of 6 months of fluticasone therapy. The change 
in FEV1 after 6 months did not significantly differ between patients who were 
randomly assigned to continue fluticasone therapy and those assigned to 
switch to placebo.
Long-term continuation of ICS therapy
Continuing fluticasone therapy from 6 to 30 months maintained the reduction 
in CD3+, CD4+ and CD8+ cell counts (Figure 2 and Table 2) after 30 months, 
compared with placebo. This was accompanied by a further -56% change in 
mast cell count (CI, -73% to -29%; P = 0.001), a 125% increase in eosinophil 
count (CI, 2% to 399%; P = 0.046), and a 101% increase in the percentage of 
intact epithelium in bronchial biopsies (CI, 10% to 268%; P = 0.024) after 30 
months (Figure 2 and Tables 2 and 4). In addition, the 30-month fluticasone 
group had lower counts of sputum neutrophils (-58% [CI, -82% to -1%); P = 
0.047), macrophages (-57% [CI, -81% to -3%]; P = 0.041), and lymphocytes 
Adjusted mean change in log-transformed bronchial cell numbers (/10-7 m2 lamina propria) over time during 
treatment with fluticasone (500 μg bid) for 30 months (FP30), fluticasone (500 μg bid) for 6 months (FP6), the 
combination of fluticasone/salmeterol (500/50 μg bid) for 30 months (FP/S) and placebo for 30 months in patients 
with COPD. Error bars represent 95% confidence intervals (CI). Data of bronchial CD3+ cells (2A), CD4+ cells (2B), 
CD8+ cells (2C), and mast cells (2D) are presented.
Figure 2. Pathological outcomes
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(-52% [CI, -76% to -5%]; P = 0.035) at 30 months than did the placebo group 
(Table 3). 
The rates of FEV1 decline from 6 to 30 months were -79 mL/y (CI, -112 
to -46 mL/y) for the placebo group, -62 mL/y (CI, -93 to -31 mL/y) for the 
6-month fluticasone group, 7.3 mL/y (CI, -21 to 35 mL/y) for the 30-month 
fluticasone group, and -16 mL/y (CI, -46 to 15 mL/y) for 30-month fluticasone 
and salmeterol group. Fluticasone significantly diminished annual FEV1 decline 
over the last 2 years of the study compared with placebo (difference, 86 mL/y 
[CI, 43 to 129 mL/y]; P < 0.001) (Figure 3, A). The improvement in methacholine 
PC20 by fluticasone compared with placebo that we observed during the first 6 
months was maintained during the following 2 years (Figure 3, B). In addition, 
maintaining fluticasone therapy reduced dyspnea scores more than placebo 
over the last 2 years of the study (-0.2 point/y [CI, -0.3 to -0.06 point/y]; 
P = 0.003) (Figure 3, C), and significantly improved SGRQ activity score (-3.1 
points/y [CI, -5.5 to -0.7 points/y]; P = 0.012) and CCQ total score (-0.1 point/y 
[CI, -0.2 to -0.01 points/y]; P = 0.036), symptom score (-0.1 points/y [CI, -0.3 
to -0.02 points/y]; P = 0.026), and functional score (-0.1 points/y [CI, -0.2 to 
-0.01]; P = 0.027) (Figure 3, D).
Placebo, 30 mo







Baseline 6 mo 30 mo Baseline 6 mo 30 mo Baseline 6 mo 30 mo Baseline 6 mo 30 mo
Patients, n 24 20 18 26 23 20 25 24 19 25 22 19
CD3+ cells 135 57 50 111 28 38 124 21 12 118 35 36
(76-197) (37-84) (24-79) (69-180) (21-45) (19-89) (63-192) (16-33) (5.5-38) (74-191) (17-54) (15-53)
CD4+ cells 44 33 24 34 11 27 68 10 22 48 11 15
(21-66) (18-67) (11-42) (24-67) (6.5-19) (12-57) (43-100) (6.0-19) (6.5-26) (26-82) (6.9-25) (11-57)
CD8+ cells 19 14 22 17 5.5 11 23 6.8 4.0 23 8.8 7.5
(10-33) (9.0-23) (12-33) (6.9-29) (3.0-9.0) (4.3-19) (11-41) (3.3-9.5) (2.0-9.5) (16-52) (6.3-19) (4.0-24)
Neutrophils 4.0 3.0 5.3 5.0 7.0 9.8 2.5 5.5 13 5.0 6.3 7.5
(2.1-8.0) (1.5-10) (2.9-15) (1.5-9.0) (3.0-11) (5.6-22) (1.5-5.0) (2.6-12) (8.5-24) (3.0-8.0) (3.0-18) (4.0-24)
Eosinophils 1.0 0.5 1.0 2.0 0.5 5.5 1.5 0.5 2.5 1.5 0.3 1.0
(0.5-5.8) (0-2.2) (0.4-3.4) (0.5-7.5) (0-1.0) (1.1-11) (0.5-3.3) (0-1.4) (1.0-8.5) (0.5-2.5) (0-3.3) (0-5.0)
Plasma cells 7.8 2.0 5.5 11 2.0 6.3 8.0 2.0 1.0 6.5 1.3 4.0
(3.5-17) (1.5-11) (2.0-12) (7.4-14) (1.0-3.0) (1.6-13) (2.8-15) (0.6-3.4) (1.0-3.0) (4.0-18) (0.4-2.5) (1.0-7.5)
Macrophages 8.3 5.3 4.0 9.3 3.5 5.3 10 4.0 3.0 9.5 4.8 4.0
(4.1-10) (2.6-12) (2.9-15) (4.5-12) (2.0-7.5) (2.3-14) (5.0-23) (2.5-7.9) (0.5-8.5) (5.5-12) (1.9-12) (0.5-21)
Mast cells 24 11 14 31 6.0 12 22 8.0 2.5 26 7.0 5.0
(17-32) (8.5-13) (9.6-18) (23-41) (3.0-9.0) (7.5-16) (16-34) (3.0-10) (0.5-4.5) (17-32) (4.4-8.8) (1.5-10)
* Cell counts are expressed as medians (25th-75th percentiles) count/10-7 m2 of subepithelium
Table 2. Bronchial inflammatory cell counts at baseline and after 6 and 30 months*
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Discontinuation of ICS therapy
Discontinuing fluticasone therapy after 6 months increased CD3+ cell count 
by 120% (CI, 24% to 289%; P = 0.007), mast cell count by 218% (CI, 99% 
to 407%; P < 0.001), and plasma cell count by 118% (CI, 9% to 336%; P 
= 0.028) at 30 months versus continuing therapy (Figure 2 and Table 2). 
Bronchial epithelial parameters and sputum inflammatory cells did not change 
significantly (Tables 3 and 4).
Discontinuing fluticasone therapy after 6 months worsened subsequent FEV1 
decline compared with continuing therapy during the last 2 years of follow-up 
(difference in slope, -70 mL/y [CI, -111 to -28 mL/y]; P = 0.001) (Figure 3, A), 
with an accompanying deterioration in methacholine PC20 (-2.6 doubling dose 
[CI, -4.1 to -1.2 doubling dose]; P < 0.001) (Figure 3, B). Stopping fluticasone 
therapy also worsened dyspnea scores by 0.2 points/y (CI, 0.08 to 0.3 points/y; 
P = 0.001) (Figure 3, C), SGRQ total score by 1.7 points/y (CI, 0.19 to 3.2 
Adjusted mean change ± 95% CI over time during treatment with fluticasone (500 μg bid) for 30 months (FP 30), 
fluticasone (500 μg bid) for 6 months (FP 6), followed by placebo (as indicated by the vertical line), the combination 
of fluticasone/salmeterol (500/50 μg bid) for 30 months (FP/S 30) and placebo (bid), in patients with moderately 
severe COPD. Changes in PC20 are expressed as mean doubling doses. Data are presented for forced expiratory 
volume in one second (FEV1) (3A), log-transformed provocation concentration of methacholine causing a 20% fall in 
FEV1 (PC20) (3B), Medical Research Council dyspnea score (3C) and Clinical COPD Questionnaire (CCQ) (3D). 
Figure 3. Clinical outcomes
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points/y; P = 0.028) and activity score by 2.9 points/y (CI, 0.6 to 5.3 points/y; 
P = 0.015), and CCQ total score by 0.1 point/y (CI, 0.04 to 0.2 points/y; P = 
0.003) and symptom score by 0.2 points/y (CI, 0.1 to 0.3 points/y; P < 0.001), 
compared with continuing therapy (data not shown).
Addition of LABAs to ICS therapy
At 6 months, combination treatment provided no additional anti-inflammatory 
effects compared with fluticasone alone; however, at 30 months, CD3+ cell 
count had increased by 126% (CI, 27% to 303%; P = 0.006) and plasma cell 
count by 144% (CI, 21% to 393%; P = 0.013) (Figure 2 and Table 2), and 
eosinophils in bronchial biopsies had changed by -55% (CI, -79% to -1%; P = 
0.047). Salmeterol had no additional effect on bronchial epithelial parameters 
or sputum inflammatory cells (Table 3 and 4).
At 6 months, combination therapy increased postbronchodilator FEV1 (96 mL 
[CI, 16 to 176 mL]; P = 0.018) (Figure 3, A) and improved dyspnea scores (-0.4 
points [CI, -0.7 to -0.04 points]; P = 0.027) (Figure 3, C) more than fluticasone 
alone. Improved FEV1 was maintained during prolonged combination therapy 
without further alteration of FEV1 decline, compared with fluticasone alone, 
but the dyspnea score increased after 30 months (0.1 points/y [CI, 0.01 to 0.3 
points/y]; P = 0.029). During the first 6 months, combination therapy resulted 
in a change of -0.3 points (CI, -0.5 to -0.07 points; P = 0.007) in CCQ total 
score, -0.3 points (CI, -0.6 to -0.04; P = 0.028) in symptom score, and -0.3 
points (CI, -0.6 to -0.08 points; P = 0.008) in functional score (Figure 3, D). 
The minimal clinically important difference of 0.4 was not reached [30). During 
the subsequent 24 months, combination therapy did significantly worse than 
* Data are expressed as medians (25th - 75th percentiles)
Table 3. Sputum inflammatory cell counts at baseline and after 6 and 30 months*
Placebo, 30 mo Fluticasone, 6 mo, Then Placebo, 24 mo Fluticasone, 30 mo
Fluticasone Plus 
Salmeterol, 30 mo
Baseline 6 mo 30 mo Baseline 6 mo 30 mo Baseline 6 mo 30 mo Baseline 6 mo 30 mo
Total cell count, 
x104 cells/mL)
168 62 107 117 101 95 175 95 58 136 114 55
(77-235) (41-212) (18-268) (53-380) (80-320) (57-164)
(101-
316)
(53-178) (23-74) (78-247) (60-201) (17-160)
Neutrophils, %
72 74 70 73 67 75 66 68 71 72 74 75
(54-80) (54-81) (50-85) (63-82) (56-79) (61-79) (50-77) (47-78) (45-79) (61-81) (64-81) (65-81)
Eosinophils, %
0.9 0.8 1.0 1.3 1.0 1.0 1.2 0.8 0.8 1.3 0.8 0.8
(0.3-2.2) (0.2-1.3) (0.2-1.8) (0.5-2.6) (0.5-1.6) (0.5-1.9) (0.3-2.2) (0.2-1.9) (0.5-1.8) (0.2-2.3) (0.4-1.3) (0.3-2.0)
Macrophages, %
22 23 22 22 20 20 29 25 19 23 19 19
(16-36) (16-39) (11-31) (13-27) (14-34) (15-28) (19-37) (17-37) (14-38) (17-32) (14-31) (16-29)
Lymphocytes, %
1.8 1.7 1.8 1.8 1.5 2.0 2.2 2.0 1.9 1.3 2.0 1.7
(1.3-3.0) (1.0-3.2) (1.2-3.7) (1.5-2.2) (1.2-2.3) (1.2-3.3) (1.2-3.1) (1.2-2.9) (1.1-2.3) (0.8-2.4) (0.7-2.8) (1.2-2.5)
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fluticasone alone on these outcomes, with a change of 0.1 point/y (CI, 0.04 to 
0.2 points/y; P = 0.003) in total score, 0.1 point/y (CI, 0.03 to 0.3 points/y; P = 
0.013) in symptom score, and 0.1 point/y (CI, 0.03 to 0.2 points/y; P = 0.012) 
in functional score.
We analyzed the data by using a model that also included individual variances 
of the slopes and obtained similar results. 
Upper panel. Correlation of changes (30 months minus baseline) in postbronchodilator forced expiratory volume in 
one second (FEV1, % predicted) with changes in log-transformed CD4
+ cell numbers (/10-7 m2) (4A) and changes 
in log-transformed mast cell numbers (/10-7 m2) (4B) in the lamina propria of bronchial biopsies in COPD patients 
treated with fluticasone propionate 30 months or placebo. Lower panel. Correlation of changes (30 months minus 
baseline) in log-transformed provocative concentration of methacholine causing a 20% fall in FEV1 (PC20) with 
changes in log-transformed CD4+ cell numbers (/10-7 m2) (4C) and changes in log-transformed mast cell numbers 
(/10-7 m2) (4D) in the lamina propria of bronchial biopsies in COPD patients treated with fluticasone propionate 30 
months or placebo.
Figure 4. Correlation between pathological and clinical outcomes
105
Smoking and treatment effects
During the study, 3 patients started smoking and 13 patients stopped smoking 
(balanced among groups). All above results remained statistically significant 
when adjusted for smoking status throughout the study, except for the 
reduction in sputum lymphocyte numbers by long-term fluticasone therapy.
Relation of treatment effects with pathology and lung function
Analyses of patients that received either fluticasone or placebo for 30 month 
showed that decreases in CD4+ cells were associated with improvements 
in predicted postbronchodilator FEV1 (Rs, -0.35; P = 0.037) (Figure 4). 
Improvements in methacholine PC20 were associated with reductions in CD3
+ 
cells (Rs, -0.36; P = 0.041), CD4+ cells (Rs, -0.38; P = 0.034), and mast cells 
(Rs, -0.46; P = 0.007), and increases in Percentage intact epithelium (Rs, 0.40; 
p = 0.024) (Figure 4).
* PAS/AB = periodic acid-Schiff/Alcian blue. 
  Data are expressed as medians (25th - 75th percentiles).
Table 4. Bronchial epithelial features at baseline and after 6 and 30 month*
Placebo, 30 mo Fluticasone, 6 mo, 
Then Placebo, 24 mo
Fluticasone, 30 mo Fluticasone Plus Salmeterol, 
30 mo
baseline 6 mo 30 mo baseline 6 mo 30 mo baseline 6 mo 30 mo baseline 6 mo 30 mo
Intact epithelium, 
%
23 22 12 30 21 15 20 20 16 29 29 25
(18-35) (10-30) (3-20) (18-42) (10-30) (4-27) (14-33) (14-28) (10-31) (16-47) (24-38) (20-50)
Squamous-cell 
metaplasia, % of 
epithelium
0 0 0 0 0 0 1.1 0 0 0 0 0
(0-30) (0-0) (0-0) (0-8.4) (0-0) (0-8.4) (0-21) (0-0) (0-0) (0-24) (0-0) (0-0)
Squamous-cell 
metaplasia, % of 
patients
24 20 24 26 26 26 25 27 25 25 26 25
PAS/AB-positive 
area, %
15 17 9.9 8.4 14 5.0 9.2 20 9.1 10 17 13
(5.9-20) (8.2-26) (4.3-27) (3.3-20) (6.1-20) (1.0-12) (3.9-15) (7.9-32) (4.6-23) (4.7-16) (8.0-24) (4.9-23)
Ki-67+ cells, per 
mm of basement 
membrane
15 6 3.4 9.9 5.4 33 12 4.1 5.4 9.2 7.3 11
(3.6-23) (0.5-28) (1.6-8.6) (3.7-34) (1.2-30) (9.3-67) (0.2-39) (0.4-12) (1.3-13) (5.6-33) (1.5-25) (6.2-36)
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Discussion
Our study shows that 2.5-year maintenance therapy with ICS in COPD reduces 
bronchial T lymphocyte and mast cell numbers and increases eosinophils 
and the integrity of bronchial epithelium, with an accompanying reduction 
in sputum cell counts. These effects are associated with a reduced rate of 
FEV1 decline and improvements in airway hyperresponsiveness, dyspnea, 
and health status. Stopping ICS therapy at 6 months leads to relapse of 
bronchial inflammation and hyperresponsiveness, dyspnea, and poorer health 
status, with acceleration of FEV1 decline. Combination therapy with ICS and 
a long-acting ß2-agonist does not provide further anti-inflammatory effects 
compared with fluticasone alone but improves the level of FEV1 without further 
influencing FEV1 decline. Our findings indicate that a subphenotype of patients 
with COPD who are steroid-naïve and have moderate airway obstruction and 
airway hyperresponsiveness are sensitive to long-term ICS therapy. These 
prolonged effects on inflammation and lung function do not imply causality but 
suggest that disease modification can be achieved in particular phenotypes of 
patients with COPD.
We observed differential effects of ICS on inflammatory cell counts. Although 
smoking may reduce corticosteroid responsiveness [31], our data show that at 
least part of the inflammation in COPD remains sensitive to this treatment. The 
contribution of CD8+ cells to inflammation and the relevant antigen-specific 
triggers in COPD are still unknown. CD4+ cells may contribute to activation 
and memory formation of CD8+ cells, as well as provide help for B cells [32]. 
Mast cells and their secreted enzymes can drive various processes relevant 
to inflammation and remodeling [33]. Although in vitro studies suggest that 
corticosteroids are less effective in inhibiting activation of mast cells than 
activation of T-cells [34], our data indicate corticosteroids can have selective 
anti-inflammatory effects in COPD. 
The observed increase in intact epithelium by ICS has also been found in 
persons with asthma [35].  Corticosteroid-induced changes in epithelial 
integrity and inflammation correlated with improvements in methacholine PC20, 
which supports the notion that airway hyperresponsiveness in COPD can be a 
marker of disease activity [36;37].
The clinical novelty of our findings is that anti-inflammatory effects observed 
with long-term ICS treatment associate with reduced FEV1 decline in 
COPD. Previous short-tem studies that investigated patients with COPD 
and similar degrees of airway obstruction [20;21;38] have shown anti-
inflammatory effects of ICS in COPD. We show that these beneficial 
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effects are maintained during long-term treatment up to 30 months. 
The detrimental effects of discontinuing ICS therapy on bronchial inflammation 
are also novel. Previous short-term studies of the combination of a LABA and 
ICS demonstrated anti-inflammatory effects versus placebo [39] or additional 
reductions of bronchial CD8+ cells and macrophages versus ICS alone [22]. 
Our data suggest that this is not a long-lasting additional effect; we observed 
a slight increase in CD3+ and plasma cells. The attenuated FEV1 decline in our 
patients with COPD contrasts with large COPD trials from the 1990s [7-9]. The 
more recent TORCH study [15] did show reductions of FEV1 decline in patients 
with COPD who received therapy ICSs, LABAs, or both. Our results suggest 
that the improvement in the level of FEV1 in the combination group might be 
due to a residual bronchodilator effect of salmeterol and not further disease 
modification. Discrepancies between the previous trials and our study may be 
due to differences in study samples, which may provide a clinical message.
Our study comprised a common subset of patients with COPD. First, by 
choosing steroid-naïve patients, we aimed to exclude patients with unknown 
previous benefits from ICS at baseline and avoid the problem of selective 
dropouts in the placebo group. Second, our patients had predominantly 
moderate degrees of airway obstruction and most demonstrated airway 
hyperresponsiveness or modest reversibility of FEV1. Recent studies [10;40] 
show that these characteristics, previously attributed to asthma alone, can 
also be components of COPD. This COPD phenotype may be particularly 
sensitive to ICS, similar to the documented beneficial effects of smoking 
cessation [37]. Of note, the decrease in postbronchodilator FEV1 in the 
placebo group was quite similar to that observed in previous studies [8;10;15]. 
We were particularly careful to exclude patients with a previous or concurrent 
diagnosis of asthma by carefully taking histories, checking family practice 
medical records, and obtaining clinical judgments from chest physicians. 
Furthermore, most patients had low numbers of eosinophils in sputum and 
biopsies (similar to those reported by Bourbeau and colleagues [22]), had 
smoked for many years, and had a mean reversibility of FEV1 to salbutamol of 
only 7% of predicted value, and most (83%) were nonreversible according to 
European Respiratory Society criteria - yet all adhered to the GOLD criteria. 
This is consistent with the patient characteristics of short-term COPD studies 
that show benefits with ICS therapy [22;39]. Airway hyperresponsiveness was 
similar to that in the Lung Health COPD study [10], which measured long-
term changes in airway hyperresponsiveness. Finally, our post hoc analysis 
showed that actual smoking throughout the study was unlikely to be a major 
108
Chapter 5  •  Effect of fluticasone with and without salmeterol in COPD 
confounder. Taken together, our findings suggest that ICS therapy, when given 
for the first time and for longer duration to steroid-naïve patients with relatively 
moderate disease, has the potential to change the clinical course of COPD.
Our study has limitations. First, only 77 of 101 analyzed patients had biopsies 
at 30 months because patients dropped out or were unwilling to have another 
bronchoscopy. This might have resulted in selection bias; however, lost-
to-biopsy rates were similar among treatment groups. Second, our study 
was not powered to examine clinical outcomes. Nevertheless, the primary 
and secondary outcome parameters were all pre-specified. According to 
international standards on clinical investigations [41], the secondary outcomes 
point toward a clinically relevant treatment benefit, given our positive findings 
in the primary outcome. In addition, the positive findings on FEV1 decline are 
consistent with the symptomatic benefit we observed [42]. Third, because 
this was an efficacy trial, we used data from adherent patients. As expected, 
the placebo group had more nonadherent patients, which may have led to 
underestimate the treatment effect. Fourth, the pathologic changes in COPD 
are not uniformly distributed among central and peripheral airways [43;44]. We 
inevitably focused on the central airways. Fifth, despite its beneficial effects, 
long-term ICS treatment has potentially meaningful adverse effects, such as 
increased frequency of pneumonia [14]. Our sample size was too small to 
draw conclusions on this.
Our study should lead to subsequent analyses of the benefits of inhaled 
steroids in COPD. Histological outcomes need to include inflammatory and 
epithelial cell activity and aspects of airway wall remodeling and fibrosis. 
Studies are also needed to determine the best inflammatory and clinical 
predictors of steroid efficacy in COPD. Finally, our results indicate a need to 
study the cost benefit of changing disease progression by using maintenance 
ICS therapy.
In conclusion, long-term maintenance therapy with ICS can reduce 
inflammation in bronchial biopsies and sputum in COPD. This is mirrored by 
attenuated lung function decline, airway hyperresponsiveness, dyspnea, and 
improved quality of life. Adding a LABA provided supplementary benefit for 
lung function but did not further alter the course of FEV1 decline. Clinicians 
who are treating patients recognize that COPD is a heterogeneous disease that 
includes various phenotypes [45]. Our observations indicate that progressive 
decline in lung function can be attenuated in steroid-naïve patients with 
moderate COPD, a long history of smoking, and airway hyperresponsiveness. 
The observed treatment response by this particular subphenotype of COPD 
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underscores the potential of tailored therapy in COPD to achieve clinical 
benefit.
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Samenvatting 
Doel: De effecten bepalen van een langdurige behandeling met 
inhalatiesteroïden, met en zonder langwerkende ß2-agonisten, op 
luchtwegontsteking en longfunctie bij COPD.
Opzet: Gerandomiseerd, placebogecontroleerd onderzoek in 2 Nederlandse 
centra (http://clinicaltrials.gov/ct2/show/NCT00158847).
Methode: 114 steroïdnaïeve patiënten met matig tot ernstig COPD (rokers en 
ex-rokers) werden dubbelblind behandeld met: fluticasonpropionaat 500 μg 2 
dd gedurende 6 (n = 31) of 30 maanden (n = 26), of met fluticasonpropionaat 
500 μg 2 dd en salmeterol 50 μg 2 dd gedurende 30 maanden (n = 28), of 
met placebo 2 dd (n = 29). Celtellingen in bronchiale biopten en geïnduceerd 
sputum dienden als primair resultaat. Luchtweghyperreactiviteit werd gemeten 
voor randomisatie, na 6 en 30 maanden; klinische parameters werden elke 3 
maanden bepaald.
Resultaten: 101 Patiënten waren meer dan 70% therapietrouw. Na 6 
maanden fluticasongebruik was het aantal lymfocyten (CD3+, CD4+ en 
CD8+) en mestcellen in de luchtwegwand verminderd (allen p < 0,005) en de 
hyperreactiviteit verbeterd (p < 0,05) ten opzichte van placebo. Deze effecten 
bleven behouden na 30 maanden. Langdurige behandeling met fluticason 
gedurende 30 maanden verminderde het aantal mestcellen en verhoogde het 
percentage intact epitheel in de bronchusbiopten. In het sputum verminderde 
het aantal neutrofielen, macrofagen en lymfocyten. Deze veranderingen 
gingen gepaard met een verminderde achteruitgang van de longfunctie en 
een verbetering van de kortademigheid en de kwaliteit van leven. Na staken 
van fluticasongebruik na 6 maanden verhoogde het aantal CD3+-cellen, 
mestcellen en plasmacellen significant en verslechterde het klinische resultaat. 
Toevoeging van salmeterol aan de behandeling verbeterde het niveau van het 
geforceerde expiratoire 1-secondevolume (FEV₁).
Conclusie: Behandeling met inhalatiecorticosteroïden kan de 
luchtwegontsteking en de versnelde afname van de longfunctie verminderen 
bij steroïdnaïeve patiënten met matig tot ernstig COPD. Het toevoegen van 
langwerkende ß2-agonisten versterkte deze effecten niet. 
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Introductie 
Kortdurende behandeling met inhalatiecorticosteroïden (ICS) heeft gunstige 
effecten bij chronische obstructieve longziekte (COPD). De effecten van 
langdurige ICS-behandeling zijn echter nog onduidelijk. 
COPD wordt gekenmerkt door een progressieve afname van longfunctie 
gecombineerd met luchtwegklachten en verslechtering van de 
gezondheidsstatus [1]. De aandoening wordt in verband gebracht met 
ontsteking in de luchtwegwand [2-4]. 
De huidige richtlijnen adviseren om patiënten met ernstige COPD en 
frequent optredende exacerbaties te behandelen met ICS in combinatie met 
langwerkende ß2-agonisten (LABA’s) [1]. ICS-behandeling leidt tot verbetering 
van symptomen, vermindering van exacerbatiefrequentie en tot initiële 
verbetering van longfunctie [5-8]. Bij staken van ICS-behandeling verslechtert 
het klinisch beeld [9]. Indien de behandeling bestaat uit een combinatie van 
ICS en een LABA verbetert het klinisch beeld meer dan bij behandeling met 
ICS alleen [10;11]. 
Een recent onderzoek suggereert dat langdurige behandeling met ICS of LABA 
de progressieve afname van het geforceerde expiratoire 1-secondevolume 
(FEV1) kan remmen bij COPD [12]. Dit is in tegenstelling tot eerdere 
onderzoeken, waaruit bleek dat langdurige behandeling met ICS of LABA bij 
COPD geen effect had op de afname van FEV1 [13-16].
De klinische effecten van ICS- en LABA-behandeling bij COPD kunnen 
gedeeltelijk berusten op anti-inflammatoire werking. Behandeling met ICS 
gedurende 2-3 maanden verminderde het aantal mestcellen, maar niet het 
aantal CD8+-cellen, neutrofielen of macrofagen in bronchusbiopten [17;18]. 
Combinatiebehandeling met ICS en LABA gedurende 3 maanden gaf meer 
anti-inflammatoire effecten dan ICS als monotherapie, [19] maar deze effecten 
werden niet op de lange termijn bestudeerd. 
Het doel van dit onderzoek was om de effecten van ICS op zowel pathologische 
als klinische kenmerken van COPD te onderzoeken tijdens een langdurige 
behandeling van 30 maanden.
Patiënten en methoden
Setting en deelnemers
Het ‘Groningen Leiden Universities Corticosteroids in Obstructive 
Lung Disease’(GLUCOLD)-project had een dubbelblinde, parallelle, 
placebogecontroleerde, gerandomiseerde opzet met 4 groepen [20]. 
Rokers en ex-rokers met > 10 pakjaren en COPD werden ingesloten (leeftijd: 
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45-75 jaar). Hun longfunctie was matig tot ernstig verstoord [1]. Exclusiecriteria 
waren: een voorgeschiedenis van astma, of huidige symptomen, diagnose 
of behandeling daarvan of -voor, en ICS-behandeling in de 6 maanden 
voorafgaande aan het onderzoek. Standaard werd geadviseerd om te stoppen 
met roken. Patiënten werden geworven in huisartsenpraktijken. De ethische 
commissies van beide centra in Leiden en Groningen keurden het onderzoek 
goed; alle patiënten gaven schriftelijke toestemming.
Randomisatie van interventies
Patiënten werden gerandomiseerd in 4 behandelgroepen: (a) 
fluticasonpropionaat 500 μg 2 dd gedurende 6 maanden, gevolgd door 
placebo 2 dd gedurende 24 maanden; (b) fluticasonpropionaat 500 μg 2 dd 
gedurende 30 maanden; (c) fluticasonpropionaat 500 μg 2 dd en salmeterol 
50 μg 2 dd gedurende 30 maanden; (d) placebo 2dd gedurende 30 maanden. 
Actieve medicatie en placebo werden geïnhaleerd via identieke Diskus-
poederinhalatoren (GlaxoSmithKline, Zeist, Nederland). Minimisatie (het gelijk 
verdelen van patiënten met hun prognostische factoren over de verschillende 
behandelarmen; elke nieuwe patiënt wordt gerandiomiseerd op basis van de 
verdeling van prognostische factoren die op dat moment aanwezig is) vond 
plaats voor centrum, geslacht, rookstatus, de verhouding FEV1: inspiratoire 
vitale capaciteit (IVC) (< 60 of ≥ 60%) en de provocatiedosis methacholine die 
nodig was om het FEV1 20% te laten dalen (PD20- methacholine) (< 2 of ≥ 2 
mg/ml).
Onderzochte parameters
De primaire uitkomstmaat was het aantal inflammatoire cellen in 
bronchusbiopten en in geïnduceerd sputum [20;21]. De details over 
bronchoscopie, biopsieverwerking en kwantificatie zijn beschreven in een 
eerder artikel met baselinegegevens [22]. Spirometrie na luchtwegverwijding 
en hyperreactiviteit (PD20-methacholine) waren secundaire uitkomstmaten 
[20]. Kortademigheid werd gemeten met een aangepaste ‘Medical research 
council(MRC)-kortademigheidschaal’; gezondheidsstatus met de ‘St. George’s 
respiratory questionnaire’ (SGRQ) en ‘Clinical COPD questionnaire’ (CCQ) 
[23]. In de CCQ is een verandering in score van 0,4 punten ten opzichte van 




Elke 3 maanden werden symptomen, gezondheidsstatus, rookstatus, 
therapietrouw (tellen van aantal doses) gemeten en spirometrie verricht. 
Bronchoscopie, sputuminductie en methacholineprovocatie werden bij de 
start uitgevoerd, en na 6 en 30 maanden.
Statistische analyse
De steekproefgrootte werd gebaseerd op fluticason-geïnduceerde 
kortetermijnverandering van de submucosale CD8+-celaantallen bij COPD 
[25]. Bij een aantal van 20 patiënten per behandelgroep is een halvering van 
CD8+-celaantallen in de fluticasongroep in vergelijking tot placebo met een 
onderscheidingsvermogen (‘power’) van 80% detecteerbaar [25]. Omdat het 
een onderzoek naar de werkzaamheid betrof, werd een per-protocolanalyse 
uitgevoerd bij alle compliante patiënten (> 70% van de voorgeschreven doses 
gebruikt).
Met lineaire ‘mixed effect’-modellen (STATA versie 9.0; StataCorp, Texas, 
Figure 1. 
Stroomdiagram van een studie naar effecten van langdurige behandeling met inhalatiecorticosteroïden bij matig 
ernstig COPD. Per behandelgroep is weergegeven het totaal aantal patiënten dat gerandomiseerd werd en dat 
therapietrouw (>70% van de voorgeschreven dosis ingenomen) was. Voor elke fase van de studie (0, 6 en 30 
maanden) zijn de aantallen patiënten vermeld die een bronchoscopie ondergingen.
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VS) werd het effect van de behandeling, tijd en de interactie van behandeling 
en tijd geanalyseerd [20]. Een post-hocanalyse onderzocht effecten van de 
rookstatus. Correlaties tussen statistisch significante behandeleffecten op 
inflammatoire cellen en longfunctie werden geanalyseerd met de spearman-
rangcorrelatiecoëfficiënt. De gegevens worden weergegeven als gemiddelden 
(SD) of medianen (interkwartielbereiken); een 2-zijdige p-waarde < 0,05 werd 
als statistisch significant beschouwd.
Resultaten
Van de 114 geïncludeerde patiënten werden 101 therapietrouwe 
patiënten geanalyseerd (Figuur 1). Van hen hadden 7 ooit een korte kuur 
met orale corticosteroïden gehad en 5 hadden ooit ICS gebruikt. De 
Karakteristieken
 






6 maanden, daarna 








man / vrouw; n / n 20 / 4 22 / 4 23 / 3 22 / 3 0,94
leeftijd; jaren 59 (8) 64 (7) 62 (8) 62 (8) 0,31
huidige roker / niet-roker; n/n 17 / 7 14 / 12 16 / 10 17 / 8 0,61
pakjaren roken; mediaan (bereik) 42 (34-54) 41 (29-57) 44 (31-55) 47 (31-56) 0,62
longfunctie
FEV1; % voorspeld
vóór luchtwegverwijding 54,1 (8,3) 56,8 (11,0) 56,6 (9,9) 55,0 (11,0) 0,74
na luchtwegverwijding 61 (8,3) 65 (8,6) 64 (9,1) 61 (9,4) 0,41
verandering in FEV1; % voorspeld 
‡ 7,1 (4,5) 7,3 (5,3) 7,1 (4,0) 6,2 (6,3) 0,87
FEV1 / IVC na luchtwegverwijding; % 47 (9,0) 51 (8,3) 49 (9,0) 46 (8,4) 0,16
geometrisch gemiddelde PD20-metacholine; mg/ml 0,7 (2,0) 0,7 (3,2) 0,4 (2,4) 0,7 (2,7) 0,64
KCO; % voorspeld 65 (19) 79 (29) 77 (22) 74 (27) 0,19
luchtwegklachten en gezondheidsstatus
MRC-dyspneu-score § 2,7 (0,8) 2,5 (0,6) 2,6 (0,6) 2,9 (1,0) 0,53
SGRQ-score; totaal || 33,5 (18,5) 25,7 (15,2) 32,9 (10,9) 28,1 (13,2) 0,27
CCQ-score; totaal ¶ 1,77 (1,3) 1,16 (0,6) 1,26 (0,6) 1,43 (0,7) 0,35
FEV1 = geforceerde expiratoire 1-secondevolume; IVC = inspiratoire vitale capaciteit; 
PD20-methacholine = de provocatieve concentratie van methacholine die een afname van 20% in FEV1 veroorzaakt; 
KCO = diffusiecapaciteit voor CO; MRC = ‘Medical research council’; SGRQ = ‘St. George´s respiratory 
questionnaire’; CCQ = ‘Clinical COPD questionnaire’.
* Waarden zijn gemiddelden (SD) tenzij anders vermeld.   
† Variantieanalyse of kruskal–wallistoets tussen groepen.  
‡ Reversibiliteit in FEV1 na inhalatie van 400 μg salbutamol.  
§ Bereik van 1 tot 5 (een hogere score betekent meer dyspneu).
|| Bereik van 0 (best) tot 100 (slechtst).    
¶ Bereik van 0 (best) tot 6 (slechtst).
Tabel 1. Studie naar effecten van langdurige behandeling met inhalatiecorticosteroïden bij  
 matig ernstig COPD; karakteristieken van 101 therapietrouwe patiënten bij aanvang  
 van de studie*
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patiëntkarakteristieken bij aanvang van het onderzoek waren vergelijkbaar 
tussen de 4 behandelgroepen (Tabel 1), evenals het aantal inflammatoire 
cellen in het sputum en de bronchusbiopten. 
ICS-behandeling
6 maanden
Behandeling met fluticason verminderde, in vergelijking tot placebo, het aantal 
bronchiale CD3+-cellen met 55% (p = 0,004), CD4+-cellen met 78% (p < 0,001), 
CD8+-cellen met 57% (p = 0,010) en het aantal mestcellen met 38% (p = 0,039; 
Figuur 2). Tegelijkertijd nam bij fluticasonbehandeling de PD20-methacholine 
toe vergeleken met placebobehandeling (1,5 verdubbelende dosering van 
methacholine; p = 0,036) (Figuur 3B), evenals de score van een onderdeel van 
de CCQ over het mentale welzijn (toename met 0,2 punten, p = 0,037). 
Figuur 2.
Uitkomsten van pathologisch onderzoek in een studie naar de effecten van langdurige behandeling met 
inhalatiecorticosteroïden bij matig ernstig COPD. De grafieken tonen de aangepaste gemiddelde verandering 
in loggetransformeerde celaantallen in bronchusbiopten (per 10-7 m2 lamina propria) tijdens behandeling met 
fluticasonpropionaat 500 μg 2 dd gedurende 30 maanden, fluticasonpropionaat 500 μg 2 dd gedurende 6 maanden, 
de combinatie van fluticasonpropionaat/salmeterol 500/50 μg 2 dd gedurende 30 maanden en placebo gedurende 
30 maanden. ‘Error bars’ geven het 95%-betrouwbaarheidsinterval weer. Weergegeven zijn de gegevens van (a) 
bronchiale CD3+-cellen, (b) CD4+-cellen, (c) CD8+-cellen en (d) mestcellen.
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30 maanden 
Tijdens de behandeling met fluticason van 6 tot 30 maanden bleef de afname 
van het aantal CD3+-, CD4+- en CD8+-cellen in bronchusbiopten behouden 
vergeleken met placebo (zie Figuur 2). Het aantal mestcellen nam verder af 
(56%, p = 0,001), het aantal eosinofielen nam toe (125%, p = 0,046) evenals 
het percentage intact epitheel (101%, p = 0,024). Daarnaast verminderde in het 
sputum het aantal neutrofielen (58%, p = 0,047), macrofagen (57%, p = 0,041) 
en lymfocyten (52%, p = 0,035) na 30 maanden, vergeleken met placebo.
Ten opzichte van de gemiddelde FEV1-waarde na 6 maanden, daalde de 
waarde na 30 maanden met 79 ml/jaar in de placebogroep, met 62 ml/jaar in 
de 6-maanden-fluticasongroep en met 16 ml/jaar in de groep met 30 maanden 
combinatietherapie. In de 30-maanden-fluticasongroep steeg de gemiddelde 
FEV1-waarde met 7,3 ml/jaar. Vergeleken met placebo, verbeterde het gebruik 
van fluticason de jaarlijkse FEV1-afname van 6 tot 30 maanden met 86 ml/jaar 
(p < 0,001; Figuur 3a). 
De verbetering van PD20-methacholine door fluticasonbehandeling in de eerste 
6 maanden, vergeleken met placebo, bleef behouden tijdens de volgende 2 
jaar (zie Figuur 3b). Gedurende de laatste 2 jaar van het onderzoek verbeterde 
fluticasongebruik de ‘kortademigheidsscore’ (p = 0,003; Figuur 3c), de ‘SGRQ-
activiteitenscore’ (p = 0,012), de totale score van de CCQ (p = 0,036) en van 
de ‘CCQ-symptoomscore’ (p = 0,026) en ‘CCQ-functionele score’ (p = 0,027; 
Figuur 3d).
Staken van ICS-behandeling
Staken van fluticasonbehandeling na 6 maanden had geen effect op de 
aantallen inflammatoire cellen in het sputum en op de epitheelparameters 
in bronchusbiopten. Wel resulteerde het staken na 6 maanden 
fluticasonbehandeling in een toename van het aantal CD3+-cellen (120%, p 
= 0,007), mestcellen (218%, p < 0,001) en plasmacellen (118%, p = 0,028) in 
bronchusbiopten na 30 maanden, vergeleken met de biopten van patiënten 
die 30 maanden fluticason hadden gebruikt (zie Figuur 2). 
De FEV1-afname van 6 tot 30 maanden was groter na stoppen dan bij 
continueren van fluticasongebruik (verschil van 70 ml/jaar; p = 0,001; Figuur 
3a). De PD20-methacholine verslechterde met 2,6 verdubbelingsdoses (p < 
0,001; Figuur 3b). De kortademigheidscore daalde met 0,2 punten/jaar (p = 
0,001; Figuur 3c), evenals de volgende scores: ‘SGRQ totale score’ (met 1,7 
punten/jaar; p = 0,028), ‘activiteitenscore’ (met 2,9 punten/jaar; p = 0,015), 
‘CCQ totale score’ (met 0,1 punt/jaar; p = 0,003) en de ‘symptoomscore’ (met 
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0,2 punten/jaar; p < 0,001) (gegevens niet getoond).
Combinatie ICS en langwerkende ß2-agonisten
Combinatiebehandeling gedurende 6 maanden gaf geen extra anti-
inflammatoire effecten vergeleken met fluticasonbehandeling alleen. Na 30 
maanden nam het aantal CD3+-cellen en plasmacellen toe (126%; p = 0,006 
respectievelijk 144%; p = 0,013; Figuur 2) en het aantal eosinofiele cellen af 
(55%; p = 0,047). Behandeling met salmeterol had geen extra anti-inflammatoir 
effect op de aantallen cellen in het sputum [20].
Na 6 maanden combinatiebehandeling verbeterde de gemiddelde FEV1-
waarde met 96 ml (p = 0,018; Figuur 3a) en de kortademigheidscores met 
0,4 punten (p = 0,027; Figuur 3c), meer dan bij fluticasonmonotherapie. Deze 
initiële verbetering van het FEV1 werd behouden tijdens de voortgezette 
combinatiebehandeling, zonder verdere beïnvloeding van de FEV1-
Figuur 3.
Klinische uitkomsten in een studie naar effecten van langdurige behandeling met inhalatiecorticosteroïden bij matig 
ernstig COPD. De grafieken tonen de aangepaste gemiddelde verandering met 95%-betrouwbaarheidsintervallen, 
tijdens de behandeling met fluticasonpropionaat 500 μg 2 dd gedurende 30 maanden, fluticasonpropionaat 500Mg 2 
dd gedurende 6 maanden gevolgd door placebo, de combinatie van fluticasonpropionaat/salmeterol 500/50Mg 2 dd 
gedurende 30 maanden en placebo. Gegevens zijn gepresenteerd als (a) geforceerde expiratoire 1-secondevolume 
(FEV1), (b) loggetransformeerde  provocatieve concentratie van methacholine die een afname van 20% in FEV1 
veroorzaakt (PD20-metacholine; veranderingen hierin zijn weergegeven als gemiddelde verdubbelingsdosis), (c) 
‘Medical research council’-dyspneu-score en (d) ‘Clinical COPD questionnaire’ (CCQ).
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daling, vergeleken met alleen fluticason. De kortademigheidscore nam 
na 30 maanden toe met 0,1 punt (p = 0,029). Tijdens de eerste 6 maanden 
combinatiebehandeling verbeterde de ‘totale CCQ-score’ (p = 0,007), 
‘symptoomscore’ (p = 0,028) en ‘functionele score’ (p = 0,008) (Figuur 3d). Het 
minimale klinisch significante verschil van 0,4 werd niet bereikt [24]. Tijdens 
de daarop volgende 24 maanden verslechterde de ‘totale CCQ-score’ (p = 
0,003), ‘symptoomscore’ (p = 0,013) en ‘functionele score’ (p = 0,012) in de 
groep met combinatiebehandeling.
Figuur 4.
Correlatie tussen verandering in pathologie en klinische uitkomsten bij COPD-patiënten behandeld met fluticason 
30 maanden of placebo. Weergegeven zijn correlaties van veranderingen (30 maanden minus baseline) in 
geforceerde expiratoire 1-secondenvolume (FEV1, % van voorspeld) na luchtwegverwijdering, met (a) veranderingen 
van loggetransformeerde CD4+-celaantallen (per 10-7 m2 lamina propria van bronchus biopten; Spearman 
rangcorrelatiecoëfficiënt  (Rs): -0,35; p: 0,037) en (b) met veranderingen in loggetransformeerde mestcelaantallen 
(per 10-7 m2 lamina propria van bronchusbiopten; Rs: -0,21; p: 0,221). Daaronder zijn weergegeven correlaties van 
veranderingen (30 maanden minus baseline) in loggetransformeerde provocatieve concentratie van methacholine 
die een afname van 20% in FEV1 veroorzaakt (PD20) met (c) veranderingen van loggetransformeerde CD4
+-
celaantallen (per 10-7 m2 lamina propria van bronchus biopten; Rs: -0,38; p: 0,034) en met (d) veranderingen in 
loggetransformeerde mestcel aantallen (per 10-7 m2 lamina propria van bronchusbiopten; Rs: -0,46; p: 0,007).
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Roken 
Alle bovenstaande resultaten bleven significant na correctie voor 
rookstatus, behalve het aantal lymfocyten in het sputum na 30 maanden 
fluticasonbehandeling.
 
Relatie pathologie en longfunctie 
Analyse van patiënten die gedurende 30 maanden fluticason of placebo 
gebruikten, toonde dat verbetering van de FEV1-waarden correleerde met 
afname van CD4+-cellen (p = 0,037; Figuur 4). Een verbetering in PD20-
methacholine correleerde met afname van CD3+-cellen (p = 0,041), CD4+-cellen 
(p = 0,034) en mestcellen (p = 0,007) en met toename van het percentage 
intact epitheel (p = 0,024; Figuur 4).
Beschouwing
Ons onderzoek bij COPD toonde aan dat gedurende een ICS-behandeling van 
2,5 jaar het aantal bronchiale T lymfocyten en mestcellen verminderde en het 
aantal eosinofielen en de bronchiale epitheliale integriteit toenam, tegelijk met 
afname van celaantallen in het sputum. Deze effecten gingen gepaard met een 
minder snelle FEV₁-afname en met verbetering van luchtweghyperreactiviteit, 
kortademigheid en gezondheidsstatus. Het stopzetten van de ICS-behandeling 
na 6 maanden deed deze positieve effecten teniet. De combinatiebehandeling 
van ICS en LABA bood geen extra anti-inflammatoire effecten vergeleken met 
fluticasonmonotherapie. Combinatiebehandeling gaf een initiële verbetering 
van FEV1 die ook op lange termijn bleef bestaan. Echter, langer doorgaan met 
behandeling gaf geen verdere beïnvloeding van de daling van FEV1ten opzichte 
van alleen inhalatiecorticosteroïden. Onze bevindingen gaven aan dat een 
subgroep van COPD-patiënten met een matige tot ernstige luchtwegobstructie, 
die steroïdnaïef zijn en hyperreactieve luchtwegen hebben, goed reageerde op 
langdurige ICS-behandeling.
Hoewel roken de reactie op behandeling met corticosteroïden kan verminderen 
[26], toonden onze gegevens aan dat een deel van de ontsteking bij COPD, 
ondanks roken, toch gevoelig is voor ICS. De bijdrage van CD8+-cellen aan 
de ontsteking en de relevante antigeen-specifieke triggers bij COPD zijn 
nog altijd niet bekend. CD4+-cellen kunnen bijdragen aan de activering en 
geheugenvorming van CD8+-cellen, evenals B-celactivatie [27]. Mestcellen en 
hun uitgescheiden enzymen kunnen diverse processen aansturen die relevant 
zijn voor luchtwegontsteking en remodelering [28]. 
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De klinische nieuwswaarde van onze bevindingen is dat anti-inflammatoire 
effecten bij COPD tijdens 2,5 jaar behandeling met ICS samengaan met een 
verminderde FEV1-achteruitgang. Eerder kortdurend onderzoek bij matig tot 
ernstig COPD toonde reeds anti-inflammatoire effecten van ICS aan [17;18;29]. 
Ons onderzoek liet zien dat deze gunstige effecten ook op de lange termijn 
behouden bleven en dat er nadelige effecten op luchtwegontsteking kunnen 
ontstaan als ICS-behandeling wordt gestopt. 
De gevonden vermindering van de FEV1-afname bij fluticasonbehandeling staat 
in contrast met eerdere onderzoeken [5-8]. Daarentegen liet het ‘TOwards a 
Revolution in COPD Health’(TORCH)-onderzoek [16] ook vermindering van 
FEV1-afname zien bij COPD-patiënten die werden behandeld met ICS, LABA’s 
of beide. Onze resultaten suggereren dat de verbetering van het FEV1-niveau 
in de combinatiegroep kan worden veroorzaakt door een luchtwegverwijdend 
effect van salmeterol en niet door een verdere verandering van de 
onderliggende ontstekings- en remodeleringprocessen. Verschillen tussen 
eerdere onderzoeken en ons onderzoek kunnen het gevolg zijn van verschillen 
in selectie van patiëntenpopulatie.
Door steroïdnaïeve COPD-patiënten te selecteren, sloten we patiënten uit 
die al gunstige effecten van ICS-behandeling hadden bij aanvang van het 
onderzoek, en vermeden we dat deze zouden uitvallen in de placebogroep. 
Onze patiënten hadden overwegend matig ernstige luchtwegobstructie en de 
meeste patiënten hadden luchtweghyperreactiviteit en geringe reversibiliteit 
van de obstructie. Hyperreactiviteit past ook bij COPD [8;30] en de reversibiliteit 
was, met gemiddeld 7%, vergelijkbaar met eerder gepubliceerd interventie-
onderzoek bij COPD [6;8;16]. We willen benadrukken dat de diagnose ‘astma’ 
bij de patiënten zorgvuldig werd uitgesloten, gebaseerd op het klinische 
oordeel van longartsen, en raadpleging van huisartsdossiers.
Ons onderzoek heeft enkele beperkingen: (a) 77 van de 101 geanalyseerde 
patiënten ondergingen na 30 maanden een bronchoscopie; het percentage 
uitvallers was echter vergelijkbaar tussen de behandelgroepen; (b) de 
onderzoeksgrootte van de studie was relatief klein om veranderingen in 
achteruitgang van de longfunctie vast te stellen. Des te opvallender is onze 
waarneming dat de ICS-geïnduceerde verbeteringen in luchtwegontsteking 
samenhangen met verbeteringen in longfunctie, hyperreactiviteit en 
luchtwegklachten; (c) dit was een onderzoek naar werkzaamheid van 
behandeling, reden waarom we alleen gegevens van therapietrouwe patiënten 
gebruikten. Zoals verwacht, waren er meer therapieontrouwe patiënten in de 
placebogroep, waardoor het behandeleffect eerder onderschat dan overschat 
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is; (d) wij onderzochten biopten van de centrale luchtwegen, terwijl de perifere 
luchtwegen een belangrijke rol spelen bij COPD [31].
Voor de dagelijkse praktijk is het belangrijk om bij deze patiënten met 
matig ernstig COPD te bepalen wat de beste voorspellers zijn voor een 
gunstige respons op ICS-behandeling. Daarnaast is het belangrijk om de 
kosteneffectiviteit te bestuderen van langdurige ICS-behandeling in een 
pragmatisch onderzoek.
Conclusie
Onze bevindingen suggereren dat behandeling met inhalatiecorticosteroïden 
(ICS), wanneer deze voor het eerst en langdurig gegeven worden aan 
steroïdnaïeve COPD-patiënten met een relatief matig ernstig ziektestadium 
en met aanwezigheid van luchtweghyperreactiviteit, de potentie heeft om 
het klinische beloop van COPD gunstig te beïnvloeden. Het verminderde de 
ontstekingsparameters in bronchusbiopten en sputum, wat weerspiegeld 
werd in verminderde achteruitgang van longfunctie, minder hyperreactiviteit 
en kortademigheid, en verbetering van de kwaliteit van leven. Het toevoegen 
van een langwerkende ß2-agonist verbetert de longfunctie, maar verandert 
de progressie van de aandoening niet. De waargenomen respons op de 
behandeling bij dit specifieke subfenotype van COPD onderstreept de 
mogelijkheid voor een behandeling op maat bij COPD en geeft daarmee een 
nieuw klinisch perspectief.
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Abstract
Background: In subgroups of patients with COPD the decline in lung function 
has been reduced by long-term inhaled corticosteroid (ICS) treatment. We 
aimed to identify which clinical, physiological and/or non-invasive inflammatory 
characteristics predict effects of inhaled corticosteroids on lung function 
decline in COPD and on inflammatory cell counts in bronchial biopsies.
Methods: Analysis was performed in 50 steroid-naive compliant patients with 
moderate to severe COPD (postbronchodilator forced expiratory volume in 
one second (FEV1) compatible with GOLD stages II-III, 30-80% of predicted), 
age 45-75 years, >10 packyears smoking and without asthma. Patients were 
treated with fluticasone propionate (500 μg bid) or placebo for 2.5 years. 
Postbronchodilator FEV1, dyspnea and health status were measured every 3 
months, lung volumes, airway hyperresponsiveness (PC20), induced sputum 
and bronchial biopsies at 0, 6 and 30 months. A linear mixed effect model was 
used for analysis.
 
Results: Predictors of attenuated FEV1 decline by fluticasone treatment 
compared to placebo included: fewer packyears smoking, preserved diffusion 
capacity, limited hyperinflation and lower inflammatory cell counts in induced 
sputum. Predictors of long-term reduction in CD3+ cells in bronchial biopsies 
were ex-smoking and increased inflammatory cell counts in sputum.
Conclusions: Long-term benefits by inhaled corticosteroids on lung function 
decline in patients with moderate to severe COPD are most pronounced in 
patients with less advanced disease and less signs of emphysema. These 
data generate novel hypotheses on phenotype-driven therapy in COPD. 
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Background 
Accelerated decline in lung function is the hallmark of chronic obstructive 
pulmonary disease (COPD). Recently, three studies provided the first evidence 
that the decline in postbronchodilator forced expiratory volume in one second 
(FEV1) can be reduced by long-term inhaled corticosteroid (ICS) treatment 
during one to three years follow-up [1-3]. This was unexpected, since most 
big trials had not shown such benefit previously [4]. There appears to be 
considerable heterogeneity in treatment effects amongst COPD patients [1; 2; 
3]. Hence, implementation of long-term ICS therapy in daily practice is difficult 
since this requires predictive, phenotypic patient characteristics to determine 
who should receive this long-term treatment [5;6]. 
Few clinical features have been reported to predict ICS response in COPD. 
A relatively large bronchodilator response was shown to predict the short-
term (months) ICS response [7-10]. Reports on long-term predictors (years) 
are, however, sparse. Current smoking may reduce long-term ICS responses 
[11-14], as well as a higher number of packyears smoked, reflecting the 
cumulative effect of smoking on lung disease [11]. In daily practice, physicians 
are tempted to use lung function reversibility as a guide for prescribing ICS. 
However, conflicting results exist whether reversibility can predict long-term 
steroid effects [11;15;16]. Furthermore, many COPD patients demonstrate 
increased airway hyperresponsiveness, a factor related to accelerated FEV1 
decline [17-19]. This possibly reflects a distinct phenotype of COPD that may 
exhibit enhanced ICS treatment response [15;20;21]. 
The progressive decline of FEV1 in COPD is associated with an inflammatory 
process in the intrapulmonary airways [2]. Such airway inflammation is 
characterised by neutrophils, macrophages, CD8+ cells and mast cells [22]. 
Inhaled corticosteroids may decrease CD3, CD4, CD8 and mast cells in 
bronchial biopsies [2]. Eosinophil and T-cell markers have been reported as 
predictors of short-term lung function responses to ICS treatment in COPD 
[23;24]. However, there are no data available to our knowledge on the 
predictive value of these and other inflammatory cells for long-term effects of 
ICS treatment on the accelerated FEV1 decline present in COPD.  
We postulated that clinical, physiological and/or non-invasive inflammatory 
characteristics can serve as predictors of long-term beneficial effects of 
inhaled corticosteroids on lung function decline in steroid-naive patients with 
moderately severe COPD. Secondly, we postulated that such features can 
also predict steroid effects on inflammatory cell counts in bronchial biopsies. 
The present a priori planned analysis was meant to be hypothesis generating 
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in order to reveal a COPD phenotype that will more likely benefit from anti-
inflammatory therapy with respect to disease progression.
  
Methods 
The present study focuses on detailed phenotyping of patients with moderate 
to severe COPD. For this purpose, 50 patients with COPD, who received 2.5 
years of treatment with inhaled corticosteroids or placebo in the GLUCOLD 
study (Groningen Leiden Universities and Corticosteroids in Obstructive Lung 
Disease) were included in the analysis. The original cohort also included 
patients who stopped inhaled corticosteroids after 6 months and patients with 
the combination therapy of inhaled corticosteroids and long-acting ß2-agonist. 
For this analysis we excluded these patients because we focused on long-
term effects of steroid therapy as such without adding long-acting ß2-agonists. 
A precise description of patient characteristics and methods can be found 
in previous reports [2;25]. Briefly, patients had irreversible lung function that 
was compatible with the Global initiative for chronic Obstructive Lung Disease 
(GOLD) stages II and III [26], and had ≥ 10 packyears smoking. Asthma was 
excluded by doctor’s diagnosis and self-reported symptoms, treatment or 
diagnosis of asthma. Participants had not been treated with inhaled and oral 
corticosteroids within 6 and 3 months of trial entry respectively, and 27/30 
patients were steroid-naive before entry of the study. The vast majority of 
patients were recruited between 2000 and 2003 from general practices 
and all patients had been clinically stable for at least 8 weeks before the 
measurements. The study was performed complying with the Helsinki 
declaration and approved by local ethics committees and all subjects gave 
written informed consent. 
The GLUCOLD study was a prospective longitudinal, randomised, double 
blind, placebo-controlled two-centre trial. Patients were randomly assigned 
to receive either fluticasone propionate (500 μg bid) or placebo for 2.5 years. 
Study medication included Diskus® dry powder inhalers (GlaxoSmithKline, The 
Netherlands), and active treatment and placebo were identical in appearance. 
Randomisation was performed by an independent randomisation centre using 
a minimisation procedure balancing treatment groups for a number of variables 
(centre, gender, current smoker, FEV1/IVC < or ≥ 60%, PC20 methacholine < or 
≥ 2 mg/ml). Measurements of symptoms and lung function were made every 
3 months, whilst lung volumes, airway hyperresponsiveness, peripheral blood 
collection, induced sputum and bronchial biopsies were obtained at baseline, 
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6 and 30 months. Compliance was checked by counting the doses on the 
Diskus® inhalers.
Spirometry was performed before and after inhalation of a short-acting 
bronchodilator, total lung capacity (TLC) and residual volume (RV) using a 
constant volume body plethysmograph and airway hyperresponsiveness to 
methacholine with the two-minute tidal breathing method [25]. Patients were 
asked about dyspnea according to the American Thoracic Society guidelines 
[27] using the modified Medical Research Council (MRC) dyspnea scale (1=no 
dyspnea  to 5= dyspnea  at rest) and the presence of chronic bronchitis (daily 
cough and sputum production for at least 3 months a year, for more than one 
year) [28]. Health status was measured using the St. George’s Respiratory 
Questionnaire (SGRQ) [29] and the Clinical COPD Questionnaire (CCQ) [30]. 
Sputum induction and processing were performed according to a validated 
technique using the so called ‘full sample’ method [2;25]. Cell counts were 
expressed as both total and differential counts. Fibreoptic bronchoscopy 
was performed using standardized procedures and sections from bronchial 
biopsies were analysed as previously described [31]. In brief, four paraffin 
embedded biopsies were cut in 4-μm thick sections and stained with antibodies 
against T lymphocytes (CD3, DAKO, Glostrup, Denmark; CD4, Novocastra, 
Newcastle upon Tyne, UK; CD8, DAKO), macrophages (CD68, DAKO), 
neutrophil elastase (NE, DAKO), mast cell tryptase (AA1, DAKO), plasma cells 
(CD138, IQ Products, Groningen, The Netherlands) and eosinophils (EG2, 
Pharmacia Diagnostics, Uppsala, Sweden) [25]. Fully automated inflammatory 
cell counting procedures on digitized images were performed [32].
Statistical analysis
Long-term (2.5 years) decline in postbronchodilator FEV1 served as the primary 
end-point. T lymphocytes in bronchial biopsies were included as secondary 
endpoints, since the GLUCOLD trial [2] was powered to assess the effect of 
inhaled corticosteroids on CD8+ cell counts in bronchial biopsies. Because 
this was an efficacy trial, per-protocol analysis included all available data from 
randomised patients who were compliant with study medication (using ≥70% 
of the prescribed dose), including data from patients who did not complete 
follow-up. Potential clinical predictor variables were a priori selected according 
to a tailored strategy developed for small datasets [33]. Guidelines suggest 
that one candidate predictor can be studied for every 10 patients [34]. Since 
the current exploratory study population consisted of 50 patients we selected 
5 clusters (with high baseline within-cluster correlation) of potential predictors: 
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(1) packyears [11]; (2) presence of chronic bronchitis; (3) lung function (baseline 
FEV1, reversibility of FEV1,[15]) PC20,[17;21] RV/TLC; (4) TLCO; and (5) absolute 
and differential cell counts in induced sputum [24;35]. Although continuous 
variables might provide more information we dichotomised variables based 
on median values in order to allow clinically meaningful interpretation of the 
results. 
A set of 2 linear mixed effect models [36] was used to identify predictors of 
1) long-term (2.5 years) ICS effect on postbronchodilator FEV1 by inhaled 
corticosteroids; and 2) long-term effects on CD3+, CD4+, CD8+ in bronchial 
biopsies. These outcomes were selected based on their significant long-
term changes by inhaled steroids [2;25].  For each potential predictor, the 
following variables were included in the model: time, treatment (placebo 
coded as 0; fluticasone coded as 1), predictor (reference coded as 0; index 
coded as 1), their interaction (treatment*predictor) and their interaction terms 
with time, using FEV1 or inflammatory cells as the dependent variable. Thus, 
the interaction term (treatment*predictor*time) reflects the additional value of 
the predictor to the effect of treatment with inhaled fluticasone compared to 
placebo on longitudinal changes in FEV1 or inflammatory cells. Index category 
Characteristic Fluticasone (n=26) Placebo (n=24)
Age, yrs 62 (8) 59 (8)
Sex , m/f 23/3 20/4
Current smoking / ex-smoking 16/10 17/7
Dyspnea ‡ 2.6 (0.8) 2.7 (0.8)
SGRQ total score † 29 (13) 33 (19)
CCQ total score § 1.3 (0.6) 1.7 (1.3)
Postbr. FEV1, % pred 63 (8) 61 (8)
Reversibility, mL 3.2 (2.1) 3.6 (2.5)
Geom. mean PC20 methacholine (DD), mg/ml 
||
0.9 (2.8) 0.5 (2.4)
RV/TLC, % 47 (9) 47 (7)
TLCO, % pred 70 (20) 59 (16)
Median IgE (IQR), IU 28 (12-128) 51 (21-119)
Characteristics of the study population per treatment group at baseline. Data represent mean (SD). || PC20 
methacholine is expressed as geometric mean (standard deviation in doubling dose (DD)). ‡range 1 to 5 (higher 
scores indicate more dyspnea); †range 0 (best) to 100 (worst score); §range 0 (best) to 6 (worst score). 
Definition of abbreviations: postbr. = postbronchodilator; FEV1 = forced expiratory volume in one second; % pred = 
percentage of predicted value; PC20 methacholine = the provocative concentration of methacholine that causes a 
decrease in FEV1 of 20%; RV/TLC = residual volume/total lung capacity; TLCO = diffusion capacity of the lung for 
carbon monoxide.
Table 1. Patient characteristics at baseline
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is defined relative to median value, and represents the more favourable 
outcome by fluticasone. Reference category is complementary. Because of 
the limited number of patients, we tested these variables univariately in the 
model. The statistical analyses were performed with STATA 11.0 (StataCorp; 
College Station TX, USA). Differences at p-values ≤0.05 (tested 2-sided) were 
considered significant.
Results
Data from 26 patients with fluticasone and 24 patients with placebo treatment 
for 30 months were used for the present analysis (Table 1). In short, most 
patients were middle-aged males, two-thirds were current smokers and 
many had been heavily smoking for many years. The vast majority of patients 
could be classified as moderately severe COPD, as based on mean (SD) 
postbronchodilator FEV₁ of 63 (9) % predicted. They were mildly impaired in 
health status, slightly reversible with moderately severe hyperresponsiveness. 
Only 3 patients ever used inhaled corticosteroids before entry of the study.
#Index category is defined relative to median value, and represents the more favourable outcome by fluticasone. 
For example: decline of FEV1 by fluticasone is diminished (=favourable outcome) in patients with a lower number 
of packyears (=index category). □Reference category is complementary to the index category. *Values are 
mean (standard deviation (SD)), unless stated otherwise. || PC20 methacholine is expressed as geometric mean 
(standard deviation in doubling dose (DD)), ‡sputum cells as Gmean (GSD). Definition of abbreviations: postbr. = 
postbronchodilator; FEV1 = forced expiratory volume in one second; % pred = percentage of predicted value; PC20 
methacholine = the provocative concentration of methacholine that causes a decrease in FEV1 of 20%; RV/TLC = 
residual volume/total lung capacity; TLCO = diffusion capacity of the lung for carbon monoxide.
Table 2. Values of predictors per stratum per treatment* 
Fluticasone (n=26) Placebo (n=24)
Predictor Index # Reference □ Index Reference
Median smoking history (IQR), packyears 31 (25-34) 51 (47-62) 35 (31-41) 55 (47-63)
Median number of years smoking, (IQR), yrs 37 (32-39) 47 (45-54) 38 (33-40) 48 (46-54)
Postbr. FEV1, % pred 69 (3.4) 54 (6.3) 69 (3.4) 58 (6.1)
Geom. PC20 methacholine (DD), mg/ml 
|| 2.3 (1.6) 0.05 (1.5) 2.4 (2.3) 0.10 (1.6)
RV/TLC, % 39 (5.1) 55 (8.2) 41 (4.1) 51 (3.3)
TLCO, % pred 83 (17.1) 54 (7.9) 74 (7.7) 48 (12.5)
Median IgE (IQR), IU 13 (9-24) 144 (84-244) 17 (6-25) 113 (31-201)
Gmean sputum total cell count (GSD), 104/ml ‡ 62 (2.1) 272 (1.6) 86 (1.7) 392 (1.8)
Sputum cell percentages
Neutrophils, % 51 (1.3) 80 (1.1) 51 (1.3) 79 (1.1)
Macrophages, % 16 (1.6) 40 (1.4) 17 (1.3) 39 (1.3)
Eosinophils, % 0.3 (2.4) 2.4 (1.6) 0.4 (2.4) 2.4 (1.7)
Lymphocytes, % 2 (1.2) 4 (1.2) 2 (1.3) 4 (1.3)
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Figure 1. Long-term predictors of FEV1 decline by fluticasone treatment




E) Sputum total cell count
C) RV/TLC
F) PC20 methacholine
Predictors of the decline of FEV1 by 2.5 year fluticasone treatment 
(ml) and placebo, stratified by median values of the predictor. A) 
packyears smoking; B) baseline FEV1 pred; C) RV/TLC; D) TLCO; 
E) total number of cell counts in induced sputum and F) PC20 
methacholine; G) percentage of eosinophils in sputum by 30 
months treatment with fluticasone compared to placebo.
#Index category (Idx) is defined relative to median value, and 
represents the more favourable outcome by fluticasone. For 
example: decline of FEV1 by fluticasone is diminished (=favourable 
outcome) in patients with a lower number of packyears (=index). 
Reference category (Ref) is complementary.
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Predictors of changes in FEV1 decline by fluticasone treatment 
over 30 months
Long-term predictors of effects of ICS on FEV1 decline are shown in Table 
2 and Figure 1. In patients with fewer packyears fluticasone improved the 
accelerated decline in FEV1 significantly more than in patients with more 
packyears, the difference being +75 ml/yr, 95%CI +10/+139, p=0.023, (Figure 
1A). Baseline FEV1 was not a predictor of ICS effect on FEV1 decline (Figure 
1B). In patients with lower RV/TLC, long-term treatment with fluticasone 
improved FEV1 decline significantly more than in patients with higher RVTLC 
(+69 ml/yr, 95%CI +4/+134, p=0.037) (Figure 1C). Finally, higher CO-diffusion 
capacity (+78 ml/yr, 95%CI +4/+153, p=0.040) (Figure 1D) and lower total 
sputum cell counts (+85 ml/yr, 95%CI +19/+152, p=0.012) (Figure 1E) were 
also predictors of ICS effect on FEV1 decline. Comparable but non-significant 
trends were found in patients with a shorter duration of smoking (Table 3), less 
airway hyperresponsiveness (Figure 1F) and a lower percentage of eosinophils 





in change of 
FEV1 ml/yr
95% CI P value
Packyears, yrs <42 +75 +10/+139 0.023
Number of years smoking, yrs <42 +63 -0.7/+127 0.052
Postbr. FEV1, % pred <64 +12 -56/+81 0.73
PC20 methacholine, mg/ml ≥0.48 +60 -6/+126 0.074
RV/TLC, % <46 +69 +4/+134 0.036
TLCO, % pred ≥65 +78 +4/+153 0.039
IgE, IU <36 +75 +11/+140 0.022
Sputum total cell count, 104/ml <169 +85 +19/+152 0.012
Sputum cell percentages
Neutrophils, % <69 +44 -23/+111 0.20
Macrophages, % >25 -34 -102/+34 0.33
Eosinophils, % <1.1 +66 -0.2/+132 0.051
Lymphocytes, % <3 -7 -74/+61 0.85
Definition of abbreviations: postbr. = postbronchodilator; FEV1 = forced expiratory volume in one second; % pred = 
percentage of predicted value; PC20 methacholine = the provocative concentration of methacholine that causes a 
decrease in FEV1 of 20%; RV/TLC = residual volume/total lung capacity; TLCO = diffusion capacity of the lung for 
carbon monoxide. #Index category is defined relative to median value, and represents the more favourable outcome 
by fluticasone. Reference category is complementary. 
Table 3. Predictors of attenuation of long-term FEV1 decline by fluticasone treatment  
Figure 1. Long-term predictors of FEV1 decline by fluticasone treatment
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Predictors of changes in T lymphocytes in bronchial biopsies 
by fluticasone over 2.5 years
Ex-smokers had a larger decrease in numbers of CD3+ cells in bronchial 
biopsies with long-term fluticasone (-48% 95%CI -9/-70, p=0.021), as 
compared to current smokers. Higher number of total cell counts in induced 
sputum predicted a larger decrease in numbers of CD3+ cells in bronchial 
biopsies by treatment with fluticasone (-48%, 95%CI -11/-70, p=0.018). 
Reduction in CD3+ cells was more prominent in patients with lower percentages 
of macrophages and higher percentages of neutrophils in sputum (-53% 
95%CI -17/-73, p=0.009; -55%, 95%CI -22/-74, p=0.004). There were no 
significant predictors of change in CD4+ and CD8+ cells in bronchial biopsies 
with long-term fluticasone. 
 
Discussion
This study demonstrates that clinical and inflammatory phenotypes can 
partly predict efficacy of long-term inhaled corticosteroid use with respect 
to preventing FEV1 decline in steroid-naive patients with moderate to severe 
COPD. Patients with fewer packyears smoked, preserved diffusion capacity 
of the lung, limited hyperinflation, and lower number of total cells in induced 
sputum benefitted most from inhaled corticosteroids. In addition, the 
inflammatory background, expressed by higher number of total cells and 
neutrophils in induced sputum, appeared to be predictive of a more effective 
reduction of the number of CD3+ in bronchial biopsies by treatment with 
fluticasone at 30 months. These data indicate that features of less advanced 
disease (fewer signs of emphysema and less hyperinflation) predict a better 
course of lung function with treatment of inhaled corticosteroids in patients 
with moderate to severe COPD. This suggests that COPD patients expressing 
milder and/or earlier stages of the disease or a subtype of COPD patients in 
whom airway obstruction is accompanied by less degrees of emphysema can 
benefit from anti-inflammatory therapy, which favors a differential approach in 
the treatment of COPD.
The long-term efficacy of fluticasone in patients with less packyears 
smoked is in line with a previous study on long-term effects of budesonide 
in patients with mild COPD who continued smoking [11], in which patients 
with <36 packyears smoked showed more benefit from budesonide. The 
present study extends these findings by showing, for the first time, that less 
impaired diffusion capacity (and less hyperinflation) predict a better effect of 
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fluticasone therapy on FEV1 decline. It has been shown previously that short-
term treatment with a combination of inhaled corticosteroids and long-acting 
ß2-agonist reduces lung hyperinflation in patients with severe COPD [37]. 
Treatment at an earlier stage of the disease is supported by recent concepts 
[38]. Interestingly, reversibility of FEV1 was not predictive of decline in FEV1, 
which suggests that steroid responsiveness in COPD may be different from 
that seen in asthma. Remarkably, long-term effects on decline in FEV1 were 
more pronounced in patients with lower number of sputum cell counts. 
Notably, eosinophil counts were not predictive of steroid-effects. This seems 
to contrast with previous studies showing benefit on FEV1 from steroids in 
patients with more eosinophilic inflammation [23;24;35]. However, the latter 
results were found in patients with more advanced COPD (FEV1 being around 
38% predicted) [23] who were followed < 1 year [23;24;35]. Taken together, 
our results consistently point towards the notion that long-term treatment with 
inhaled corticosteroids can be predicted by clinical and inflammatory features 
in particular phenotypes suggestive of less advanced COPD.
To our knowledge this is the first study showing that efficacy of long-term 
inhaled corticosteroid use on FEV1 decline can be predicted by clinical and 
inflammatory features in steroid-naive patients with moderate to severe COPD. 
Obviously, there are some limitations to our study. The limited sample-size 
only allowed univariate analyses of the predictors. However, the fact that the 
long-term treatment effects on FEV1 decline over 2.5 years were consistently 
predicted by a number of indicators of less advanced disease supports the 
plausibility of our findings. We did not assess different cut-off values that are 
known in clinical research in order to avoid multiple testing and data driven 
decisions [33]. Instead, we used specific cut-off values based on medians of 
predictor variables. The continous character of a variable maximises preditive 
capacity. However, by using medians the clinical interpretation may improve. 
We only included patients who used ≥70% of the prescribed fluticasone dose 
in our analysis. This strategy was chosen because our study was designed as 
an efficacy trial. However, data from patients who did not complete follow-up 
were included in the analysis. For this analysis we used data from a subgroup 
of patients from the original randomised controlled trial. We excluded the 
salmeterol-fluticasone propionate arm of the original protocol, because we 
found no long-term effect of adding salmeterol on lung function decline and 
excluding this arm simplified the analysis.
How can we interpret these data? Glucocorticosteroids are highly effective in 
other chronic inflammatory lung diseases such as asthma. In contrast, it has 
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been suggested that patients with other inflammatory diseases such as COPD 
are more steroid-resistant [39]. Indeed, the big trials during the past decade 
have not observed efficacy by inhaled steroid on the decline of FEV1 in COPD 
[4]. However, our results suggest that certain phenotypes of COPD, including 
patients with fewer packyears smoked, less hyperinflation, better CO-diffusion 
capacity and lower inflammatory load are characterised by preserved, long-
term sensitivity to steroids. Multiple distinct mechanisms contribute to steroid 
resistance. Excessive activator protein-1 found in asthma reduces interaction 
from glucocorticosteroid receptor with transcriptional coactivator molecules 
resulting in steroid resistance [40]. In COPD, advanced oxidative stress 
reduces histone deacetylase-2 (HDAC2) so that inflammation might become 
less sensitive to anti-inflammatory effects of steroids [41]. The latter has been 
associated with the effect of current smoking [42], and indeed our results 
show a reducing effect on the number of CD3+ cells in bronchial biopsies 
in ex-smokers. Our observation also suggests that fewer packyears rather 
than current smoking status predict a better efficacy of long-term inhaled 
steroids on decline of FEV1 This suggests that a relatively higher cumulative 
amount of smoking contributes to the irreversibility of the damage. In addition, 
our findings are in keeping with the notion that advanced inflammation in 
COPD with mechanical changes of the airways, as indirectly reflected by 
hyperinflation, may contribute to relative glucocorticosteroid resistance. The 
same holds for damage of the airways and lung tissue due to progressive 
loss of elastic recoil, as reflected by reduced CO-diffusion capacity that is 
compatible with emphysema. Taken together, our data raise the hypothesis 
that treatment with inhaled corticosteroids at an earlier stage of the disease 
or in patients with less emphysema and/or less hyperinflation, may provide a 
window of opportunity to slow down the progression of the disease.
These data have implications for clinical care. We studied COPD patients with 
mainly moderate disease severity. Even though most studies on treatment 
predictors have been performed in more severe disease, the majority of 
patients in day-to-day care have less advanced COPD. Subgroups of patients 
with COPD such as those with more emphysema have been shown to display 
accelerated decline of FEV1 [43].  Our study generates the hypothesis that 
treating these patients as early as possible before damage has occurred could 
be of major importance and may slow down the disease. Taken together, 
our data raise the point that certain subgroups such as patients with less 
advanced disease or those with a particular subphenotype of COPD with 
less emphysema might benefit from a differential therapeutic approach. This 
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novel hypothesis requires external validation in larger subsets of patients with 
moderate to severe COPD, before our results can be generalized into daily 
practice. This approach would allow extending current recommendations 
in COPD guidelines by offering a promising perspective for subgroups of 
patients with COPD towards the potential of slowing down the progression of 
the disease
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Abstract
Aims: It is unknown to what extent daily patient-monitored outcomes are 
responsive to long-term therapy in COPD. This study assessed the long-term 
effects of inhaled corticosteroids with or without long-acting ß2-agonists on 
day-to-day symptoms and Peak Expiratory Flow (PEF) in mostly steroid-naive 
patients with moderate to severe COPD.
Methods: In a double blind, placebo controlled study 114 patients received 
short-term (6 months) or long-term (30 months) fluticasone propionate 500 
μg twice daily (bid), long-term fluticasone/salmeterol 500 μg/50 μg bid (single 
inhaler), or placebo bid. The clinical COPD questionnaire (CCQ) was used to 
measure day-to-day health status. 2-Week diary cards with daily CCQ and 
PEF were collected every three months. 
Results: Short-term addition of salmeterol to fluticasone treatment improved 
mean daily total and functional CCQ score (-0.2, p=0.008; -0.3, p=0.002, 
respectively) and improved mean morning PEF from baseline (10.6 l/min, 
p<0.002). Long-term treatment with inhaled corticosteroids improved the mean 
daily total and functional CCQ score (-0.09/yr, p=0.003; -0.12/yr, p<0.001 
respectively) and improved change in morning PEF from baseline (2.46 l/
min/yr, p=0.052). Stopping inhaled corticosteroids after 6 months worsened 
the mean daily total, symptom and functional CCQ score (0.09/yr, p=0.003; 
0.14/yr, p=0.001; 0.07/yr, p=0.043). More patients had a relevant worsening 
of the CCQ total score (OR 10.4, p=0.024) and less patients had a relevant 
improvement in morning PEF change (OR 15.0, p=0.009). Addition of long-
acting ß2-agonists to inhaled corticosteroids provided short-term benefits.
Conclusions: Long-term therapy with inhaled corticosteroids improves daily 
reported general and functional health status in a group of patients with mostly 
steroid-naive, moderate to severe COPD. Stopping inhaled corticosteroids 
worsens health status and addition of long-acting ß2-agonists provides initial 
benefits. Part of self-monitored outcomes were clinically relevant. This study 
indicates modest benefit of long-term combination therapy on self-monitored 
outcomes in COPD. 
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Introduction  
The current raise in disease prevalence of Chronic Obstructive Pulmonary 
Disease (COPD) in a greying society will enhance the burden to society 
enormously (www.goldcopd.org) [1]. Patients with COPD experience 
themselves day-to-day symptoms and limitations in physical activity, with an 
adverse impact on health status [2]. Currently the emphasis in healthcare is 
shifting from physician-based to patient-centred care and self-monitoring of 
respiratory symptoms provides the opportunity to engage patients in their 
care [3;4]. Therefore, regular assessments made by the patients themselves 
are needed, which may better reflect treatment impact from the patient 
perspective whilst providing direct feedback in a standardized way. 
Patient diary cards and brief questionnaires can be used as direct measures for 
self-monitoring. Diary cards assess daily questions on respiratory symptoms 
and lung function. The clinical COPD questionnaire (CCQ) is a short practical 
tool that can be used to evaluate the effect of treatment on symptoms [5;6]. 
The weekly CCQ has been shown to be able to discriminate between stable 
state of COPD and exacerbations, and may be used in early detection of 
exacerbations [7]. Self-monitoring can be used to assess treatment effects. 
However, the responsiveness of the daily CCQ to long-term treatment in 
stable COPD is as yet unknown. 
Large epidemiological studies did not show long-term effects of inhaled 
corticosteroids on physiological outcome in COPD, such as the decline of 
forced expiratory volume in one second (FEV₁) [8;9]. However, COPD is a 
heterogenous disease and in certain subgroups of patients long-term therapy 
with inhaled corticosteroids (ICS) can improve dyspnea and FEV₁ decline in 
patients with moderate to severe COPD[10], whilst discontinuation worsens 
dyspnea and FEV₁ decline [11]. Hence, self-monitoring may provide relevant 
additional signals of treatment benefits during long-term treatment of COPD 
patients. In addition, self-monitoring may strengthen the adherence to chronic 
medications when immediate and clinically important impact on symptoms 
and lung function can be demonstrated [12]. 
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We hypothesised that maintenance treatment with inhaled corticosteroids 
with and without ß2-agonists improves self-monitored day-to-day health 
status and lung funtion in patients with  moderate to severe COPD. To that 
end, we examined effects of 2.5 years versus 6-month treatment of fluticasone 
propionate with and without salmeterol, as well as cessation of fluticasone on 
day-to-day health status and Peak Expiratory Flow (PEF) in COPD. In addition, 
the number of patients with a minimally important clinical change in outcome 
was explored.
Methods
We conducted a 2.5 year prospective longitudinal, randomised, double blind, 
placebo-controlled two-centre trial, called the Groningen Leiden University 
Obstructive Lung Disease (GLUCOLD) study. The methodology has been 
described in detail previously [11;13]. Briefly, patients had irreversible 
lung function loss that was compatible with the Global initiative for chronic 
Obstructive Lung Disease (GOLD) stages II and III, and had ≥ 10 pack years 
smoking [1]. Asthma was excluded by doctors diagnosis and self-reported 
symptoms, treatment or diagnosis of asthma. Participants with inhaled and 
oral corticosteroids within 6 and 3 months of trial entry were not included in 
the study. Seven patients ever used a short-term course of corticosteroids and 
only five patients ever used maintenance therapy with inhaled corticosteroids. 
The vast majority of patients were recruited from general practices between 
2000 and 2003 and all patients had been clinically stable for at least 2 months 
before entry. The study was approved by local ethics committees and all 
subjects gave written informed consent. 
Patients were randomly assigned to receive either 500 μg fluticasone 
propionate (FP) twice daily for 2.5 years, 500 μg FP twice daily for 6 months, 50 
μg FP/salmeterol (S) twice daily for 2.5 year or placebo (P). Study medication 
included Diskus® dry powder inhalers (GlaxoSmithKline, The Netherlands), 
and active treatment and placebo were identical in appearance. Randomisation 
was performed by an independent randomisation centre using a minimisation 
procedure balancing treatment groups for a number of variables (centre, 
gender, current smoker, FEV₁/IVC < or ≥ 60%, PC20 methacholine < or ≥ 2 mg/
ml). Regular visits with measurements of symptoms and lung function were 
made every 3 months. Methacholine challenge was performed at 0, 6 and 
30 months. Compliance was checked by counting the doses on the Diskus® 
inhalers.
153
Patients completed 2-weeks diary cards every three months prior to the visit. 
Records were reviewed at each visit. Amongst validated disease-specific 
health status questionnaires such as the clinical COPD Questionnaire (CCQ) 
and the COPD assessment Test (CAT) [14], we have chosen to use the 
daily CCQ measure day-to-day health status. The CCQ is a 10-item health 
status questionnaire from which the following scores were assessed: total, 
symptom, functional and mental scores (0=best score, 6=worst score). Daily 
Peak Expiratory Flow (PEF) measurements were performed three times in the 
morning and three times in the evening. The best of three measurements in 
the morning was used for analysis. Patients were asked not to use rescue 
medication 6 hours prior to the measurement. The minimal important difference 
(MID) of the CCQ that represents a clinically relevant change in health status 
is 0.4 points [15]. There is no validated MID for PEF measurements in patients 
with COPD. However, the Understanding Potential Long-term Impacts on 
Function with Tiotropium (UPLIFT) trial showed that two-third of patients with 
COPD experienced a clinically meaningful reversibility of 15% PEF at baseline.
[16] This is comparable to the MID known in patients with asthma [17]. 
Therefore, a change of 15% was defined as clinically relevant (i.e. minimal 
important difference) PEF. 
Spirometry was measured after 400 mcg salbutamol, according to 
standardized guidelines [13]. 
Statistical analysis 
The power of the GLUCOLD study was based on the primary outcome and 
included the standard deviation (0.77) of the fluticasone-induced short-term 
change in submucosal CD8+ cell counts in COPD patients [11;18]. Because 
this was an efficacy trial, per-protocol analysis included all available data from 
randomised patients who were compliant with study medication (using ≥70% 
of the prescribed dose), including data from patients who did not complete 
follow-up. A linear mixed effects model was used for analysis of mean CCQ 
scores and PEF values. The linear mixed models included the main effect 
of treatment (3 indicators), the main effect of time (2 indicators) and the 
interaction of treatment and time. Treatment effects were assessed from: a. 
long-term treatment with inhaled fluticasone vs placebo, b. discontinuation of 
fluticasone after 6 months vs its continuation, and c. the additional treatment 
effect of adding salmeterol to fluticasone vs fluticasone alone. Apart from 
analysis of the outcome parameters as continuous variables, patients were 
classified in the following 4 categories by health status and PEF for clinical 
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interpretation: 1) number of patients with a (relevant) improvement that 
reached the minimal important difference (MID); 2) the number of patients with 
a (non-relevant) improvement lower than the MID; 3) number of patients with 
a (non-relevant) worsening lower than the MID; 4) number of patients with a 
(relevant) worsening that reached the MID. A logistic random effects model 
was used for analysis. All analyses were performed with STATA 11.
Results 
From 114 patients, 101 patients were adherent. Data from 88 patients who 
performed diary cards at baseline were analysed. 82 Patients had moderate 
COPD at baseline with GOLD stage II and 6 patients had severe COPD, stage 
III (Table 1).
Short-term effects of ICS with or without salmeterol on clinical control 
and lung function
Short-term addition of salmeterol to fluticasone treatment improved mean 
daily total and functional CCQ score compared with placebo (-0.2/6months, 
p=0.008; -0.3, p=0.002, respectively) and improved mean morning PEF from 
baseline (10.6 l/min per 6 months, p<0.002, Table 2, Figure 1). A lower CCQ 
score indicates improved health status. Figure 2 shows the number of patients 
with a (relevant) improvement or worsening of health status and lung function 
during follow-up. Fewer patients had a relevant worsening of the CCQ total, 
Values are mean±standard deviation (SD); definition of abbreviations: mo=months; ‡Clinical COPD Questionnaire 
with range 0 (best) to 6 (worst score); †Peak Expiratory Flow (PEF); §the Global initiative for Chronic Obstructive 
Lung Disease (GOLD).
Table 1. Baseline characteristics per treatment group* 
Placebo, 30 mo Fluticasone  6 mo, 







Mean daily CCQ ‡ score
- total score 1.42 (1.2) 0.95 (0.5) 1.10 (0.5) 1.21 (0.7)
- symptom score 1.82 (1.0) 1.49 (0.6) 1.67 (0.6) 1.68 (0.7)
- functional score 1.38 (1.3) 0.85 (0.7) 1.01 (0.6) 1.18 (0.9)
- mental score 0.71 (1.3) 0.089 (0.2) 0.13 (0.3) 0.36 (0.6)
Stable mean PEF †, l/min 271 (66) 337 (88) 333 (112) 305 (83)
GOLD § 
- stage II, n 19 19 23 21
- stage III, n 2 2 1 1
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functional and mental score by adding salmeterol to short-term fluticasone 
(OR 11.1, p=0.014; OR 12.6, p=0.007; OR 15.4, p=0.021, respectively, Figure 
2). More patients had a relevant worsening of PEF with short-term therapy 
with fluticasone as compared to placebo (OR 53, p=0.010, Figure 2). 
Definition of abbreviations: ‡Clinical COPD Questionnaire; †Peak Expiratory Flow (PEF). 
Table 2. Effects of  inhaled corticosteroids with or without long-acting ß2-agonists on clinical  
 control and PEF
Change from baseline 
Effect of long-term 
continuation with fluticasone 
Effect of cessation with 
fluticasone  at 6 mo
Addition of short-term 
salmeterol 
Addition of long-term 
continuation with salmeterol
coeff, 95% CI, P value coeff, 95% CI, P value coeff, 95% CI, P value coeff, 95% CI, p-value
Mean daily CCQ ‡ score
- total score   -0.09, -0.15 to -0.03, 0.003   0.09, 0.03 to 0.15, 0.003   -0.22, -0.39 to -0.06, 0.008   0.11, 0.05 to 0.17, <0.001
- symptom score   -0.08, -0.17 to 0.001, 0.053  0.14, 0.06 to 0.22, 0.001   -0.21, -0.45 to 0.03, 0.087   0.11, 0.03 to 0.2, 0.008
- functional score   -0.12, -0.19 to -0.06, <0.001   0.07, 0.002 to 0.13, 0.043  -0.30, -0.49 to -0.11, 0.002  0.12, 0.05 to 0.18, 0.001
- mental score   -0.04, -0.09 to 0.01, 0.13   0.02, -0.03 to 0.07, 0.38   -0.12, -0.26 to 0.03, 0.12   0.07, 0.02 to 0.12, 0.007
Stable mean PEF †, l/min 2.46, to -0.02 to 4.94, 0.052  -2.42, -4.92 to 0.09, 0.058  10.6, 3.9 to 17.3, 0.002 -1.23, -3.7 to 1.25, 0.33 
Figure 1. Change in CCQ score and PEF by fluticasone
Adjusted mean change ± 95% CI over time during treatment with fluticasone (500 μg bid) for 30 months (FP 30), 
fluticasone (500 μg bid) 6 months (FP 6), followed by placebo, the combination of fluticasone/salmeterol (500/50 μg 
bid) 30 months (FP/S 30) and placebo (bid), in patients with moderate to severe COPD. Data are presented for: A) 
mean Clinical COPD Questionnaire (CCQ) Total score; and B) mean CCQ Symptom score; C) mean CCQ Functional 
score and D) Peak Expiratory Flow (PEF, l/min).
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Figure 2. A) Number of patients with a relevant improvement or worsening of total CCQ score  
 and B) relevant change in PEF from baseline
Relevant changes over time are presented during treatment with fluticasone (500 μg bid) for 30 months (FP 30), 
fluticasone (500 μg bid) for 6 months (FP 6), followed by placebo, the combination of fluticasone/salmeterol (500/50 
μg bid) for 30 months (FP/S 30) and placebo (bid), in patients with moderate to severe COPD. Data are presented 
for: A) total Clinical COPD Questionnaire (CCQ) score; and B) Peak Expiratory Flow (PEF). Four categories are 
shown: 1) relevant improvement depicted in upper part; 2) improvement that is not clinically relevant (upper middle 
part); 3) worsening that is not clinically relevant (lower middle part); 4) relevant worsening (lower part).
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Long-term effects of ICS with or without salmeterol on clinical control 
and lung function
Long-term continuation with fluticasone improved mean daily total and 
functional CCQ score after 2.5 years, compared to placebo (-0.09/yr, p=0.003; 
-0.12, p< 0.001, Figure 1) and improved change (non-significant) in morning 
PEF from baseline (2.46 l/min/yr, p=0.052, Figure 1). Fewer patients had 
a relevant (non-significant) worsening of the CCQ functional score by using 
long-term therapy with fluticasone (OR 5.4, p=0.054, Figure 2). Cessation of 
fluticasone at 6 months worsened the mean daily total, symptom and functional 
CCQ score at 2.5 years versus long-term fluticasone (0.09/yr, p=0.003; 
0.14/yr, p=0.001; 0.07/yr, p=0.043, Figure 1) and worsened change (non-
significant) in morning PEF from baseline (-2.42/yr, p=0.058). More patients 
had a relevant worsening of the CCQ total score by stopping fluticasone (OR 
10.4, p=0.024) and less patients had a relevant improvement in morning PEF 
change from baseline (OR 15.0, p=0.009, Figure 2). Long-term continuation 
of salmeterol increased (worsened) the CCQ score on the dimensions total 
(0.11/yr, p<0.001), symptom (0.11/yr, p=0.008), functional (0.12/yr, p=0.001) 
and mental (0.07/yr, p=0.007) compared to fluticasone alone (Figure 1). 
Discussion 
The findings of the present study show that long-term treatment with inhaled 
corticosteroids improves patient-reported day-to-day health status and 
functional performance in steroid-naive patients with moderate to severe 
COPD. Stopping fluticasone treatment at 6 months worsens daily patient-
reported health status, symptoms and functional performance. Addition of a 
long-acting ß2-agonist to ICS provides short-term benefit on health status, 
functional performance and PEF, but does not provide an additional long-term 
benefit. The observed effects on health status and PEF partly reached the 
minimal important difference (MID) of 0.4 points for the CCQ and 15% change 
from baseline for PEF. These long-term effects on daily reported health status 
point to some benefits for patients in daily symptoms and lung function. 
The novelty of this study is that COPD patients with stable disease benefited 
from long-term inhaled corticosteroids as reflected in self-monitored daily 
health status and lung function. In asthma, self-monitoring of asthma control 
including symptoms and PEF is recommended in combination with an action 
plan common in clinical trials and it has been shown that this may enhance 
adherence to monitoring the disease [12;17]. In addition, in clinical trials such 
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as the Gaining Optimal Asthma control (GOAL) study PEF data were used 
to measure effects of ICS and combination therapy on asthma control [19]. 
However, it is likely that the monitoring approach that has been found useful in 
asthma cannot simply be extrapolated to COPD [20]. 
Our findings with patient-monitored outcomes in COPD demonstrate that 
COPD seems to be a treatment responsive disease. Indeed, controlled trials 
have provided a rationale for treatment in specific subgroups of patients with 
COPD [1]. The combination of ICS and long-acting ß2-agonist has provided 
positive effects on 3-monthly measured health status and lung function [10;11]. 
Inhaled corticosteroids decrease exacerbations in more severe disease and 
improve quality of life [8]. Three studies reported benefits from long-term 
combination therapy in specific groups of patients [10;11;21] We extended 
these findings by showing positive effects on patient centred, daily reported 
health status and PEF. 
Although the present study showed positive effects of inhaled corticosteroids 
on day-to-day health status and PEF, there are some limitations. A relatively 
small number of patients was enrolled in the study, since sample size was 
based on inflammatory cell counts in bronchial biopsies as primary outcome 
of the study. Although long-term treatment with ICS was effective at the 
patient level, there was a limited number of patients where effects reached the 
MID. First, this may be COPD-specific, due to the notion that COPD patients 
are generally older than asthma patients, having more complex multi- and/or 
co-morbidity and are more readily adapting to their disease due to the slow 
disease progression. Second, it may be explained in part by differences in 
populations. The original MID for the CCQ was established in patients with more 
advanced disease, and who were admitted to the hospital for an exacerbartion 
of COPD [15]. Third, the MID can be determined by different methods, which 
may influence the MID [22;23]. In addition, the individual patient is the only one 
who can judge whether there is an improvement or worsening that is clinically 
relevant [24;25]. Finally, prior to the study, patients were mostly steroid-naïve. 
Since many patients in daily practice use combination therapy, this may 
hamper generalisation of the results. However, because of the present study 
design, the observed effects of ICS were not biased by carry-over effects from 
previous treatment.
How can we interpret our findings? Long-term self-monitoring has been shown 
to positively influence the impact of exacerbations on health status, and 
decrease respiratory symptoms of exacerbations [26]. Therefore, one might 
argue that self-monitoring should be part of disease management in COPD. 
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These programs include many aspects such as education about the disease, 
optimisation of evidence based medication and self-management. In patients 
with relatively mild disease monitoring patients with integrated disease 
management improved health status and exercise capacity [27;28]. Disease 
management programs include non-medical and medical interventions. 
Interestingly, we found that long-term ICS improved daily reported health 
status and functional impairment in moderate to severe stable COPD. This 
could promote regular physical activity, which is associated with higher CO-
diffusion capacity, muscle strength and exercise capacity as well as lower 
levels of systemic inflammation [29]. This suggests that long-term ICS provide 
modest benefit at the patient level in certain COPD patients. 
In conclusion, long-term ICS improves day-to-day health status, functional 
impairment and PEF in a patients with mostly steroid-naïve, moderate to 
severe COPD. Stopping ICS worsens health status and addition of long-
acting ß2-agonist provides initial benefits. Part of the observed effects were 
clinically relevant. This study suggests that the benefits of long-term effects of 
combination therapy on clinical health status and PEF in moderate to severe 
COPD is modestly experienced at the patient level. 
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Introduction
Chronic obstructive pulmonary disease (COPD) is highly prevalent and one of 
the most common causes of chronic morbidity and mortality world-wide [1]. 
The WHO (World Health Organisation) predicts an increase in COPD-related 
deaths in the up-coming years [2]. In the past, COPD has been viewed as an 
irreversible and untreatable disease. However, in the most recent decades, 
research has focused increasingly on COPD and current research offers a 
more optimistic point of view.  
COPD is a heterogeneous disease characterised by airway symptoms, 
impaired quality of life, enhanced airflow limitation, emphysema and extra-
pulmonary co-morbidities that vary interindividually in expression and severity. 
Airway inflammation is widely accepted to be the central feature of COPD, 
leading to destruction of lung parenchyma, goblet cell hypertrophy and tissue 
remodelling. Because of the complexity of the disease, it is important that the 
goal for therapy focuses on these multiple components. 
This thesis focuses on clinical phenotyping in COPD and effects of therapy on 
various components of the disease including: health status, chronic bronchitis, 
the effects of inhaled corticosteroid and long-acting bronchodilator drugs on 
airway inflammation, clinical phenotypes and the decline in FEV₁, predictors of 
the effects of therapy and monitoring of daily self-reported symptoms and lung 
function. The Groningen Leiden Universities and Corticosteroids in Chronic 
Obstructive Lung Disease (GLUCOLD) study was a prospective longitudinal, 
randomised, double blind, placebo-controlled two-centre trial. Patients were 
randomly assigned to receive either fluticasone propionate (500 μg bid) or 
placebo for 2.5 years. The main conclusions are presented below, followed by 
a general discussion and directions for future research.
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Conclusions
Clinical symptoms and airway inflammation 
•  Airflow limitation, other features previously associated with 
asthma, i.e. bronchodilator reversibility, total serum IgE and airway 
hyperresponsiveness and airway inflammation are distinctive, largely 
independent components of COPD (Chapter 2).
•  Airway inflammation independently contributes to impaired health status 
in COPD: the larger the percentage of sputum macrophages, the more 
impaired health status was (Chapter 3).
•  Chronic bronchitis reflects an inflammatory sub-phenotype among 
patients with moderate to severe COPD that is characterised by a distinct 
inflammatory cell profile in sputum and bronchial biopsies. The presence 
of chronic bronchitis is associated with a differential distribution of 
eosinophils in the airway wall and sputum, and higher percentages of 
macrophages in sputum (Chapter 4).
Long-term therapy with inhaled fluticasone propionate, with and without 
salmeterol
•  Long-term inhaled steroid therapy can provide prolonged anti-
inflammatory efficacy in COPD, associated with attenuated decline 
in lung function. Our results suggest that disease progression may be 
slowed in subgroups of steroid-naïve patients with moderate to severe 
COPD (Chapter 5). 
•  Patients with fewer pack years smoking, preserved diffusion capacity of 
the lung, limited hyperinflation, and lower number of total cells in induced 
sputum benefited most from inhaled corticosteroids. In addition, higher 
number of total cells and neutrophils in induced sputum, appeared to 
be predictive of a more effective reduction of the number of CD3+ in 
bronchial biopsies by treatment with fluticasone during 30 months. This 
suggests that COPD patients expressing milder and/or earlier stages of 
the disease or a subtype of COPD patients in whom airway obstruction 
is less determined by  emphysema can benefit from anti-inflammatory 
therapy, which favours a differential approach in the treatment of COPD 
(Chapter 6).
•  Long-term treatment with inhaled corticosteroids improves patient-
reported day-to-day general and functional health status in patients with 
moderate to severe COPD, whereas stopping fluticasone at 6 months 
worsens daily health status, symptoms, functional performance and peak 
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expiratory flow (PEF) Combination of ICS and a long-acting ß2-agonist 
improves initial additional positive effects on health status, functional 
performance and PEF. Part of self-monitored outcomes were clinically 
relevant (Chapter 7).
Heterogeneity of the disease
It is widely recognized that COPD is a complex syndrome with irreversible 
airflow limitation that is associated with airways inflammation, but is also 
characterised by different pulmonary and extra-pulmonary components. 
Previous large epidemiological studies examined COPD patients as a distinct, 
but single disorder. However, it is now time to look further than just regarding 
all COPD patients as having the same disease and to focus on assessing the 
complexity of the syndrome of COPD. Remarkably, in June 2012 a PubMed-
based literature search produced 1059 hits when searching for papers on 
“COPD phenotype or subgroup” amongst the 35,942 papers that are dealing 
with COPD. The data in the present thesis provides good evidence that COPD 
phenotyping is clinically relevant, strongly suggesting that phenotyping will 
improve current clinical practice and individualised treatment options [3-10]. 
In chapter 2 we have examined the heterogeneity in COPD by factor analysis. 
This analysis was used to categorise various clinical and inflammatory 
characteristics into specific independent domains of the disease without a priori 
assumptions. Airflow limitation, features previously associated with asthma 
(bronchodilator reversibility, total serum IgE and airway hyperresponsiveness) 
and airway inflammation were distinctive, largely independent components 
of COPD. Previous studies focused primarily on clinical features [11;12], 
whereas we extended these findings by distinguishing a separate domain for 
airway inflammation. Interestingly, there was a distinct domain for ‘asthma-
like’ characteristics. These features have been suggested to be linked to the 
progression of the disease. However, in chapter 6 we have seen that these 
characteristics were not predictive of the effects of therapy on the decline in 
FEV₁, indicating that these characteristics may reflect different components 
in COPD than in asthma. This fits with modern views on the phenotypic 
characteristics that are discriminating (and sometimes are shared) between 
asthma and COPD [13].
Health status
The most important features from the patients’ perspective are worsening 
of airway symptoms, limited physical activity and psychological distress, 
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resulting in decreased health status. Patients seek medical help with their 
clinical physician to feel better and clinicians will probably try to positively 
influence the distress with life-style advises or medical therapy. So, why should 
we bother about time-consuming measurements such as lung function, airway 
hyperresponsiveness, hyperinflation or even worse, invasive measurements 
such as induced sputum or bronchial biopsies? Reason for this is that clinical 
meaningful outcomes such as symptoms in COPD cannot easily be used as 
surrogate markers for the underlying components of the disease. It is well-
known that health status is only marginally associated with FEV₁ and the 
effect of therapy on health status can be influenced by many other aspects 
of the disease such as older age [14]. If medical therapy is able to modify the 
underlying process of the disease, and hence can slow down the progression 
of the disease this will be an important reason to provide therapy, even in the 
absence of distressing symptoms. 
One of the main components in COPD is airway inflammation. In our study, 
we examined whether there is an association between health status and 
inflammatory cell counts in induced sputum and bronchial biopsies (Chapter 
3). Health status as measured with the SGRQ, was associated with higher 
inflammatory cell counts in induced sputum. Worse total SGRQ scores as well 
as the subdomains “symptom” and “activity” scores were associated with 
higher percentages macrophages in sputum. Patients with <15% macrophages 
had a total score of 27 and this score was worse by >4 points in patients 
with >15% macrophages, which exceeds the clinical threshold in SGRQ that 
is considered to be clinically relevant [15]. Interestingly, the inflammatory 
process was a stronger determinant of health status than other physiological 
measurements. Only hyperinflation showed a consistent independent influence 
on health status. Expiratory airflow limitation in COPD increases the time that 
lungs need to fully empty. With increasing respiratory rate this will lead to 
dynamic hyperinflation, a major drive for dyspnea. Neutrophils are considered 
as an important inflammatory cell in COPD, which can be linked to the severity 
of the disease. However, macrophages also may play an important role in the 
lungs of patients with COPD. Macrophages can be recruited to the bronchiolar 
epithelium and release a number of inflammatory cytokines such as tumour 
necrosis factor (TNF-α) or produce elastolytic enzymes that eventually may 
contribute to the development of emphysema and the progression of the 
disease, which could possibly influence health status. Only part of health 
status could be explained by this type of airway inflammation. This indicates 
that a distinct pathological phenotype contributes to health status.
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Few long-term studies reported effects of therapy on health status. In the 
Inhaled Steroids in Obstructive Lung Disease (ISOLDE) study health status was 
measured with the SGRQ during 3 years. Usage of ICS positively influenced 
health status in patients with moderate to severe COPD. In addition, the 
combination of ICS and a LABA can improve health status [16] where long-
term tiotropium can slow down decline of health status [17]. Controversial 
effects in studies can be due to differences in population characteristics such 
as baseline exacerbation frequency or different drop-outs [14].
Our study showed that in our subgroups of patients with moderate to severe 
COPD long-term maintenance therapy with ICS improved SGRQ activity and 
CCQ total, symptom and functional scores, whereas stopping ICS worsened 
SGRQ total and activity score, and both CCQ total and symptom scores 
(Chapter 5). Adding a LABA to ICS improved improved short term CCQ total, 
symptoms and functional scores. However, during the subsequent 24 months, 
combination therapy did significantly worse on these outcomes compared 
with fluticasone alone. In conclusion, health status is an overall measure of 
impairment that is associated with a distinct inflammatory profile and can be 
influenced by long-term ICS therapy in subgroups of patients with COPD. 
We observed positive effects on daily reported health status and lung 
function in patients with stable disease (Chapter 7). Long-term monitoring in 
combination with therapy in COPD has been shown to decrease the impact 
of exacerbations on health status, and decrease symptoms of exacerbations 
[18]. However, the number of patients with a minimal important difference was 
limited, which may hamper adherence to chronic medication in moderately 
severe COPD.  
Chronic bronchitis
Despite the fact that 30% of patients with COPD have symptoms of chronic 
bronchitis, it is still controversial whether this points to a benign disorder or a 
relevant sub-phenotype. It is not yet clear how a normal lung changes into a 
lung where mucus production is exaggerated, contributing to obstruction of 
the upper and lower airways. Aiming at the underlying airway inflammation 
might be of therapeutic value. This is not an easy approach since the pathology 
in COPD is complex. It might be considered as a ‘burning process’ driven by 
inflammatory cells, pro-inflammatory cytokines and oxidative stress. The lungs 
react with an innate and adaptive response to clear this burning process. 
Inability to restrict this innate and adaptive immune response may contribute 
to remodelling, increasing mucous glands and mucus-producing cells in 
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the surface epithelium. Inflammatory mediators such as neutrophil elastase 
are important secretagogues for mucin producing cells. The exaggerated 
mucin production and defective clearance is responsible for the mucus 
hypersecretion and presence of chronic bronchitis.
In this thesis the presence of chronic bronchitis was associated with a distinct 
inflammatory cell profile in the airways, as measured in a large sample of 
induced sputum and bronchial biopsies (Chapter 4). Remarkably, patients 
with chronic bronchitis had significantly fewer eosinophils in biopsies and 
higher percentages of sputum eosinophils than COPD patients without these 
symptoms. This is suggestive of a preferential distribution of eosinophils 
towards the airway lumen in COPD patients with chronic bronchitis. In 
chapter 4 we conclude that the clinical symptoms of chronic bronchitis reflect 
a distinct sub-phenotype among patients with manifest COPD, as based 
on inflammatory cells in induced sputum and bronchial biopsies. This may 
be important when trying to tackle the underlying inflammation in order to 
reduce symptoms in patients. However, effects of treatment  with ICS with or 
without salmeterol was not different between COPD patients with and without 
chronic bronchitis (Chapter 5) and the presence of chronic bronchitis was 
not a predictor of the effect of therapy on the accelerated decline in FEV₁ in 
our study (Chapter 6). Therefore, according to our data it is still controversial 
whether chronic bronchitis can be considered as a relevant phenotype within 
COPD.  
Long-term therapy with inhaled fluticasone propionate, with and without 
salmeterol
It is well-known that ICS can suppress the inflammatory process effectively in 
asthma. A potential similar effect on airways inflammation in COPD was the 
reason to prescribe this therapy on great scale in these patients. However, 
the effects in large studies of COPD are much more modest than in asthma. 
Current guidelines recommend maintenance treatment with ICS only in 
patients with advanced disease and a history of recurrent exacerbations. 
However, two recent studies suggested that prolonged therapy with ICS and a 
long-acting ß2-agonist can attenuate FEV₁ decline in COPD. 
The results of our study show that long-term maintenance therapy with 
fluticasone improves the rate of FEV₁ decline in the steroid-naïve patients 
with moderate to severe COPD included in our study (Chapter 5). This is 
accompanied by sustained improvement of airway hyperresponsiveness and 
reduced dyspnoea. Adding salmeterol to fluticasone provides a sustained 
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improvement in FEV₁-level and dyspnoea, but does not further improve the 
rate of FEV₁ decline and slightly worsens health status. 
Effects on clinical measurements  
Previous studies showed initial improvement in FEV₁, but could not 
demonstrate benefit on the subsequent annual FEV₁ decline in COPD [19-22]. 
We did not find an initial improvement in FEV₁, yet we believe that we were 
able to detect longstanding improvements in FEV₁ decline due to differences in 
study design. The vast majority of our patients was completely steroid-naïve, 
whereas over 50% of patients used steroids in previous studies [16;21;23-25]. 
By choosing steroid-naïve patients, we aimed to avoid patients with unknown 
previous benefits by inhaled steroids at baseline, and to limit drop-outs on 
placebo treatment. Furthermore, we used relatively high inhaled steroid doses 
in patients with predominantly mild to moderate COPD, who were examined in 
only two centers in which we took great care to apply the same methodology. 
The observed improvements in airway hyperresponsiveness and dyspnoea 
corroborate results from a previous study, showing that ICS can reduce 
airway hyperresponsiveness and dyspnoea after 9 and 33 months [22]. 
Discontinuation of ICS led to relapse of these disease features in our study, 
extending previous findings where stopping ICS led to a prompt deterioration 
in FEV₁ [24] and corroborating that inclusion of steroid naive patients may 
have been a decisive contribution to the differential effect between ICS and 
placebo. In keeping with previous reports, addition of salmeterol to fluticasone 
provided a consistent improvement in the level of FEV₁, yet we could not show 
further modification of long-term decline in FEV₁  [16;23]. Short-term addition 
of salmeterol improved daily reported health status and peak expiratory flow, 
which reached minimal important differences. Therefore, patients may actually 
experience the benefits in daily life. This suggests that addition of a LABA to 
ICS can be provided in order to relieve instant symptoms, but does not affect 
disease progression.  
Effects on inflammatory cell counts
Our study shows that 2.5-year maintenance therapy with ICS in COPD reduces 
bronchial T lymphocyte and mast cell numbers, whilst increasing the number 
of  eosinophils and integrity of bronchial epithelium, which was accompanied 
by a reduction in sputum cell counts. Previous short-tem studies investigating 
COPD patients have shown different anti-inflammatory effects of ICS in COPD 
[26-28]. 2-Month treatment in a small sample of patients with COPD showed 
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a reduction in sputum neutrophils and total cells by high dose budesonide in 
patients with moderate disease [29]. 3-Month treatment with the combination 
therapy of ICS and LABA reduced IL-8 and MMP-9, but did not statistically 
influence total number of cells in induced sputum compared with tiotropium 
in older patients with a FEV₁ around 55% of predicted and relatively poor 
quality of life (SGRQ total score of around 45) [30]. 3-Month treatment with 
ICS alone reduced subepithelial mast cells, but not CD8, CD68 or neutrophils 
in bronchial biopsies compared to placebo in 30 patients with an FEV₁ around 
45% of predicted [31]. 13 Week treatment with the combination of 2 times daily 
250/50 fluticasone and salmeterol reduced eosinophils in sputum and CD8, 
CD4, CD45 in bronchial biopsies, but not CD68 macrophages in 140 patients 
with moderate to severe COPD [32]. In addition, combination therapy reduced 
differential neutrophils and total eosinophils. This study did not include an 
ICS or LABA alone treatment group. 3-Month combination treatment with 
SFP (50/500, twice daily) suppressed CD8+ T cells and CD68 macrophages 
in bronchial biopsies compared to placebo, but failed to find a result with 
fluticasone alone [33]. One possible explanation for the less clear effect of ICS 
on suppression of inflammation in COPD as compared to asthma may be the 
reduced expression of the enzyme histone deacetylase-2, which is required by 
ICS to switch off activated inflammatory genes in more advanced disease [34]. 
However, our study showed that beneficial effects in subgroups of patients 
with more moderate disease can be maintained during long-term treatment up 
to 30 months. Interestingly, the positive findings on inflammatory effects are 
consistent with positive effects on lung function decline and symptoms, which 
points towards a clinically relevant treatment benefit. 
Who will benefit? Towards clinical phenotyping
In this thesis, the most important clinical question to be answered is who will 
benefit from ICS with or without LABA. The patient with COPD sitting in front 
of you when being a GP or pulmonologist is bothered by his or her symptoms 
and doctor and patient have to jointly decide whether to start with therapy. 
This is not an easy question and this thesis may add a small piece to the 
puzzle. Clinical phenotyping focuses on differences between individuals with 
COPD with regard to the effects of therapy on outcome. Figure 1 shows an 
example of visualising clinical phenotypes according to treatment effects. This 
is a dynamic model where, based on new evidence, phenotypes can switch 
between the left and right circle. This figure does not contain information on 
clinical phenotypes with an effect on clinical outcome, because we focused on 
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the effects of therapy, as it is important for daily practice. 
Chapter 6 shows that in our subgroup of patients with COPD, patients who 
had fewer packyears smoked, preserved diffusion capacity of the lung, limited 
hyperinflation, and lower number of total cells in induced sputum benefited 
most from inhaled corticosteroids. In addition, a higher number of total cells 
and neutrophils in induced sputum predicted a more effective reduction of 
the number of CD3+ in bronchial biopsies by treatment with fluticasone at 30 
months. This may suggest that earlier stages of the disease or a subtype of 
COPD patients in whom airway obstruction is accompanied with less severe 
emphysema predict a better course of lung function with treatment of ICS in 
patients with moderate to severe COPD. This extends findings from Lee et al, 
showing that short-term treatment response to ICS was smaller in patients 
with an emphysyma-dominant phenotype compared to the obstruction-
dominant phenotype and moderate to severe COPD [35].
The severity in COPD is currently based on the level of FEV1, symptoms 
and future risk of exacerbations [1]. However, it is the question whether to 
focus solely on these features [36]. In additon, it unclear whether early stages 
of disease should be treated or should we wait till there is more advanced 
disease? COPD is a disease with early (small) airway narrowing with continuos 
presence of inflammation where later in advanced disease tissue repair 
contributes to airway remodeling including irreversibe fibrosis [37]. Results 
from the Trial of Inhaled Steroids and Long-acting ß2-agonists (TRISTAN) 
study showed that clinical benefits were not restricted to more advanced 
Figure 1. Clinical phenotypes in COPD: a dynamic model 
173
disease as based on the level of FEV₁ and it is important also to focus on 
more mild disease where is much more to gain [38]. In our study, patients with 
less emphysema benefited more from ICS. The ECLIPSE study showed that 
emphysema as assessed with CT was associated with more rapid decline in 
FEV₁ in patients with more severe disease (FEV₁ 48% of predicted) [39]. In 
a recent study 279 patients with COPD (GOLD stage I:26%, II:45%, III:24%, 
IV:5%) were followed for five years [40]. Emphysema severity as measured 
by either %KCO of CT scan was independently associated with a rapid 
decline in FEV₁. This supports our findings that a clinical phenotype defined 
by emphysema should be considered in clinical trials with COPD or in daily 
practice, given its possible consequences for therapy.    
Patients with asthma are more sensitive to the anti-inflammatory actions 
of corticosteroids than patients with COPD. Interestingly, in COPD 
several characteristics associated with asthma, such as bronchodilator 
responsiveness, airway hyperresponsiveness and eosinophilic inflammation 
have been reported to predict beneficial effects of ICS. However, in our study 
patients with asthma were carefullly excluded by doctor’s diagnosis and self-
reported symptoms, treatment or diagnosis of asthma. It is interesting whether 
the presence of asthmatic characteristics in COPD could point to a specific 
phenotype. Previous studies showed more benefit in COPD patients with more 
bronchodilator responsiveness [41-43]. However, these results have not been 
confirmed by others [21]. In 32 patients with mild to moderate COPD, manitol 
hyperresponsiveness was significantly associated with eosinophil numbers 
and soluble markers in sputum [44]. Because of the high specificity and low 
sensitivity this suggests that mannitol hyperresponsiveness can be used as a 
guidance for individualised treatment. However, this has to be confirmed in 
clinical trials. Reversibility in our study was not a predictor of clinical outcome 
and suggests that the underlying mechanisms contributing to reversibility in 
COPD may be different from reversibility in asthma. A previous study did not 
find improvement in FEV₁ after 6 weeks of treatment with ICS of patients with 
COPD who where hyperresponsive to adenosine 5’-monophosphate, which is 
an indirect stimulus [45]. We extended these findings by showing that airway 
hyperresponsiveness was no predictor of the long-term beneficial effects of 
ICS. Sputum eosinophils have been predictive of a larger increase of FEV₁, 
health status and exacerbations in studies with a duration up to one year. 
82 patients with severe COPD (FEV₁ around 38% of predicted) were treated 
according to their symptoms or to both symptoms and eosinphilic inflammation. 
Intriguingly, guidance by eosinophilic inflammation led to a reduction in the 
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frequency of hospital admissions [46]. In our subgroup of patients we did 
not find such effect with maintenance therapy with ICS for 2.5 years. Rather 
than specific characteristics of asthma our data point to the direction that in 
certain subgroups of COPD such as patients with less advanced disease or 
a subphenotype with less emphysema, ICS may be beneficial. This may aid 
in the process of unraveling wich clinical phenotypes are important in COPD 
(Figure 1). Current guidelines advise long-term treatment only in patients 
with advanced disease and frequent exacerbations. External validation of 
our results in larger subsets of patients with moderate to severe COPD is 
necessary to be able to generalise our results into daily practice. This would 
allow extending current recommendations in COPD guidelines by offering a 
more optimistic perspective for subgroups of patients with COPD. 
Limitations 
We believe that the strength of our study is that it was designed to investigate 
the potential benefits of continuation of inhaled corticosteroids, with and 
without long-acting ß2-agonists, in patients with stable, moderate to severe 
COPD who in the vast majority had not been treated with these drugs in the 
past. We examined long-term treatment and its discontinuation in the same 
study, including a placebo-arm. It has been shown that discontinuation of 
previously prescribed ICS in COPD leads to increased exacerbation rate [23], 
which may have increased the number of drop-outs in the placebo-groups of 
other studies. By including steroid-naïve patients in the present study, such 
selective drop-out was avoided, and this may explain the significant benefits 
of ICS on lung function decline as observed in the present study. 
Still, some limitations apply to our study. For clinical endpoints, the number 
of patients was relatively low due to our primary aim to examine bronchial 
inflammation. This is the likely explanation for observing only small effects on 
health status. In addition, due to practical reasons, we did not include a 5th 
arm investigating salmeterol alone, but based on previous studies it can be 
anticipated that salmeterol has no disease modifying effect by itself [25;47]. 
This was an efficacy trial. Therefore, only data from patients using more than 
70% of the prescribed dose were analysed. This may have underestimated 
the (detrimental) treatment effects in the placebo group due to expected drop-
outs in this group. The sample size of our study was too small to investigate 
adverse events. Several studies reported a higher probability of having 
pneumonia as an adverse event among patients using ICS. The TORCH trial 
reported a higher risk on pneumonia with long-term fluticasone [48]. This 
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was supported by an updated meta-analysis showing a significant increased 
risk on pneumonia with ICS (RR 1.57, 95% CI1.41-1.75) [49]. It could be that 
usage of ICS leads to local immunosuppressive effects inducing an increased 
susceptibility to infections, especially in patients with more advanced disease.
A detailed profile of the underlying inflammatory pathology is difficult to obtain. 
Pathological changes in COPD appear in central and peripheral airways and 
in the parenchyma, whereas in the lungs of smokers the inflammatory cells 
are not uniformly distributed [50]. The small airways play an important role in 
the pathogenesis of COPD [51] and by using bronchial biopsies of the larger 
airways and induced sputum, we focused only on the central airways.
Conclusion 
Many COPD studies performed in the past were large epidemiological trials 
directed at clinical data or specifically directed at the inflammatory process in 
small samples with a small duration. However, the patient with COPD in front 
of the doctor experiences symptoms as a result of the complex pathogenesis 
of the disease. Physicians are trained to look at the patient as a whole. This 
should include understanding the patient and his disease perception, the 
symptoms and limitations belonging to the disease, but also the underlying 
components of the multiple pathways leading to progression of the disease 
[52]. Besides impairment in lung function other factors such as hyperinflation, 
emphysema, cough and sputum, and persistent inflammation should be 
evaluated, also in patients with less advanced COPD. Only then, we can put 
a step forward towards clinical phenotyping directed at individualised therapy 
[53]. The unique setting of the GLUCOLD study has provided the cooperation 
between multiple departments resulting in detailed phenotyping of patients 
with predominantly moderate COPD, including clinical as well as inflammatory 
data from induced sputum and bronchial biopsies. By showing that certain 
subgroups of COPD such as patients with less advanced disease or a 
subphenotype with less emphysema can benefit from inhaled corticosteroids, 
our results may offer an indication for a promising perspective for subgroups 
of patients with COPD towards the potential of slowing down the progression 
of the disease in the future.     
Current implications in daily practice 
Patient-centred care is the solution for improvement of quality of care and 
costs for chronic disease. Primary care may provide a setting where patient-
centred care can be implemented. GPs can deliver integrated care with 
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other health care providers. Continuity of nearby presence of care can help 
the patient with integrating personal goals in daily life. So, how can we build 
bridges between evidence based medicine and practical daily care. It is 
increasingly known that diagnoses such as COPD are strongly related to other 
chronic diseases such as cardiovascular disease [54] and in the future we 
may go beyond specific diagnoses towards fingerprints of inflammation and/
or RNA/DNA. However, we are not there yet and have to take one step at a 
time. Interpreting current guidelines is difficult since many patients with COPD 
have been and still are excluded from large randomised controlled trials [55]. 
So how can we start with implementing current knowledge in daily care? Is it 
sufficient to treat patients ad hoc? Do we rely on symptoms, exacerbations 
and FEV₁ or should we pro-actively focus on clinical phenotyping, including 
extended assessment in early disease? With increasing costs in society in the 
nearby future, the latter may be difficult to obtain with the enormous amount of 
patients with asthma and COPD. More simply, we cannot measure everything 
in every patient at any moment. It will be an enormous challenge to examine 
which patients with mild or more advanced disease will need early extended 
assessment in order to improve care (and reduce costs in the end). 
The authors’ perspective
How can we implement current evidence into daily practice? At this moment, 
I work as a general practitioner in a large primary care practice in The 
Hague. Around 1,000 patients (from a total of 10,500 registered persons) 
have a diagnosis of asthma and/or COPD. Together with lung physicians, 
we have started implementing integrated care. The novelty in our project is 
that caretakers from first and secondary care communicate in a structured 
and efficient way, in order to decide which patient needs further assessment 
using innovative e-health instruments. With current political movements in the 
Netherlands, the future will show whether programs like this will be stimulated, 
facilitated or stopped by the government. For now, a specialised lung nurse will 
make a detailed assessment of the patients’ disease using questionnaires and 
spirometry within the primary care practice. Teleconsultation will be used to 
improve communication and feedback between primary and secondary care. 
If necessary, patients will have a secondary assessment in the hospital, with 
the intention of returning to primary care within 3 months of time. Few patients 
will actually be referred to a hospital. In addition, patient-centered care will be 
enhanced by usage of an internet based self-management programme, www.
PatientCoach.nl. This programme was developed in Leiden for patients with 
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chronic disease and provides the possibility to optimise disease management, 
including the possibility of communication between the patient and the 
caretaker as well as scientific evaluation. Registration with the programme is 
integrated in the electronic registration system of the primary care physician. 
Currently, we are performing an implementation study with PatientCoach for 
patients with moderate asthma in primary care (IMPlementation strategies of 
internet-based Asthma Self-management Support in usual carE (IMPASSE) 
Trial). Patients with asthma can monitor their asthma symptoms and lung 
function at home with a consequent medication advice according to an 
algorithm based on current guidelines. In addition, we have started the 
Pulmonary Rehabilitation of Asthma and COPD: a Trial of sustained Internet-
based Self-management Support (PRACTISS) study. The aim of this study is 
to assess the cost-effectiveness of sustaining self-management support via 
PatientCoach as compared to usual care in patients with 1) severe asthma 
who have completed pulmonary rehabilitation in Davos and 2) COPD patients 
who have completed pulmonary rehabilitation in the Rijnlands Rehabilitation 
Centre in The Netherlands. 
The simplest reason for taking all of these efforts is to improve chronic care 
and reduce the enormous distress that patients experience from their chronic 
disease, accompanied with a decrease in costs. By structuring basic daily 
care we may try to find a way not just to measure everything in every one, 
but to focus on clinical phenotyping, setting personal goals and individualised 
care. By performing research with new topics such as biomarkers or e-health 
and integrating primary and secondary care, patients may benefit. This may 
lead eventually towards integrated disease management, individualised care, 
improved quality of life, and possibly slowing down the progression of chronic 
disease. 
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Abbreviations 
α1AT Alpha-1 Antitrypsin
BAL  Bronchoalveolar Lavage
Body box Plethysmography
CCQ  Clinical COPD Questionnaire
Chest X-ray Chest radiograph
COPD  Chronic Obstructive Pulmonary Disease
CRP  C-Reactive Protein
CT  Computed Tomography
DNA Deoxyribonucleic Acid
ECG Electrocardiogram 
ECLIPSE  Evaluation of COPD Longitudinally to Identify   
 Surrogate Endpoints 
FEV1 Forced Expiratory Volume in one second
FIV1 Forced Inspiratory Volume in one second
GM-CSF  Colony-Stimulating Factor
GLUCOLD Groningen Leiden Universities Corticosteroids in   
 Obstructive Lung Disease study
GOLD guidelines  Global Initiative for COPD guidelines
Hb  Hemoglobine
ICS  Inhaled Corticosteroids
IgE Immunoglobuline
IL-8 Interleukin (IL)-8
IMPASSE  IMPlementation strategies of internet-based Asthma  
 Self-management Support in usual carE trial 
ISOLDE  Inhaled Steroids in Obstructive Lung Disease
KCO transfer factor for carbon-monoxide 
LABA  Long-Acting ß2-Agonist
LTB4 Leukotriene B4 
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LUMC  Leiden University Medical Center
MMPs  Matrix Metalloproteinases
6 MWD 6-Minute Walk test
NWO  Netherlands Organization for Scientific Research
N2 sb test single-breath nitrogen test 
PEF Peak Expiratory Flow
PC20 methacholine  the provocative concentration of methacholine that  
 causes a decrease in FEV1 of 20%
PRACTISS  Pulmonary Rehabilitation of Asthma and COPD:   
 a Trial of sustained Internet-based    
 Self-management Support study 
TNF-α Tumor Necrosis Factor-α
TGF-ß  Transforming Growth Factor
QOL-RIQ Quality of Life for Respiratory Illness Questionnaire
Rand36 Short Form Health Survey
RNA Ribonucleic Acid
SAB  Stichting Astma Bestrijding
SGRQ  St. George Respiratory Questionnaire study 
SLPI  Leucocyte Protease Inhibitor
TIMPs Tissue Inhibitor of Metalloproteinases
TRISTAN  Trial of Inhaled Steroids and Long-acting   
 ß2-agonists study 
TORCH  Towards a Revolution in COPD Health study
UMCG  University Medical Center Groningen
VAS Visual Analogue Scale
TLC Total Lung Capacity
CO-diffusion capacity Carbon-monoxide-diffusion capacity
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Chapter 9  •  Nederlandse samenvatting (Dutch)
In dit proefschrift staat onderzoek naar behandeling met geïnhaleerde 
ontstekingsremmers (inhalatiecorticosteroïden) bij patiënten met een 
chronisch obstructieve longziekte (COPD) centraal. In het eerste deel van 
deze samenvatting wordt ingegaan op de recente inzichten op het gebied van 
COPD. In het tweede deel wordt de inhoud van het proefschrift stapsgewijs 
besproken. 
COPD 
Patiënten met COPD hebben een verminderde functie van de longen. COPD is 
een Engelse afkorting voor Chronic Obstructive Pulmonary Disease. Het is een 
verzamelnaam voor onder andere chronische bronchitis en longemfyseem. 
Chronische bronchitis is een term die door artsen gebruikt wordt voor patiënten 
die meer dan 3 maanden per jaar gedurende meer dan één jaar hoesten en 
daarbij slijm (mucus) opgeven. Bij longemfyseem zijn diep in de longen de 
longblaasjes en het longweefsel beschadigd waardoor de ‘rek’ uit de longen 
is gehaald. COPD komt veel voor: in elke huisartspraktijk in Nederland zijn er 
gemiddeld 60 patiënten die deze aandoening hebben. Het merendeel van de 
patiënten met COPD heeft matig tot ernstig COPD en wordt door de huisarts 
behandeld. De meest kenmerkende klachten zijn hoesten, slijm opgeven 
en benauwdheid. Voor de term “benauwdheid” worden ook veel andere 
omschrijvingen gebruikt, zoals ‘minder lucht’, ‘kortademigheid’, ‘kort van 
adem’ of ‘benauwd gevoel op de borst’, en in het Gronings “achter de poest”. 
Het treedt vooral op bij inspanning. Alleen bij patiënten met ernstig COPD 
komt ook benauwdheid in rust voor. Indien er in korte tijd een verergering van 
klachten ontstaat, noemen we dat een ‘exacerbatie’. Een exacerbatie wordt 
vaak veroorzaakt door infecties in de luchtwegen, meestal optredend in de 
wintermaanden. 
Een belangrijk kenmerk van COPD is de verminderde functie van de longen. 
Dit wordt in medische termen luchtwegobstructie genoemd. Om de diagnose 
COPD te stellen wordt hiervoor de functie van de longen gemeten met een 
longfunctiemeter. Voor deze meting moet de patiënt rustig en diep inademen 
en dan zo hard en lang mogelijk uitademen. De diagnose COPD kan pas 
worden gesteld als de longfunctie na inname van specifieke medicijnen die 
de luchtwegen open zetten, zogeheten luchtwegverwijders, nog steeds 
verminderd is. Bij COPD zijn de longen onherstelbaar beschadigd en de 
longfunctie zal naarmate de patiënt ouder wordt verminderen. De weerstand 
bij uitademen is bij patiënten met COPD verhoogd. De lucht kan er wel goed 
in, maar niet goed uit. Om te begrijpen wat hier gebeurt, zou je een wasknijper 
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 Figuur 1. Patiënten perspectief 
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op je neus kunnen zetten en dan door een rietje ademen. Dit geeft een idee 
hoe iemand met COPD zich voelt.
Patiëntenperspectief
Voor de patiënt zijn luchtwegklachten en beperkingen in het dagelijkse 
leven het belangrijkst (Figuur 1). De klachten en exacerbaties die met de 
aandoening gepaard gaan kunnen leiden tot een minder goede kwaliteit 
van leven. Hierbij kun je denken aan meer moeite om sport te beoefenen, te 
spelen met de kleinkinderen of trappen te lopen. Bij ernstiger COPD kunnen 
ziekenhuisopnames erg belastend zijn. Bij wetenschappelijk onderzoek is 
kwaliteit van leven gemeten met specifieke vragenlijsten. Hierbij bleek dat 
kwaliteit van leven maar matig is gerelateerd aan de onderliggende longfunctie. 
Er zijn dus patiënten met mild COPD met veel klachten en patiënten met 
ernstig COPD met weinig klachten. Dit kan komen doordat kwaliteit van leven 
ook beïnvloed wordt door andere factoren als depressie. Er zijn weinig studies 
die de relatie tussen kwaliteit van leven en onderliggende ontsteking van de 
luchtwegen hebben onderzocht. 
Risicofactoren 
Het roken van sigaretten is de belangrijkste risicofactor voor het krijgen 
van COPD. Eén op de vijf mensen die veel rookt of gerookt heeft zal COPD 
ontwikkelen. Van de patiënten die COPD hebben gekregen heeft ongeveer 
90% gerookt.
Verschillende fenotypes
De ene patiënt met COPD is de andere niet. Er zijn patiënten die vooral 
last hebben van chronische bronchitis, hoesten en slijm opgeven, maar 
ook patiënten die vooral last hebben van periodes met een verergering van 
hun klachten, die we exacerbaties noemen. De verschillende types van de 
aandoening kunnen we beschrijven als fenotypes. Maar wat is nu precies 
een fenotype? Er bestaan meerdere definities, maar voor de praktijk is het 
belangrijk om naar een verzameling kenmerken te zoeken die klinisch relevant 
zijn voor bijvoorbeeld de behandeling. Een klinisch fenotype kan worden 
gedefinieerd als “een enkel of een combinatie van kenmerk(en) die het verschil 
beschrijft tussen individuen onderling en gerelateerd is aan klinisch belangrijke 
uitkomsten zoals kwaliteit van leven of effect van behandeling”. Een klinisch 
fenotype wordt bepaald door een combinatie van genetische factoren 
(genotype), omgevingsfactoren en klinisch relevante uitkomsten voor een 
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bepaalde aandoening. Een klinisch fenotype is hiermee bij een patiënt in de tijd 
vaak enigszins variabel. Als bijvoorbeeld omgevingsfactoren veranderen, kan 
het zijn dat een patiënt nu wel binnen een fenotype valt, of zelfs binnen een 
ander fenotype dan daarvoor. Welke fenotypen zijn van belang voor COPD?
Chronische bronchitis 
Ongeveer een derde van de patiënten met COPD heeft chronische bronchitis. 
Dit kan klinisch worden gedefinieerd als aanwezigheid van dagelijks hoesten 
en slijm opgeven gedurende tenminste 3 maanden per jaar gedurende 
meer dan 1 jaar. Het is evident dat hoesten en slijm opgeven patiënten erg 
kunnen hinderen in hun dagelijks leven. Er is daarnaast veel discussie of 
chronische bronchitis een speciaal fenotype is dat behandeld kan worden om 
de achteruitgang van de aandoening af te remmen. Al in de jaren ‘50 werd 
gedacht dat roken de slijmproductie kon bevorderen, waardoor langdurige 
infectie aanwezig was met als gevolg beschadiging van de longen (Britse 
hypothese). Echter, dit kon niet worden aangetoond in andere studies en 
lang werd toen gedacht dat hoesten en slijm onschuldige klachten waren. In 
meer recente studies werd een verband gevonden tussen veel slijm opgeven 
en achteruitgang van de longfunctie. Bij patiënten met chronische bronchitis 
werden meer ontstekingscellen gevonden bij slijmproducerende cellen in 
de luchtwegen wat kan duiden op een onderliggende oorzaak. Mogelijk zijn 
ontstekingscellen de motor achter de vermeerderde slijmproductie met 
bijbehorende hoestklachten. Dit zou betekenen dat chronische bronchitis niet 
zo maar een onschuldig fenotype is bij COPD, maar dat de aanwezigheid of 
de mate van chronische bronchitis van belang kan zijn voor de ontwikkeling 
van de aandoening. 
Frequente exacerbaties
Een exacerbatie is een tijdelijke verergering van luchtwegklachten. Dit kan 
enorme impact hebben op patiënten. Stel je bijvoorbeeld de volgende patiënt 
voor (eigen ervaring uit de praktijk): de heer T is een man van 65 jaar. Hij heeft 
matig ernstig COPD en is verkouden. Na een week gaat dit niet over zoals bij 
veel mensen het geval is, maar krijgt hij alleen maar meer klachten. Hij krijgt 
verhoging, gaat meer hoesten en is kortademig bij zeer geringe inspanning. De 
huisarts komt langs en constateert een behoorlijke verergering van zijn COPD 
(exacerbatie). Hij besluit de man naar het ziekenhuis te sturen, waar deze een 
aantal dagen moet blijven om weer op te knappen. Het is goed voor te stellen 
dat deze periode veel impact heeft op de man en zijn familie. 
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Het hebben van veel exacerbaties lijkt een risicofactor te zijn voor overlijden 
en een versnelde achteruitgang van de longfunctie. Het zijn vooral patiënten 
met ernstig COPD die meer frequente en ernstiger exacerbaties hebben. 
Echter, de ‘Evaluation of COPD Longitudinally to Identify Surrogate Endpoints’ 
(ECLIPSE) studie heeft laten zien dat patiënten met zowel mild als ernstig 
COPD veel exacerbaties kunnen hebben, wat duidt op een apart fenotype. Er 
zijn verschillende studies die laten zien dat je exacerbaties kunt voorkomen. 
Door het opstellen van een individueel actieplan worden exacerbaties eerder 
ontdekt en vroegtijdige behandeling kan leiden tot een vermindering van duur 
en ernst van de exacerbatie. Behandeling met inhalatiecorticosteroïden al 
dan niet met langwerkende luchtwegverwijders kan het aantal exacerbaties 
doen verminderen. In nationale en internationale richtlijnen wordt daarom 
geadviseerd patiënten met frequente exacerbaties te behandelen met 
inhalatiecorticosteroïden. Interessante resultaten van een recente studie laten 
zien dat een onderhoudsbehandeling met antibiotica het aantal exacerbaties 
kan doen verminderen bij patiënten met matig ernstig COPD. Deze studie liet 
echter ook bijwerkingen zien zoals 5% meer gehoorsverlies bij de onderzochte 
patiënten. Samenvattend zijn er verschillende studies die laten zien dat het 
hebben van frequente exacerbaties op een apart fenotype duidt, waardoor het 
risico op exacerbaties in de recente internationale richtlijnen is opgenomen als 
leidraad bij het behandelen van patiënten met COPD. 
Versnelde achteruitgang van longfunctie
De versnelde achteruitgang van de longfunctie is een hoofdkenmerk van 
COPD. Het wordt wereldwijd gebruikt als een objectieve meting om de ernst 
van de aandoening te beschrijven. Bij gezonde personen daalt de longfunctie 
met de leeftijd ongeveer 25-30 ml per jaar. Bij patiënten met COPD is dit meer, 
en daalt de longfunctie met gemiddeld 60 ml per jaar. In het begin hebben de 
longen veel reserve en kunnen patiënten met COPD weinig last hebben van de 
verminderde longfunctie. Echter, bij een deel van de COPD-patiënten daalt de 
longfunctie veel sneller. Mogelijk duidt dit op een apart fenotype waar winst 
behaald kan worden met intensiever controleren (monitoren) en behandelen.  
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Naast de longfunctie zijn er meer objectieve kenmerken van COPD. Er zijn 
patiënten die last hebben van hyperreactiviteit (prikkelbaarheid van de 
luchtwegen). Hyperreactiviteit is geassocieerd met de versnelde achteruitgang 
van de longfunctie wat mogelijk duidt op een apart fenotype. Een ander 
kenmerk is hyperinflatie, waarbij er sprake is van een toename van lucht in 
de longen die een patiënt niet meer uit kan ademen. Dit wordt versterkt door 
obstructie of vernauwing van de luchtwegen en/of emfyseem. Bij inspanning 
zal hyperinflatie toenemen waardoor patiënten vaak meer benauwd worden. 
Bij andere patiënten staat emfyseem op de voorgrond. De diverse uitingen 
en verschillen in het onderliggend ziektebeeld bieden mogelijkheden voor 
verschillen in behandeling.
 
Ontsteking in de longen
De kleine luchtwegen (minder dan 2 mm in doorsnede) zijn de belangrijkste 
plaats voor luchtwegobstructie bij COPD. Een recente studie onderzocht 
de relatie tussen obstructie in deze kleine luchtwegen en emfyseem. Met 
een Computer Tomografy (CT) zijn longen onderzocht bij 78 patiënten die 
een transplantatie hadden ondergaan. Een belangrijk resultaat was dat het 
aantal kleine luchtwegen was verminderd bij patiënten met mild COPD en 
verder afgenomen bij patiënten met ernstig COPD. Dit suggereert dat de 
vernauwing en verlies van de kleine luchtwegen voorafgaat aan het ontstaan 
van emfyseem. 
Pathogenese 
Pathogenese kan worden gedefinieerd als het ontstaan van ziekte door 
opeenvolgende veranderingen van structuur en functie van cellen, weefsel 
of organen door de effecten van microbiële, chemische of fysische 
invloeden. De pathogenese bij COPD wordt gekenmerkt door een complexe 
ontstekingsreactie ten gevolge van het inhaleren van schadelijke stoffen. 
Het roken van sigaretten veroorzaakt een ontstekingsreactie in de longen. 
Echter, ongeveer 20% van de rokers ontwikkelt COPD en het lijkt erop dat 
de ontstekingsreactie bij deze patiënten versterkt is of abnormaal gereguleerd 
doordat ze er extra gevoelig voor zijn. Bij patiënten met COPD blijft een groot 
deel van de ontstekingsreactie ook actief nadat patiënten stoppen met roken.
Pathologische fenotypes
Er zijn verschillende pathologische fenotypes bekend. Chronische bronchitis 
is gekoppeld aan een overproductie van slijm, wat mogelijk aangestuurd kan 
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worden door een ontstekingsreactie in de slijmklieren en bekleding van de 
luchtwegen. Emfyseem wordt veroorzaakt doordat de luchthoudende blaasjes 
in de longen kapot gaan. Dit kan deels komen door onvoldoende herstel van 
het longweefsel. De kleine luchtwegen zijn vaak als eerste aangedaan en 
lijken bij vroege stadia van COPD in aantal te verminderen. Er is in onderzoek 
een toename gevonden van verschillende ontstekingscellen. Het weefsel 
kan kapot gaan als direct gevolg van de ontsteking en afbraak van het 
elastische longweefsel, waardoor bij het uitademen de (kleine) luchtwegen 
eerder dichtklappen. Daardoor blijft lucht achter in de longen, hetgeen wij 
hyperinflatie noemen. Daarnaast kan het weefsel beschadigd worden door een 
overdreven herstel van het longweefsel. Als gevolg van deze beschadigingen 
kan er een structurele verandering van het longweefsel optreden, ook 
wel verbindweefseling of fibrose genoemd. De luchtwegen verdikken en 
vernauwen, wat bij kan dragen aan de verminderde longfunctie. Overproductie 
van slijm en slijmproppen draagt verder aan bij aan de obstructie. Echter, 
de verschillende onderliggende mechanismen maken het erg moeilijk om de 
verschillende pathologische processen in fenotypes onder te verdelen.
Luchtwegontsteking is het basiskenmerk van COPD. De ontsteking komt 
voor in de gehele longen en er zijn verschillende manieren om dit te meten. 
In het GLUCOLD onderzoek hebben patiënten bronchoscopiëen ondergaan. 
Hierbij wordt met een flexibel slangetje in de luchtwegen gekeken en een 
hapje (biopt) uit het longweefsel genomen. Dit weefsel kan worden bewerkt 
en onderzocht. Het is een belastend onderzoek en het wordt door ons als 
onderzoekers zeer gewaardeerd dat patiënten met COPD in ons onderzoek 
hieraan mee wilden werken. Een andere manier om ontsteking te onderzoeken 
is een slijmonderzoek. Ook dit is vrij belastend en wordt in de praktijk 
alleen in sommige ziekenhuizen verricht. Minder belastend onderzoek is 
bloedonderzoek. Recent onderzoek laat zien dat er ook nieuwe technieken 
zijn die belangrijke resultaten laten zien bij COPD. Met een speciaal apparaatje 
(‘elektronische neus’) kan de uitgeademde lucht worden gemeten en 
onderzocht. Deze uitgeademde lucht van patiënten met COPD is gerelateerd 
aan een specifiek ontstekingsprofiel wat suggereert dat het gebruikt kan 
worden om een fenotype vast te stellen bij COPD. 
Ontsteking en afweer 
Bij COPD is bij daarvoor gevoelige patiënten met COPD sprake van een 
abnormale toename van de ontstekingsreactie van de longen als gevolg van 
schadelijke stoffen (Figuur 2).
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Bij iemand die schadelijke stoffen inhaleert of een luchtweginfectie doormaakt 
komen prikkelende stoffen in de luchtwegen terecht. Deze botsen als eerste 
op de luchtwegwand en het aangeboren afweersysteem. Dit is de eerste 
verdedigingslinie. Als de stofjes door de luchtwegwand heen komen, ontstaat 
een golf van reacties van het afweersysteem. De reactie is gunstig voor het 
Figuur 2. Aangeboren en verworven afweer
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opruimen van de infectie, maar kan zo sterk zijn dat er schade (ontsteking) 
ontstaat. De ontsteking zelf heeft ook weer als doel om de infectie of het 
schadelijke stofje te bestrijden. Belangrijke cellen in dit proces bij COPD zijn 
neutrofiele granulocyten, macrofagen en CD8+ T lymfocyten. Daarnaast zijn er 
aanwijzingen dat CD4+ T lymfocyten, mestcellen en eosinofiele cellen een rol 
spelen.
Neutrofiele granulocyten gaan naar delen in de longen toe om wonden te 
helen. Geactiveerde neutrofielen kunnen slijmproductie stimuleren. Helaas kan 
een teveel aan neutrofielen ook schade berokkenen en kunnen afgescheiden 
stofjes zoals elastase emfyseem bevorderen. Een andere belangrijke cel is 
de macrofaag. Het aantal macrofagen is toegenomen in de luchtwegen en in 
het slijm van patiënten met COPD. Ook de macrofaag kan schadelijke stofjes 
afscheiden die bijdragen aan het ontstaan van emfyseem. Eosinofielen en 
mestcellen spelen een belangrijke rol bij patiënten met astma, maar lijken ook 
een rol te spelen bij COPD. Eosinofiele cellen spelen bijvoorbeeld een rol bij 
exacerbaties en het sturen van behandeling. Epitheel cellen zijn oppervlakkige 
cellen in de luchtwegwand en scheiden diverse stofjes af die van invloed zijn 
op de ontsteking. Na de eerste reactie van het aangeboren afweersysteem 
zijn dendritische cellen verantwoordelijk voor het stimuleren van het 
verworven afweersysteem. Het verworven afweersysteem kan specifieke 
stofjes herkennen en onthouden om de afweer goed te reguleren. Belangrijke 
ontstekingscellen zijn hierbij T lymfocyten (CD4+ en CD8+) en B lymfocyten. 
Een belangrijke functie van CD8+ cellen is het aanvallen van virussen door 
celdood van geïnfecteerde cellen. De rol van CD4+ is wat minder duidelijk. 
Deze cellen scheiden diverse stofjes af en zijn de zogenaamde T helper cellen. 
Ze ‘helpen’ door het activeren van de B lymfocyten en ondersteunen activiteit 
van de CD8+ cellen. In de GLUCOLD studie werd gevonden dat patiënten 
met COPD meer B lymfocyten hebben dan patiënten zonder COPD. De rol 
van B lymfocyten is nog niet geheel opgehelderd. Een toename kan worden 
gestimuleerd door virussen of bacteriën en dient mogelijk als bescherming 
tegen infecties. Recente studies hebben aangetoond dat mestcellen meer 
voorkomen in de luchtwegen bij patiënten met COPD dan bij gezonde mensen. 
Weefselherstel en remodelling 
Het gevolg van bovenstaande mechanismen is dat de longen zich proberen 
te herstellen of gaan reorganiseren (remodelling). Als er geen goede balans 
is tussen schade en herstel leidt dit tot onherstelbare schade aan de longen. 
Reorganisatie van weefsel veroorzaakt vernauwing van de luchtwegen, 
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verdikking van de wanden en verandering van het longweefsel (parenchym). 
Het is de vraag of de reorganisatie altijd schadelijk is. Mogelijk geeft 
bijvoorbeeld een verdikking van de luchtwegen een betere bescherming tegen 
agressieve stoffen van buiten af. De schade die ontstaat bij de longblaasjes 
geeft een verslapping van het weefsel. Elastase (afkomstig van de neutrofiel) is 
een bijzonder stofje dat elastische vezels af kan breken waardoor de rek uit de 
longen gaat wat leidt tot emfyseem. 
Behandeling 
Een van de peilers bij de behandeling is het verbeteren van leefgewoonten. 
En dan vooral het stoppen met roken, omdat dit een duidelijk positief 
effect heeft op de klachten, het aantal exacerbaties en de achteruitgang in 
longfunctie. In het verleden werd COPD gezien als een onbehandelbare 
aandoening. De aandoening kan nog altijd niet worden genezen, maar in de 
afgelopen jaren wordt toch iets positiever tegen de behandeling aangekeken. 
Er zijn voor patiënten met mild tot matig ernstig COPD twee belangrijke 
soorten medicijnen. Er zijn kort- en langwerkende luchtwegverwijders. Deze 
medicijnen kunnen de luchtwegen meer open zetten en daarmee de patiënt 
meer lucht geven. Daarnaast zijn er medicijnen die inhalatiecorticosteroïden 
oftewel ontstekingsremmers worden genoemd. Dit zijn medicijnen die zoals 
de naam al zegt de ontsteking in de luchtwegen zouden moeten remmen. Bij 
patiënten met astma werkt dit inderdaad zo. Patiënten met astma hebben ook 
een obstructie in de luchtwegen, maar deze is in tegenstelling tot bij COPD, 
wel herstelbaar. Bij patiënten met COPD ligt het iets ingewikkelder. Vier grote 
studies uit de jaren ‘90 lieten zien dat ontstekingsremmers de achteruitgang 
van de longfunctie niet af konden remmen. In de afgelopen jaren hebben 
diverse studies een positief effect laten zien van inhalatiecorticosteroïden 
al dan niet met langwerkende luchtwegverwijders op kwaliteit van leven 
en exacerbaties bij patiënten met COPD. Een aantal studies liet zien dat 
inhalatiecorticosteroïden een goed effect hebben bij patiënten met veel 
exacerbaties. Momenteel is dit dan ook de reden dat deze medicijnen alleen 
worden geadviseerd bij patiënten met frequente exacerbaties. Echter, er zijn 
heel erg veel patiënten die minder dan twee exacerbaties per jaar hebben. 
In de dagelijkse praktijk krijgen toch ook heel veel patiënten uit deze grote 
groep deze medicijnen. Het is een uitdaging aan de wetenschap om te 
onderzoeken of er meer fenotypes zijn die baat hebben bij de behandeling met 
inhalatiecorticosteroïden. 
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Het doel van de studie
Deze studie doet onderzoek naar gedetailleerde fenotypering van COPD 
en effecten van behandeling met inhalatiecorticosteroïden al dan niet met 
langwerkende luchtwegverwijders. Het is gebaseerd op analyses van de 
“Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease” 
(GLUCOLD) studie. 
De onderzoeksdoelen van het huidige proefschrift zijn: 
1) Zijn klinische symptomen en luchtwegontsteking verschillende 
componenten van COPD?
2) Draagt luchtwegontsteking bij aan verminderde kwaliteit van leven?
3) Is chronische bronchitis een apart fenotype?
4) Heeft onderhoudshandeling met ontstekingsremmers een effect op de 
chronische ontsteking en symptomen bij COPD?
5) Kan het effect van ontstekingsremmers al dan niet met langwerkende 
luchtwegverwijders voorspeld worden?
6) Heeft onderhoudsbehandeling met ontstekingsremmers al dan niet met 
langwerkende luchtwegverwijders een effect op de dagelijkse kwaliteit 
van leven en longfunctie bij patiënten met COPD?
Wat was de opzet van de GLUCOLD studie? 
De GLUCOLD studie is door wetenschappelijke onderzoekers geïnitieerd, 
uitgevoerd en geanalyseerd. De patiënten in de studie werden toegelaten 
als ze 45-75 jaar oud waren, (ex)-rokers en longfuncties tussen de 30 en 
80% hadden vergeleken met gemiddelde personen van gelijke leeftijd of 
geslacht. Patiënten mochten geen astma hebben. De metingen vonden 
plaats tussen 2003 en 2007. Patiënten werden ingedeeld in de volgende vier 
behandelgroepen (Figuur 3):
1) Kortdurend (6 maanden) geïnhaleerde ontstekingsremmers 
(inhalatiecorticosteroïden, fluticasone), gevolgd door placebo. Een 
placebo is een nep medicijn.
2) Langdurend (2,5 jaar) inhalatiecorticosteroïden
3) Combinatie van inhalatiecorticosteroïden met langwerkende 
luchtwegverwijders (salmeterol)
4) Langdurend placebo 
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In eerste instantie is het effect op ontstekingsparameters in longweefsel 
(biopten) onderzocht (Figuur 4). Daarnaast zijn elke 3 maanden 
luchtwegklachten gemeten, kwaliteit van leven, rookstatus, bloedonderzoek, 
therapietrouw en longfunctiemetingen. Op 0, 6 en 30 maanden zijn 
bronchoscopiën, slijmonderzoek en hyperreactiviteitsmetingen verricht*.
Figuur 3. Opzet van de studie
Figuur 4. Metingen  
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Conclusies van dit onderzoek
Klinische symptomen en ontsteking
•  Luchtwegobstructie, hyperreactiviteit en ontsteking zijn aparte, 
grotendeels onafhankelijke componenten van COPD (Hoofdstuk 2).
•  Ontsteking in de luchtwegen draagt onafhankelijk bij aan de verminderde 
kwaliteit van leven bij patiënten met COPD (Hoofdstuk 3).
•  Chronische bronchitis reflecteert een fenotype gebaseerd op een 
specifiek ontstekingsprofiel, waarbij eosinofiele cellen in de luchtwegen 
lijken te verschuiven van de wand naar het lumen en er een hoger 
percentage macrofagen in het sputum is (Hoofdstuk 4).
Langdurig behandelen met geïnhaleerde ontstekingsremmers al dan niet 
met lang werkende luchtwegverwijders
•  Langdurig behandelen met geïnhaleerde ontstekingsremmers heeft in 
deze studie bij deze patiënten met COPD een remmend effect op de 
ontstekingscellen. Dit is geassocieerd met een gunstig effect op de 
achteruitgang van de longfunctie. Langwerkende luchtwegverwijders 
verbeteren de longfunctie op de korte termijn, een effect dat op de 
lange termijn wordt behouden. Onze resultaten suggereren een effect 
van inhalatiecorticosteroïden op de voortgang van de aandoening 
bij bepaalde groepen patiënten met matig ernstig COPD die daarvoor 
merendeels niet behandeld waren met ontstekingsremmers   
(Hoofdstuk 5).
•  Patiënten die minder hebben gerookt, een betere zuurstof opname 
capaciteit hebben in de longen, minder hyperinflatie en een lager totaal 
aantal cellen in hun slijm hebben een grotere kans om te profiteren van 
inhalatiecorticosteroïden. Dit suggereert dat patiënten met milder COPD, 
een eerder stadium of een bepaald fenotype van de ziekte waarbij COPD 
minder wordt bepaald door emfyseem meer profijt kunnen hebben van 
geïnhaleerde ontstekingsremmers (Hoofdstuk 6).
•  Langdurig behandelen met geïnhaleerde ontstekingsremmers verbetert de 
dagelijkse symptomen, terwijl stoppen na 6 maanden dagelijkse kwaliteit 
van leven en longfunctie benadeelt. Langwerkende luchtwegverwijders 
geven een kortdurend effect (Hoofdstuk 7). 
Heterogeniteit van COPD 
‘De ene patiënt met COPD is de andere niet’. In hoofdstuk 2 hebben we de 
diversiteit van patiënten met COPD onderzocht. De GLUCOLD studie is een 
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studie waarbij we patiënten met COPD zeer gedetailleerd in kaart hebben 
gebracht. Er is gekeken naar klachten van de patiënt en kwaliteit van leven, 
maar ook naar complexe mechanismen die de onderliggende aandoening 
COPD bepalen. Al deze verschillende kernmerken zijn in een bepaalde analyse 
gehergroepeerd om te kijken of er een onderlinge samenhang is. Hier bleek 
dat longfunctie, ontsteking, en kenmerken die eerder aan astma werden 
toebedeeld aparte componenten zijn. Dit suggereert dat het mogelijk is 
fenotypes te definiëren binnen de grote groep patiënten met COPD.
Kwaliteit van leven
Het belangrijkste voor de patiënt met COPD zijn niet de afwijkingen aan de 
luchtwegen en het longweefsel, maar de luchtwegklachten en beperkingen 
die hij of zij in het dagelijks leven ervaart en die een verminderde kwaliteit 
van leven veroorzaken. Dus, waarom zouden we ingewikkelde en belastende 
metingen als broncoscopiëen en slijmonderzoek verrichten? Het blijkt uit 
onderzoek dat luchtwegklachten geen directe afspiegeling zijn van de 
ontsteking van de onderliggende aandoening. Uiteindelijk is het natuurlijk wel 
de onderliggende aandoening die op de lange termijn voor voortgang van 
de ziekte en voor de uiteindelijke klachten zorgt. Daarbij is ontsteking een 
belangrijk aangrijpingspunt voor behandeling om de voortgang van de ziekte 
af te remmen. Daarom is het van belang niet alleen naar klachten, maar ook 
naar de onderliggende mechanismen van de aandoening te kijken. Veel studies 
kijken of naar klachten of naar ontsteking, maar weinig studies kijken naar het 
geheel. In de GLUCOLD studie is nauwkeurig onderzocht of er een verband 
is tussen de klachten die belangrijk zijn voor de patiënt en de onderliggende 
ontsteking (Hoofdstuk 3). De resultaten lieten zien dat kwaliteit van leven was 
gerelateerd aan meer ontstekingscellen in slijm. Symptomen en activiteiten 
waren gerelateerd aan hogere percentages macrofagen in slijm. Deze 
resultaten suggereren dat een speciaal pathologisch fenotype van invloed kan 
zijn op de kwaliteit van leven bij patiënten met matig ernstig COPD. 
Langdurig behandelen met inhalatiecorticosteroïden verbeterde diverse 
aspecten van kwaliteit van leven in ons onderzoek, terwijl stoppen met deze 
medicijnen kwaliteit van leven verslechterde. Toevoegen van langwerkende 
luchtwegverwijders aan ontstekingsremmers verbeterde in eerste instantie de 
kwaliteit van leven, maar op de lange termijn verslechterde de kwaliteit van 
leven weer. Langdurig behandelen met ontstekingsremmers gaf vergelijkbare 
effecten op kwaliteit van leven gemeten door patiënten thuis (Hoofdstuk 7). 
Niet voor alle patiënten was dit een klinisch relevante verbetering.
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Chronische bronchitis
Ongeveer een derde van alle patiënten met COPD heeft chronische bronchitis 
(langdurig hoesten en slijm). Het is nog altijd niet duidelijk hoe een gezonde long 
kan veranderen in een COPD-long die veel meer dan de normale hoeveelheid 
slijm produceert. Je zou de cellen van een COPD-long kunnen vergelijken met 
een smeulend vuurtje. Soms is het rustig, soms flakkert het vuur op. Het kan 
worden gestimuleerd door prikkelende stoffen als rook of uitlaatgassen, maar 
ook de long zelf doet mee. Deze stimuleert de afweer om het vuur te bestrijden. 
Bij de COPD-long wordt de afweer overdreven gestimuleerd. De balans tussen 
schade en herstel is weg. Er komen meer slijmcellen, meer slijmproductie en 
een minder effectief schoonmaaksysteem van al dat slijm dat de luchtwegen 
verstopt. De patiënt blijft daarom hoesten om het slijm maar kwijt te raken. 
Echter, veel is nog onduidelijk over de precieze werking van dit proces.
In de huidige studie was chronische bronchitis gerelateerd aan een specifiek 
ontstekingspatroon van de luchtwegen (Hoofdstuk 4). Het bleek dat patiënten 
met chronische bronchitis minder eosinofiele cellen in het longweefsel hadden, 
terwijl er meer eosinofiele cellen in slijm werden gevonden. Dit kan interessant 
als aangrijpingspunt voor specifieke therapie. In de groep patiënten van de 
GLUCOLD studie hebben we een effect gevonden van langdurig behandelen 
met geïnhaleerde ontstekingsremmers. Echter, er was geen verschil in effect 
tussen patiënten met en zonder chronische bronchitis (Hoofdstuk 5). Ook 
hebben we onderzocht of we konden voorspellen bij wie deze therapie werkt. 
Hiervoor hebben we onderzocht bij wie er een langdurig effect bestond van 
de ontstekingsremmers op de achteruitgang van de longfunctie. Het hebben 
van chronische bronchitis bleek in deze studie geen voorspeller te zijn. Het 
is algemeen bekend dat het hebben van chronisch bronchitis een belangrijk 
fenotype is als je naar kwaliteit van leven kijkt. In onze groep patiënten bleek 
het echter geen fenotype te zijn dat relevant is voor de huidige vormen van 
therapie.
 
Langdurig behandelen met inhalatiecorticosteroïden al dan niet met 
langwerkende luchtwegverwijders
Bij een groot deel van de patiënten met astma kunnen ontstekingsremmers 
de ontsteking afremmen waardoor patiënten minder klachten hebben en 
de voortgang van de aandoening kan worden afgeremd. Omdat astma en 
COPD beide obstructieve longziekten zijn met ontsteking als basiskenmerk 
van de ziekte werd ook bij COPD op grote schaal ontstekingsremmers 
voorgeschreven. Echter, bij COPD zijn de effecten minder duidelijk dan bij 
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astma. De huidige richtlijnen adviseren alleen inhalatiecorticosteroïden voor 
te schrijven bij frequente exacerbaties. Grote studies begin jaren 2000 lieten 
zien dat er geen effect was op de versnelde achteruitgang van de longfunctie. 
Twee recente studies nuanceren dit enigszins. In de GLUCOLD studie hebben 
we een aantal positieve klinische effecten gevonden van de behandeling met 
inhalatiecorticosteroïden al dan niet met langwerkende luchtwegverwijder. Bij 
patiënten die na 6 maanden doorbehandeld werden met ontstekingsremmers 
verminderde de achteruitgang van de longfunctie op de lange termijn. Dit werd 
begeleid door een aanhoudend effect op de hyperreactiviteit en vermindering 
van kortademigheid. Deze lange termijneffecten waren geassocieerd 
met effecten op ontsteking, gemeten in biopten en slijm. Stoppen met 
ontstekingremmers had een nadelig effect op de longfunctie, hyperreactiviteit, 
kortademigheid en kwaliteit van leven en de ontstekingscellen in de 
luchtwegen en het slijm. Toevoegen van een langwerkende luchtwegverwijder 
aan de ontstekingsremmer gaf een verbetering van de longfunctie en klachten 
op de korte termijn, echter doorgaan gaf geen extra effecten ten opzichte van 
ontstekingsremmers alleen.
Maar hoe kun je nu de verschillen verklaren tussen de resultaten van deze 
studie en eerdere studies waar geen effecten werden gevonden? Mogelijk 
komt dit door verschillen tussen de onderzochte patiëntengroepen. De 
personen in onze studie hadden bijvoorbeeld de afgelopen 6 maanden 
geen ontstekingremmers gebruikt en de meesten hadden deze medicijnen 
zelfs nooit eerder gebruikt. In andere studies gebruikte meer dan 50% van 
de patiënten eerder ontstekingsremmers. In de GLUCOLD studie is een 
hoge dosering ontstekingsremmers gebruikt wat mogelijk meer effect kan 
opleveren. Het additionele effect van langwerkende luchtwegverwijders op de 
korte termijn in onze studie komt overeen met resultaten van andere studies. 
Onze studie liet echter zien dat langer doorbehandelen geen extra effect gaf 
op de aandoening. 
Langdurig behandelen verminderde het aantal T cellen en mestcellen, terwijl 
het aantal eosinofielen vermeerderde en het oppervlakte epitheel verbeterde. 
Dit werd begeleid door een afname in slijmcellen. Andere studies laten 
verschillende effecten zien, zoals minder eosinofiele cellen in slijm, minder 
CD8+ en CD4+ cellen, of minder macrofagen in longweefsel. Een mogelijke 
verklaring waarom de ontsteking bij patiënten met COPD resistent kan zijn 
voor ontstekingsremmers is een afname histone deacetylase-2 in meer ernstig 
COPD. Resultaten van de GLUCOLD studie suggereren dat er bepaalde 
effecten van inhalatiesteroïden mogelijk zijn bij een deel van de patiënten 
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met minder ernstig COPD. Het is interessant dat de effecten op klinische 
uitkomsten parallel lopen aan effecten op ontsteking in de luchtwegen en slijm.
 
Wie heeft wel baat bij de behandeling en wie niet? 
“Towards clinical phenoptyping”
In dit proefschrift is de belangrijkste vraag welke patiënt met COPD baat 
heeft bij gebruik van inhalatiecorticosteroïden. Het is duidelijk dat niet iedere 
patiënt met COPD baat heeft bij deze medicijnen. Daarom is het belangrijk op 
zoek te gaan naar specifieke fenotypes, oftewel groepen patiënten met een 
gezamenlijk kenmerk, die hier wel beter van worden. Een fenotype staat niet 
vast. Patiënten kunnen in de loop van de tijd tot een bepaalde groep gaan 
horen zoals de groep met kenmerken van chronische bronchitis (hebben van 
veel hoesten en slijm). Anderzijds kan de wetenschap nieuwe inzichten geven 
waarbij bepaalde fenotypes toch baat hebben bij een bepaalde behandeling. 
In onderstaande Figuur 5 wordt dit schematisch weergegeven. 
In de GLUCOLD studie kwam naar voren dat er een beter effect was op de 
achteruitgang van de longfunctie bij patiënten die minder gerookt hebben, met 
longen die beter zuurstof op kunnen nemen, minder hyperinflatie (vergrootte 
luchthoudendheid) hebben en minder ontstekingscellen in slijm hebben. Dit 
suggereert dat het beter werkt in een eerder stadium van de aandoening of bij 
Figuur 5. Fenotypes in COPD: een dynamisch model 
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patiënten die minder last hebben van emfyseem (‘rek uit de longen’). Hierbij is 
het belangrijk om te weten dat dit gold voor patiënten uit deze studie met matig 
ernstig COPD waarvan de meesten nooit eerder inhalatiecorticosteroïden 
hadden gebruikt. 
Momenteel wordt de ernst van COPD gebaseerd op de longfunctie, 
luchtwegklachten en op toekomstig risico op exacerbaties. Echter, het is de 
vraag of dit de enige kenmerken zijn waar je op kunt varen. Het is de vraag of 
je moet wachten met behandelen tot er veel en onherstelbare veranderingen / 
beschadigingen zijn opgetreden in de longen of dat je eerder wilt behandelen 
om erger te voorkomen. Een andere grote studie, de ‘Trial of Inhaled Steroids 
and Long-acting ß2-agonists’ (TRISTAN) studie liet zien dat het inderdaad 
belangrijk is om ook al in een eerder stadium in te grijpen met behandeling 
zodat er meer winst te behalen valt op de lange termijn. Onze studie liet zien 
dat patiënten met minder emfyseem meer baat hadden bij behandeling met 
inhalatiecorticosteroïden. De ECLIPSE studie liet zien dat emfyseem gemeten 
met een CT-scan geassocieerd was met een snellere achteruitgang van de 
longfunctie. Dit geeft aan dat het een fenotype is dat belangrijk kan zijn bij 
COPD. Inhalatiecorticosteroïden werken beter bij astma dan bij COPD. In 
onze studie zijn patiënten met astma nauwkeurig uitgesloten van deelname. 
Kenmerken van astma zijn bijvoorbeeld reversibiliteit (directe verbetering van 
de longfunctie na toedienen van een luchtwegverwijder), hyperreactiviteit 
(prikkelbaarheid van de longen), eosinofiele cellen in slijm. Deze kenmerken 
leken in onze studie onderling samen te hangen (Hoofdstuk 2). Je kunt je 
afvragen of de medicijnen beter werken bij COPD patiënten die ook enkele 
kenmerken hebben van astma. In onze studie waren astmakenmerken als 
reversibiliteit, hyperreactiviteit of eosinofiele cellen in slijm geen voorspellers 
van het effect op de snelle achteruitgang van de longfunctie. Onze resultaten 
wijzen eerder op een beter effect bij patiënten met een eerder stadium van 
COPD of fenotypes met minder emfyseem. Deze inzichten zouden opnieuw 
moeten worden getest in grotere groepen patiënten om te kunnen zeggen dat 
het voor alle patiënten met COPD geldt. Als onze resultaten worden bevestigd 
door andere studies zouden de richtlijnen verder uitgebreid kunnen worden 
met een potentieel optimistisch perspectief voor een deel van de patiënten 
met COPD. 
Beperkingen van de GLUCOLD studie
In de wetenschap moet je kritisch naar resultaten kijken. Er zijn altijd beperkingen 
te bedenken, de wereld is niet zwart wit en er kan nooit een bewijs worden 
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gevonden voor een hypothese. De belangrijkste beperking in onze studie is 
mijns inziens de generaliseerbaarheid naar de praktijk. In de opzet van de 
studie wilden we primair het effect onderzoeken van inhalatiecorticosteroïden 
op de ontstekingscellen in slijm en biopten bij patiënten met matig ernstig 
COPD. Om dit goed te kunnen onderzoeken wilden we patiënten includeren 
die tevoren minstens 6 maanden geen inhalatiecorticosteroïden hadden 
gebruikt. In de praktijk bleken echter, ondanks de conservatieve richtlijnen 
met betrekking tot inhalatiecorticosteroïden, veel patiënten deze medicijnen 
toch in te nemen waardoor ze niet met het onderzoek mee mochten doen. 
Daardoor was het moeilijker om een grote groep patiënten te vinden die met 
ons onderzoek mee konden doen. Ook was het totaal aantal metingen in de 
GLUCOLD studie en de belasting van 3 bronchoscopiën per persoon een 
reden voor mensen om niet mee te willen doen. 
Maar de studie heeft ons inziens ook hele sterke punten. De GLUCOLD studie 
is uniek om een aantal redenen. Het is de grootste biopten studie ter wereld, 
waarbij ontsteking is onderzocht op 3 momenten gedurende 2,5 jaar. Astma 
werd nauwkeurig uitgesloten. De patiënten zijn heel goed in kaart gebracht. 
Hierbij is aandacht gegeven aan veel klinische kenmerken als luchtwegklachten, 
kwaliteit van leven, longfunctie, maar ook aan meer ingewikkelde kenmerken 
als hyperreactiviteit, hyperinflatie, ontstekingscellen in slijm en luchtwegweefsel 
in biopten gedurende een lange onderzoeksperiode. Alle data zijn nagekeken, 
dubbel ingevoerd en gecheckt op inconsequenties. Het is ook belangrijk om 
te weten dat de studie is geïnitieerd, ontworpen, uitgevoerd en opgeschreven 
door wetenschappers zonder inmenging van de industrie (die de studie wel 
financieel heeft ondersteund, maar geen invloed had op de analyse). 
Het is een belangrijke vraag in hoeverre je met resultaten van 114 patiënten 
een uitspraak kan doen over alle patiënten met matig ernstig COPD. Voor het 
aantonen van effecten op luchtwegklachten en kwaliteit van leven is het fijn 
als je een grote groep patiënten hebt. Als je geen effect kunt vinden kan dit 
komen doordat er te weinig mensen onderzocht zijn. Echter, als je wel effecten 
vindt, zoals in dit onderzoek beschreven, zijn de effecten sterk genoeg om 
zelfs in een kleine groep aantoonbaar te zijn. Daarbij is het van belang dat 
de effecten bij elkaar pasten en elkaar niet tegenspraken. Desondanks moet 
elke wetenschapper kritisch blijven en zal er meer onderzoek moeten volgen 




De patiënt met de chronische longziekte COPD die naar de dokter gaat, wil 
over het algemeen minder klachten en een voortschrijding van de aandoening 
voorkomen. Dokters zijn getraind om naar de patiënt en zijn aandoening als 
geheel te kijken. Dit is nog niet zo gemakkelijk. COPD is een zeer heterogene 
en complexe aandoening met kenmerken van klachten, ontsteking en schade 
in de longen. Sommige patiënten hebben veel klachten en toch maar ‘mild’ 
COPD, maar ook kan het zijn dat patiënten weinig klachten hebben bij ernstig 
COPD. Dit houdt in dat we niet alleen af moeten gaan op de klachten die een 
patiënt heeft, maar verder moeten kijken naar de onderliggende aandoening. 
Naast luchtwegklachten zouden we bij een deel van de patiënten ook de 
longfunctie moeten meten, hyperinflatie of zelfs ontsteking op een zo min 
mogelijk invasieve manier, ook bij patiënten in een eerder stadium van de 
ziekte. De unieke setting van de GLUCOLD studie heeft hier een stap in gezet 
door matig ernstige COPD patiënten zeer gedetailleerd in kaart te brengen 
en te onderzoeken wat de effecten van behandeling zijn. Hierbij blijken in de 
onderzochte onderzoeksgroep bepaalde patiënten met COPD met minder 
gevorderd ziektebeeld of fenotypes met minder emfyseem meer baat te 
hebben van inhalatiecorticosteroïden. Dit geeft een hoopvol perspectief voor 
een deel van de patiënten met COPD op het doen afremmen van de voortgang 
van de aandoening in de toekomst.
  
Wat betekent dit voor de dagelijkse praktijk?
De patiënt staat centraal. De huisartspraktijk is een van de mogelijkheden om 
dit te realiseren. Een huisarts staat dicht bij de patiënt en kan als een spin in 
het web fungeren om de patiënt te begeleiden bij een chronische aandoening. 
Met wetenschap zijn we op zoek naar antwoorden die betrekking hebben op 
ziekte en behandeling. De vraag is: hoe kunnen we een brug slaan tussen 
wetenschap en wat belangrijk is voor de patiënt? Wellicht zullen we ons in 
de toekomst minder richten op specifieke diagnoses, maar meer op unieke 
vingerafdrukken van bijvoorbeeld ontsteking, het mRNA of DNA. Echter, zover 
zijn we nog lang niet. Hoe kunnen we de huidige kennis uit de wetenschap dan 
toepassen in de praktijk? Is het voldoende om patiënten ad hoc te behandelen 
op basis van luchtwegklachten? Of moeten we verder kijken en ons voordeel 
doen met kennis uit de wetenschap en meer gebruik maken van profielen 
zoals die nu onderzocht worden in meerdere studies. Eerder behandelen zou 
schade kunnen voorkomen. Vandaar dat voorspelling van gunstige effecten 
van behandeling bij COPD voor de praktijk zo belangrijk is. Deze twee zaken 
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lijken vanzelfsprekend, maar het is nog wel de vraag hoe je dit moet realiseren. 
Meten is weten, maar het is eenvoudigweg veel te kostbaar om alles te 
meten bij alle patiënten. Het is een enorme uitdaging voor de wetenschap, 
zorgverleners en patiënten samen om precies te weten welke patiënten in 
een vroeg stadium van de ziekte veel metingen nodig hebben of behandeling 
vergen om erger te voorkomen. 
Perspectief van de auteur
Het is een uitdaging om niet alleen met deze nieuwe informatie over COPD 
en de behandeling in de praktijk te werken, maar ook in het algemeen om 
bij te dragen aan het slaan van een brug tussen de nieuwste resultaten van 
wetenschappelijk onderzoek en de dagelijkse (huisartsen)praktijk. Op dit 
moment werk ik als huisarts in een huisartsenpraktijk in Den Haag en als 
onderzoeker verbonden aan het LUMC in Leiden. In deze huisartsenpraktijk 
hebben ongeveer 1000 patiënten een diagnose astma of COPD (op een 
totaal van 10.500 ingeschreven patiënten). Samen met longartsen willen we 
graag niet alleen de huidige behandeling, maar ook de organisatie van de 
behandeling van deze patiënten nog verder verbeteren. Hiervoor zijn we een 
nieuw samenwerkingsproject gestart, waarbij ook de Zorggroep een rol speelt. 
Hierbij willen we schotten weghalen tussen eerste en tweede lijn en goed 
uitzoeken welke patiënt bij welke behandelaar hoort. Zoveel als mogelijk zullen 
we hierbij gebruik maken van fenotypering, maar ook van innovatieve e-health 
instrumenten. De toekomst zal moeten uitwijzen of dergelijke projecten 
worden tegengehouden of juist gestimuleerd en gefinancierd door de overheid 
of zorgverzekeraars. In het huidige project zal een longverpleegkundige 
vragenlijsten afnemen en longfuncties meten. Via teleconsultatie wordt advies 
gevraagd aan de longarts. Het is hierbij de bedoeling patiënten beter in kaart 
te brengen, zodat ze beter behandeld kunnen worden en alleen patiënten 
die het echt nodig hebben worden verwezen naar het ziekenhuis. Daarnaast 
zullen patiënten de mogelijkheid hebben hun astma/COPD te monitoren met 
behulp van een zelfmanagement programma via internet, genaamd www.
PatientCoach.nl. Dit programma is ontwikkeld in Leiden om patiënten beter te 
kunnen begeleiden, is geïntegreerd met registratiesystemen van de huisarts 
om beter te kunnen communiceren en is tevens bedoeld voor wetenschappelijk 
onderzoek. 
Momenteel wordt het programma geïmplementeerd bij huisartsen in de regio 
Leiden en Den Haag bij patiënten met matig ernstig astma (IMPLementation 
strategies of internet-based Asthma Selfmanagement Support in usual 
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care (IMPASSE). Patiënten kunnen hierbij hun eigen luchtwegklachten 
en longfunctie thuis monitoren met zo nodig advies om hun medicatie aan 
te passen volgens de huidige richtlijnen. Daarnaast zijn we gestart met de 
“Pulmonary Rehabilitation of Asthma and COPD: a Trial of sustained Internet-
based Self-management Support (PRACTISS) studie”; het doel hierbij is om 
patiënten met astma in Davos en COPD in het Rijnlands Revalidatiecentrum 
na revalidatie thuis verder te begeleiden. 
Naast bovenstaande werkzaamheden neem ik sinds kort deel aan de 
kerngroep en de wetenschapscommissie van de landelijke “COPD & Astma 
Huisartsen Advies Groep” (www.cahag.nl). 
De meest eenvoudige reden om al deze moeite te doen is zorg voor chronische 
longziekten te verbeteren en de enorme impact die dit voor patiënten heeft 
in hun dagelijkse leven te verminderen, gecombineerd met zo laag mogelijke 
kosten. Door de zorg slim te structureren, willen we niet alles meten bij 
iedereen, maar ons richten op fenotypering van patiënten en het stellen van 
individuele doelen. Met behulp van wetenschap op nieuwe terreinen met min 
of meer eenvoudige hulpmiddelen als een ‘elektronische neus’ of e-health 
zal dit in de toekomst verder moeten worden onderbouwd. Uiteindelijk kan 
dit leiden naar geïntegreerde zorg, individuele zorg, verbeterde kwaliteit van 
leven, efficiëntere kostenbesteding en mogelijk het doen afremmen van de 
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ze een klinische stage Orthopedie gedaan in de praktijk van dr. C. de Bree in 
Neukirchen, Duitsland en een stage bij huisarts M.H.M. de Meijer in Cadzand 
in Zeeland. Na het doctoraal examen heeft zij gedurende een half jaar een 
klinische stage Interne Geneeskunde verricht onder begeleiding van Dr G. 
Geyskes in het ziekenhuis Nieuw Nickerie in de republiek Suriname. In 1998 
behaalde ze haar artsexamen. 
Hierna startte ze haar promotieonderzoek bij de afdelingen Public health en 
Eerstelijnsgeneeskunde, Longziekten en Medische Besliskunde in het Leids 
Universitair Medisch Centrum (LUMC) te Leiden. Gedurende de daarop 
volgende jaren bekwaamde ze zich in het verrichten van onderzoek middels 
het volgen van symposia en congressen. Daarnaast volgde ze diverse 
epidemiologische cursussen in het LUMC, te Schiermonnikoog, aan het VU 
Medisch Centrum in Amsterdam en de Erasmus Universiteit van Rotterdam. 
Van 2003 tot 2008 volgde zij de opleiding Huisartsgeneeskunde in het LUMC 
te Leiden. Aansluitend heeft ze een inventarisatie gemaakt van ‘Evidence 
Based Medicine’ in de huisartsopleiding in Nederland aan de afdeling Public 
health en Eerstelijnsgeneeskunde te Leiden. 
Vanaf 2008 heeft ze verschillende functies en betrekkingen. Ze werkt 
parttime als huisarts in huisartspraktijk ‘Akelei’ te  Den Haag (http://
www.akeleihuisartsenzorg.nl). Tevens werkt ze als onderzoeker bij de 
afdeling Medische Besliskunde in het LUMC te Leiden. Hier werkt ze 
als coördinator van multicenteronderzoek en begeleider van fellows bij 
diverse promotieonderzoeken naar astma en COPD, onder andere naar de 
ontwikkeling van een internetbased programma voor zelfmanagement bij 
astma en COPD (www.PatientCoach.nl). In de regio ’s-Gravenhage houdt 
ze zich bezig met astma en COPD. Ze neemt deel aan de werkgroep COPD 
van de Transmurale Stichting te Den Haag (http://www.transmuralezorg.
nl). Met de afdeling Longziekten van het HAGA ziekenhuis en de zorggroep 
ELZHA werkt ze samen om de zorg van astma en COPD te verbeteren. Jiska 
neemt deel aan de COPD en Astma Huisartsen Advies Groep (CAHAG) en 
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zal zich de komende jaren meer gaan richten op taken van de kerngroep en 
wetenschapscommissie. 
Zij is getrouwd met Jean-Philippe, werkzaam bij de ING als compliance officer 
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begeleiden, materiaal te verzamelen en bewerken, de data te checken. We zijn 
heel goede vriendinnen geworden en hebben lief en leed met elkaar gedeeld. 
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Singapore en heel veel dank voor al je support.
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